What changed in this filing

/stocks — the workspaceLOADING

Item 9A. Controls and Procedures

2026-03-17 compared with 2025-03-18 · 782 added, 775 removed, 1003 unchanged (61% of the section changed)

6 unchanged sentences

Attestation Report of the Registered Public Accounting Firm.

This annual report does not include a report of management’s assessment regarding internal control over financial reporting or an attestation report of the company's registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).

Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company;

and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Under the supervision and with the participation of our management, including our principal executive officers and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2024, based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013).

Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2024.

We are an emerging growth company, and are furthermore neither an accelerated filer nor a large accelerated filer, in each case as defined in Rule 12b-2 under the Exchange Act.

Therefore, we are not required under Section 202 of the Sarbanes-Oxley Act (and the SEC rules and regulations thereunder) to provide an attestation report on management’s assessment of our internal control over financial reporting from a registered public accounting firm in this Annual Report.

Changes in Internal Control over Financial Reporting

2 unchanged sentences

(a) Unreported Information .

The Company does not have any information required to be disclosed in a Current Report on Form 8-K during the fourth quarter of the year ended December 31, 2024 that has not yet been reported.

The Company does not have any information that was required to be disclosed in a Current Report on Form 8-K during the fourth quarter of the year ended December 31, 2025, that has not yet been reported.

(b) Insider trading arrangements .

4 unchanged sentences

Management and Board of Directors

The below table and biographies below it provide certain information known as of the date of this Annual Report concerning the persons who currently serve as directors and executive officers of New Silexion.

Each director holds office until his or her successor is duly elected or appointed and qualified in accordance with applicable law or until his or her death, resignation or removal in accordance with law and our governing documents, including our Articles, which went into effect upon the Closing of the Business Combination.

4 unchanged sentences

Mirit Horenshtein Hadar, CPA

EVP of Finance Affairs, Chief Financial Officer and Secretary

Ilan Hadar , 55, was appointed as Chief Executive Officer of New Silexion, serving on a full-time basis, effective upon the Business Combination, and has served as our (previously, Silexion’s) Chairman of the Board since May 2024.

Previously, he served as Managing Director of Silexion from April 2022 until the Business Combination.

Hadar has over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies, as described below, over which time period he has acquired the experience and skills to serve as a valuable member of the board of directors of a company such as Biomotion Sciences.

In addition to his current role at Silexion, Mr.

Hadar has served as the Chief Executive Officer of Painreform Ltd (Nasdaq:

PRFX) since November 2020, a position he will relinquish following the consummation of the Business Combination.

Prior to joining Painreform and Silexion, Mr.

Chief Financial Officer and Secretary

Ilan Hadar , 56, was appointed as Chief Executive Officer of Silexion, serving on a full-time basis, effective upon the Business Combination, and has served as our (previously, Silexion Israel’s) Chairman of the Board since May 2024.

Previously, he served as Managing Director of Silexion Israel from April 2022 until the Business Combination.

Immediately prior to his roles at Silexion Israel and our company, Mr.

Hadar served as the Chief Executive Officer of Painreform Ltd (Nasdaq:

PRFX) from November 2020 until the consummation of the Business Combination in August 2024.

Prior to joining Painreform and Silexion Israel, Mr.

Hadar served as Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd.

1 unchanged sentence

VYNE) from 2014 until August 2020, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital markets and mergers and acquisitions.

Prior to his role at Foamix, Mr.

Before his role at Foamix, Mr.

Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company.

Before his tenure at Pfizer, Mr.

Hadar served as Finance Manager at HP Indigo Ltd., a world-leading company in digital printing and, prior to that, served as Finance Director at BAE Systems, the third-largest defense company in the world, where he was responsible for all financial activities of BAE Systems Israel.

Prior to his tenure at Pfizer, Mr.

Hadar served as Finance Manager at HP Indigo Ltd., a world-leading company in digital printing, and before that, served as Finance Director at BAE Systems, the third-largest defense company in the world, where he was responsible for all financial activities of BAE Systems Israel.

From 1998 to 2006, Mr.

3 unchanged sentences

We believe Mr.

Hadar is qualified to serve on our board of directors due to his extensive knowledge as Silexion’s Managing Director, and his extensive commercial, financial and managerial experience with high-tech and pharmaceutical companies, both private and public.

Abramov, 63, was appointed as a director of New Silexion effective upon the consummation of the Business Combination.

Abramov’s experience of over 15 years in multiple roles in changing and growing companies and markets within dynamic environments, and in particular his multi-disciplinary experience in R&D, consulting, taxes, sales, business development, finance and government, lend to his being an appropriate board member of Biomotion Sciences.

Hadar is qualified to serve on our board of directors due to his extensive knowledge as our Chairman and Chief Executive Officer, and his extensive commercial, financial and managerial experience with high-tech and pharmaceutical companies, both private and public.

Abramov, 65, was appointed as a director of Silexion effective upon the consummation of the Business Combination.

Abramov has served as Managing Director of Hewlett Packard Inc.

14 unchanged sentences

Abramov is qualified to serve on our board of directors due to his extensive financial and business management experience.

Ruth Alon , 73, became a director of New Silexion effective upon the consummation of the Business Combination.

Alon’s international experience of over 30 years in the high-tech medical industry and with Israeli life sciences companies, in particular, make her a prospective valuable member of the board of directors of Biomotion Sciences.

Ruth Alon , 74, became a director of Silexion effective upon the consummation of the Business Combination.

Alon’s international experience of over 30 years in the high-tech medical industry and with Israeli life sciences companies, in particular, make her a valuable member of our board of directors.

Alon is the Founder and Chief Executive Officer of Medstrada, which was started in 2016.

2 unchanged sentences

Currently, Ms.

Alon also serves on the board of directors of a number of private and public companies as a member or chairperson, including Vascular Biogenics Ltd.

VBLT), Brainsgate and KadimaStem.

Alon also serves on the board of directors of a number of private and public companies as a member or chairperson, Alpha Tau medical (Nasdaq:

DRTS), Brainsgate, Treos Bio, Angiolutions and CorNeat Vision.

Alon previously worked on Wall Street where she held senior positions as a senior medical device analyst with Montgomery Securities (from 1981 to 1987) and Kidder Peabody & Co.

9 unchanged sentences

Alon is qualified to serve on our board of directors given her above-described extensive experience in the high-tech medical industry and with Israeli life sciences companies, in particular.

Ilan Levin , 59, who was the co-founder, Chairman and Chief Executive Officer of Moringa, was appointed as a director of New Silexion after its formation in April 2024 and has continued as a director following the consummation of the Business Combination.

Ilan Levin , 60, who was the co-founder, Chairman and Chief Executive Officer of Moringa, was appointed as a director of Silexion after its formation in April 2024 and has continued as a director following the consummation of the Business Combination.

Levin has been involved, for approximately 25 years, as an executive and venture capital/private equity investor in high-tech, Israel-related ventures.

20 unchanged sentences

Levin is qualified to serve on our board of directors given his above-described experience in managing growth companies that develop technology, and his knowledge of that industry in Israel in particular.

Avner Lushi , 58, was appointed as a director of New Silexion effective upon the consummation of the Business Combination.

His experience of over 20 years and skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him suitable to provide similar support as a member of the board of directors of Biomotion Sciences.

Avner Lushi , 59, was appointed as a director of Silexion effective upon the consummation of the Business Combination.

His experience of over 20 years and skills acquired in his managing roles at an Israeli life sciences venture capital fund and in life sciences investment banking make him suitable to provide support to our company as a member of our board of directors.

Lushi co-founded Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF), which currently includes two approximately $100 million funds focused on introducing Israeli and other foreign companies in the field of life sciences to the Chinese market, in which he also serves as a Managing Partner & CEO of the GP since 2016.

5 unchanged sentences

Since 2005, Mr.

Lushi has served as an independent director on the boards of nine public companies, including, currently, Brainsway Ltd.

Lushi has served as an independent director on the boards of eleven public companies, including, currently, Brainsway Ltd.

BWAY) and Ginegar Plastic Products Ltd.

4 unchanged sentences

Lushi is qualified to serve on our board of directors due to his extensive executive and board experience with life sciences companies.

Shlomo Noy , MD PhD, 71, was appointed as a director of New Silexion effective upon the consummation of the Business Combination.

Professor Noy’s international-level expertise in healthcare management, tech transfer, building ecosystems and focusing hospitals on research and clinical trials will provide important knowledge to the Biomotion Sciences board of directors in the realm of Israeli research and clinical trial activities.

Shlomo Noy , MD PhD, 73, was appointed as a director of Silexion effective upon the consummation of the Business Combination.

Professor Noy’s international-level expertise in healthcare management, tech transfer, building ecosystems and focusing hospitals on research and clinical trials provides important knowledge to our board of directors in the realm of Israeli research and clinical trial activities.

Professor Noy has served as Chief Medical Officer of GIBF since January 2017.

6 unchanged sentences

Noy is qualified to serve on our board of directors due to his extensive medical and health care management experience.

Amnon Peled , PhD, 65, was appointed as a director of New Silexion in December 2024.

Amnon Peled , PhD, 66, was appointed as a director of Silexion in December 2024.

Professor Peled has served as an associate professor at Hadassah Medical Center, Jerusalem since August 2000.

5 unchanged sentences

He completed postdoctoral training at Harvard Medical School and the Weizmann Institute.

We believe that Professor Peled’s extensive knowledge of our product candidate and our industry make him well-suited to serve on our board of directors.

Executive Officers

Mitchell Shirvan , Ph.D., 71, has served as the Chief Scientific and Development Officer of New Silexion since the Business Combination, and, before the Business Combination, of Silexion, since April 2022.

Prior to joining Silexion, Dr.

Mitchell Shirvan , Ph.D., 72, has served as the Chief Scientific and Development Officer of Silexion since the Business Combination, and, before the Business Combination, of Silexion Israel, since April 2022.

Prior to joining Silexion Israel, Dr.

Shirvan served as the Senior Vice President of R&D and V.P.

9 unchanged sentences

in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.

Mirit Horenshtein Hadar , 41, has served as the Chief Financial Officer and Secretary of New Silexion since the Business Combination, and served as the Executive Vice President of Finance Affairs at Silexion before the Business Combination, beginning in January 2024.

Mirit Horenshtein Hadar , 42, has served as the Chief Financial Officer and Secretary of Silexion since the Business Combination, and served as the Executive Vice President of Finance Affairs at Silexion Israel before the Business Combination, beginning in January 2024.

From August 2023 to January 2024, Ms.

2 unchanged sentences

GAAP financial reporting and FP&A functions, and has led the accounting and reporting of complex M&A transactions, integration processes and public offerings.

Prior to joining Silexion, from January 2021 to December 2022, Ms.

Prior to joining Silexion Israel, from January 2021 to December 2022, Ms.

Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd.

1 unchanged sentence

GAUZ), a nanotechnology company that develops and markets smart glass and vision control technologies.

Since December 2022, Ms.

Horenshtein Hadar continues to serve as an external advisor to the finance department at Gauzy.

From December 2022 through July 2025, Ms.

Horenshtein Hadar served as an external advisor to the finance department at Gauzy.

Prior to Gauzy, Ms.

12 unchanged sentences

issuers often do.

Composition of the New Silexion Board After the Business Combination

New Silexion’s business and affairs are managed under the direction of our board of directors (which we sometimes refer to herein as the “ New Silexion Board ”).

Under the terms of the Articles, the New Silexion Board may be composed of between three and nine directors, as may be amended from time to time exclusively by ordinary resolution under Cayman Islands law, being a resolution passed by a simple majority of the shareholders of New Silexion as, being entitled to do so, vote in person or by proxy at a general meeting (an “ Ordinary Resolution ”).

The size of the New Silexion Board was set by our shareholders as seven members effective upon the Closing.

Ilan Hadar serves as Chairman of the New Silexion Board.

In September 2024, Ilan Shiloah, who was appointed to the New Silexion Board effective upon the Closing, stepped down from the Board, citing competing demands on his time, thereby leaving the size of the Board as six members.

Subsequently, in December 2024, the Board appointed Dr.

Amnon Peled to fill the Board seat previously held by Mr.

Shiloah, thereby restoring the size of the New Silexion Board to seven members.

Pursuant to the Articles, New Silexion’s directors are appointed by an Ordinary Resolution at an annual general meeting.

Composition of the Silexion Board

Our business and affairs are managed under the direction of our Board.

Under the terms of the Articles, the Board may be composed of between three and nine directors, as may be amended from time to time exclusively by ordinary resolution under Cayman Islands law, being a resolution passed by a simple majority of the shareholders of Silexion as, being entitled to do so, vote in person or by proxy at a general meeting (an “ Ordinary Resolution ”).

The size of the Silexion Board was set by our shareholders as seven members effective upon the Closing.

Ilan Hadar serves as Chairman of the Board.

Pursuant to the Articles, our directors are appointed by an Ordinary Resolution at an annual general meeting.

Unless the Board resolves that the election of nominees of the Board (referred to as “ Nominees ”) or of nominees of any shareholders entitled to present such nomination (referred to as “ Alternate Nominees ”) will be determined by plurality vote, the Nominees or Alternate Nominees shall be appointed by Ordinary Resolution at the annual general meeting at which they are proposed for election.

2 unchanged sentences

Under that procedure, a shareholder must deliver notice of such nomination or proposed item of business to the principal executive offices of the Company not later than 90 days nor earlier than 120 days prior to the one-year anniversary of our previous year’s annual general meeting.

If we did not hold an annual general meeting the previous year (as is the case in 2025, since we did not hold an annual general meeting in 2024), or if the date of the current year’s annual general meeting has been changed by more than 30 days from the date of the previous year’s annual general meeting, such shareholder’s notice must be so delivered no later than the deadline to be set by the Board, with such deadline being a reasonable time (as determined by the Board) before the Company begins to print and send its related proxy materials for the current year’s annual general meeting.

If we did not hold an annual general meeting during the previous year, or if the date of the current year’s annual general meeting has been changed by more than 30 days from the date of the previous year’s annual general meeting, such shareholder’s notice must be so delivered no later than the deadline to be set by the Board, with such deadline being a reasonable time (as determined by the Board) before the Company begins to print and send its related proxy materials for the current year’s annual general meeting.

The Chairman of the Board may refuse to acknowledge the introduction of any shareholder proposal not made in compliance with the foregoing procedures.

3 unchanged sentences

(c) a description of all arrangements or understandings between the shareholder and each Alternate Nominee and any other person (naming such person) pursuant to which the nomination is be made by the shareholder;

(d) the consent of the Alternate Nominee to serve as a director of New Silexion if so appointed and (e) a declaration signed by the Alternate Nominee declaring that there is no limitation under applicable law for the appointment of such nominee and that all of the information that is required under applicable law to be provided to New Silexion in connection with such an appointment has been provided.

The New Silexion Board may refuse to acknowledge the nomination of any person not made in compliance with the foregoing procedure.

(d) the consent of the Alternate Nominee to serve as a director of Silexion if so appointed and (e) a declaration signed by the Alternate Nominee declaring that there is no limitation under applicable law for the appointment of such nominee and that all of the information that is required under applicable law to be provided to Silexion in connection with such an appointment has been provided.

The Silexion Board may refuse to acknowledge the nomination of any person not made in compliance with the foregoing procedure.

Under the charter of the corporate governance and nominating committee (described below under “ Corporate Governance and Nominating Committee” ) , any Alternate Nominee proposed by a shareholder will be considered by that committee in accordance with the criteria developed by that committee, whereby the committee will determine whether to recommend the nomination of the Alternate Nominee by the Board as a whole for election at the next annual general meeting.

New Silexion’s Chief Executive Officer is responsible for the company’s day-to-day management.

The Chief Executive Officer is appointed by, and serves at the discretion of, the New Silexion Board, subject to his employment agreement.

All other executive officers are proposed for appointment by the Chief Executive Officer, subject to approval by the New Silexion Board, and will be subject to the terms of any applicable employment or consulting agreements that we may enter into with them.

Silexion’s Chief Executive Officer is responsible for the Company’s day-to-day management.

The Chief Executive Officer is appointed by, and serves at the discretion of, the Silexion Board, subject to his employment agreement.

All other executive officers are proposed for appointment by the Chief Executive Officer, subject to approval by the Silexion Board, and will be subject to the terms of any applicable employment or consulting agreements that we may enter into with them.

Board Committees

The New Silexion Board has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and the responsibilities described below.

Each of these committees operates under a written charter, approved by the New Silexion Board and effective upon the Closing, that satisfies the applicable Nasdaq rules, copies of which are available on the investor relations portion of our website.

Members will serve on these committees until their resignation or until otherwise determined by the New Silexion Board.

The New Silexion Board may establish other committees as it deems necessary or appropriate from time to time.

The Silexion Board has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and the responsibilities described below.

Each of these committees operates under a written charter, approved by the Board and effective upon the Closing, that satisfies the applicable Nasdaq rules, copies of which are available on the investor relations portion of our website.

Members will serve on these committees until their resignation or until otherwise determined by the Board.

The Board may establish other committees as it deems necessary or appropriate from time to time.

Audit Committee

Our audit committee consists of Dror J.

Abramov, Ruth Alon and Dr.

Amnon Peled, with Mr.

Abramov, Ruth Alon, and Professor Amnon Peled, with Mr.

Abramov serving as chair.

1 unchanged sentence

The Nasdaq listing standards require that the audit committee be composed of at least three members.

The New Silexion Board has determined that each of Messrs Abramov and Peled, and Ms.

The Silexion Board has determined that each of Messrs Abramov and Peled, and Ms.

Alon, meets the definition of “independent director” for purposes of serving on the audit committee under Rule 10A-3 of the Exchange Act and the Nasdaq listing standards, and also meets the financial literacy requirements of the Nasdaq listing standards.

In addition, the New Silexion Board has determined that Mr.

In addition, the Board has determined that Mr.

Abramov qualifies as an “audit committee financial expert” within the meaning of the SEC regulations.

The primary purpose of the audit committee is to discharge the responsibilities of the New Silexion Board with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits and to oversee our independent registered public accounting firm.

The primary purpose of the audit committee is to discharge the responsibilities of the Silexion Board with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits and to oversee our independent registered public accounting firm.

The principal functions of the audit committee include, among other things:

helping the New Silexion Board oversee our corporate accounting and financial reporting processes;

helping the Board oversee our corporate accounting and financial reporting processes;

managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;

8 unchanged sentences

Our compensation committee consists of Dror J.

Abramov, Amon Peled and Ruth Alon.

Abramov, Professor Amnon Peled, and Ruth Alon.

Alon serves as the chair of the compensation committee.

The New Silexion Board has determined that each of Messrs.

The Silexion Board has determined that each of Messrs.

Abramov and Peled, and Ms.

Alon, meets the definition of “independent director” for purposes of serving on the compensation committee under the Nasdaq listing standards, including the heightened independence standards for members of a compensation committee.

The primary purpose of our compensation committee is to discharge the responsibilities of the New Silexion Board in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate.

The primary purpose of our compensation committee is to discharge the responsibilities of the Board in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate.

The principal functions of the compensation committee include, among other things:

reviewing, approving and determining, or making recommendations to the New Silexion Board regarding the compensation of our chief executive officer, other executive officers and senior management;

reviewing, evaluating and recommending to the New Silexion Board succession plans for our executive officers;

reviewing and recommending to the New Silexion Board the compensation paid to our non-employee directors;

reviewing, approving and determining, or making recommendations to the Board regarding the compensation of our chief executive officer, other executive officers and senior management;

reviewing, evaluating and recommending to the Board succession plans for our executive officers;

reviewing and recommending to the Board the compensation paid to our non-employee directors;

administering our equity incentive plans and other benefit programs;

3 unchanged sentences

We have appointed a corporate governance and nominating committee that currently consists of Dror J.

Abramov, Ilan Levin, Amnon Peled and Ruth Alon.

Abramov, Ilan Levin, Professor Amnon Peled, and Ruth Alon.

The chair of the committee will be chosen from among the committee’s members.

The New Silexion Board has determined that each of Messrs.

The Board has determined that each of Messrs.

Abramov, Peled and Levin, and Ms.

1 unchanged sentence

Our corporate governance and nominating committee is responsible for, among other things:

identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by shareholders, to serve on the New Silexion Board;

considering and making recommendations to the New Silexion Board regarding the composition and chairmanship of the committees of the New Silexion Board;

instituting plans or programs for the continuing education of the New Silexion Board and the orientation of new directors;

developing and making recommendations to the New Silexion Board regarding corporate governance guidelines and matters;

identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by shareholders, to serve on the Board;

considering and making recommendations to the Board regarding the composition and chairmanship of the committees of the Board;

instituting plans or programs for the continuing education of the Board and the orientation of new directors;

developing and making recommendations to the Board regarding corporate governance guidelines and matters;

overseeing our corporate governance practices;

overseeing periodic evaluations of the New Silexion Board’s performance, including committees of the New Silexion Board;

overseeing periodic evaluations of the Board’s performance, including committees of the Board;

contributing to succession planning.

2 unchanged sentences

These reporting persons are also required to furnish us with copies of all Section 16(a) forms they file.

Based solely on our review of such forms furnished to us and written representations from certain reporting persons, we believe that all (if any) filing requirements applicable to our executive officers, directors and greater than 10% beneficial owners during the year ended December 31, 2024 were fulfilled in a timely manner.

Code of Business Conduct and Ethics

Prior to the completion of the Business Combination, we adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

Delinquent Section 16(a) Reports

Each of our non-employee/ non-affiliate directors who received an equity grant from the Company on February 9, 2025 (consisting of (i) 794 restricted share units (RSUs), under which an equivalent number of ordinary shares may become issuable upon vesting and settlement, and (ii) 935 options to purchase an equivalent number of underlying ordinary shares at a price of $18.90 per share) belatedly reported that grant on Form 4, which was filed in each case on December 31, 2025.

Those non-employee/ non-affiliate directors consist of Dror Abramov, Ruth Alon, Avner Lushi, Shlomo Noy, and Amnon Peled.

In addition, our director Ilan Levin and the Moringa sponsor (in which Mr.

Levin holds a controlling interest), which is a 10% shareholder of ours, belatedly reported on Form 4 the acquisition by the sponsor of 450,000 ordinary shares on September 15, 2025, upon our conversion of amounts due to the sponsor under the A&R Sponsor Promissory Note, which report on Form 4 was filed on January 27, 2026.

Code of Ethics and Business Conduct

Prior to the completion of the Business Combination, we adopted a written code of ethics and business conduct that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

A copy of the code is posted on the investor relations portion of our website at www.silexion.com/investors .

2 unchanged sentences

We have adopted an insider trading policy that governs the purchase, sale, and other transactions in our securities by directors, senior management, and employees, which policy is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and the Nasdaq listing standards applicable to us.

A copy of our insider trading policy is filed as Exhibit 19.1 to this Annual Report.

A copy of our insider trading policy serves as Exhibit 19.1 to this Annual Report and is incorporated herein by reference.

Executive Compensation.

Unless the context requires otherwise, references in this “Executive Compensation” section to “we,” “our,” “us” and the “Company” generally refer to our company on a consolidated basis, for all periods following the completion of the Business Combination (on August 15, 2024), and to our wholly-owned subsidiary, Silexion Therapeutics Ltd., an Israeli company (“Silexion”), and its subsidiaries, for all periods prior to the completion of the Business Combination.

The following tables and accompanying narrative set forth information about the compensation, for 2024 and 2023, provided to our chief executive officer (or person serving in an equivalent position) and the two most highly compensated executive officers (other than our chief executive officer) who were serving as executive officers as of December 31, 2024, each of whom served as an executive officer of Silexion prior to the completion of the Business Combination.

Unless the context requires otherwise, references in this “Executive Compensation” section to “we,” “our,” “us” and the “Company” generally refer to our company on a consolidated basis, for all periods following the completion of the Business Combination (on August 15, 2024), and to our wholly-owned subsidiary, Silexion Therapeutics Ltd., an Israeli company (“Silexion Israel”), and its subsidiaries, for all periods prior to the completion of the Business Combination.

The following tables and accompanying narrative set forth information about the compensation, for 2025 and 2024, provided to our chief executive officer (or person serving in an equivalent position) and the two most highly compensated executive officers (other than our chief executive officer) who were serving as executive officers as of December 31, 2025, each of whom also served as an executive officer of Silexion Israel prior to the completion of the Business Combination.

These executive officers consist of:

Ilan Hadar, who was Silexion’s Managing Director and now serves as New Silexion’s Chairman and Chief Executive Officer;

Mirit Horenshtein Hadar, who was Silexion’s EVP Finance and now serves as New Silexion’s Chief Financial Officer;

Mitchell Shirvan, who was Silexion’s— and is now New Silexion’s— Chief Scientific and Development Officer.

Ilan Hadar, who was Silexion Israel’s Managing Director and now serves as Silexion’s Chairman and Chief Executive Officer;

Mirit Horenshtein Hadar, who was Silexion Israel’s EVP Finance and now serves as Silexion’s Chief Financial Officer and Secretary;

Mitchell Shirvan, who was Silexion Israel’s- and is now Silexion’s- Chief Scientific and Development Officer.

These executive officers are referred to in this section as our “named executive officers” or “NEOs.”

6 unchanged sentences

Mirit Horenshtein Hadar

Chief Financial Officer (formerly EVP Finance of Silexion) (4)

Chief Financial Officer & Secretary (formerly EVP Finance of Silexion)

Mitchell Shirvan

1 unchanged sentence

Amounts reported for the named executive officer and paid in New Israeli Shekels are converted from New Israeli Shekels to U.S.

dollars using the 2024 and 2023 (as applicable) average exchange rates as published by Bank of Israel of 3.699 and 3.689 New Israeli Shekels, respectively, to 1 U.S.

dollars using the 2025 and 2024 (as applicable) average exchange rates as published by Bank of Israel of 3.452 and 3.699 New Israeli Shekels, respectively, to one U.S.

The amounts in this column include payments for a leased car or car maintenance, contributions to a pension fund, compensation fund, and continuing education fund, or payments in lieu of a continuing education fund.

This was for a part-time (75%) position prior to, and a full-time position following, completion of the Business Combination.

For 2023, Ms.

Horenshtein Hadar’s compensation was for a period of 4.5 months during which she served as a part-time consultant in a Strategy & Corporate Finance Advisory capacity.

This was for a part-time (80%) position prior to, and a full-time position following, completion of the Business Combination.

Hadar served in a part-time (75%) position for Silexion prior to the Business Combination (which was completed in August 2024), and has served in a full-time position for our company since that time.

Shirvan served in a part-time (80%) position for Silexion prior to the Business Combination (which was completed in August 2024), and has served in a full-time position for our company since that time.

Narrative Disclosure to Summary Compensation Table

7 unchanged sentences

Equity Compensation

From time to time, we have granted equity awards under the Silexion Therapeutics Ltd.

We did not grant any new equity compensation to the named executive officers during the year ended December 31, 2025.

In February 2026, following the automatic increase (effective as of January 1, 2026) to the number of ordinary shares available under our 2024 Equity Incentive Plan (described further below) due to the automatic “evergreen” provision of that plan, our compensation committee approved certain “catch-up” equity grants to our named executive officers, who had not received any equity grants since the Closing of the Business Combination and whose percentage of equity holdings in our company were below customary levels.

Pursuant to that approval by the compensation committee, Ilan Hadar, Dr.

Mitchell Shirvan and Mirit Horenshtein Hadar received grants of restricted share units (RSUs) for 64,350, 49,726 and 49,726 underlying ordinary shares, respectively, which RSUs were fully vested upon grant and settled immediately for the underlying ordinary shares.

From time to time prior to 2025, we have also granted equity awards under the Silexion Therapeutics Ltd.

2013 Equity Incentive Plan, which was replaced by the Silexion Therapeutics Ltd.

2023 Equity Incentive Plan (the “ 2013 Plan ” and “ 2023 Plan ”, respectively, collectively referred to as the “ Silexion Plans ”), as incentives to attract, retain and motivate our named executive officers.

During 2024, we granted restricted share units (RSUs) that could be settled for 16,821, 6,308 and 14,718 ordinary shares of Silexion, to Ilan Hadar, Mirit Horenshtein Hadar, and Dr.

Mitchell Shirvan, respectively (each such number of Silexion ordinary shares does not reflect the exchange ratio in the Business Combination or the subsequent reverse share split of New Silexion).

The vesting of those RSUs accelerated upon the Closing of the Business Combination, entitling each such officer to receive New Silexion ordinary shares in accordance with the exchange ratio upon the Closing.

During 2022, Silexion granted 32,400 and 16,200 options to purchase Silexion ordinary shares to Ilan Hadar and Dr.

Mitchell Shirvan, respectively (each such number of options does not reflect the equity exchange ratio in the Business Combination or the subsequent reverse share split of New Silexion).

2023 Equity Incentive Plan (the “ 2013 Plan ” and “ 2023 Plan ”, respectively, collectively referred to as the “ Silexion Israel Plans ”), as incentives to attract, retain and motivate our named executive officers.

All compensation amounts appearing in the Summary Compensation Table above in the “Stock Awards” column reflect grants under the Silexion Israel Plans.

During 2024, we granted RSUs that could be settled for 1,121, 420 and 981 ordinary shares of Silexion Israel, to Ilan Hadar, Mirit Horenshtein Hadar, and Dr.

Mitchell Shirvan, respectively (each such number of Silexion Israel ordinary shares reflects the exchange ratio in the Business Combination or the subsequent reverse share splits of Silexion).

The vesting of those RSUs accelerated upon the Closing of the Business Combination, entitling each such officer to receive Silexion ordinary shares in accordance with the exchange ratio upon the Closing.

The expense that we realized for each year in respect of each RSU award to the applicable NEO is reflected in the “Stock Awards” column of the above Summary Compensation Table.

During 2022, Silexion Israel granted 956 and 478 options to purchase Silexion Israel ordinary shares to Ilan Hadar and Dr.

Mitchell Shirvan, respectively (each such number of options reflects the equity exchange ratio in the Business Combination and the subsequent reverse share splits of Silexion).

Vesting of those options was to occur over a period of 48 months, provided that Ilan Hadar or Dr.

Mitchell Shirvan, as applicable, remains engaged by Silexion (or a Silexion affiliate), and is subject to the Silexion Plans.

Upon consummation of an initial public offering of Silexion’s securities or an M&A Transaction (as defined in Silexion’s articles of association), which included the Business Combination, the vesting of those options was to accelerate, such that all unvested options were to immediately vest, provided that such IPO or M&A Transaction was to be consummated after January 1, 2023.

Mitchell Shirvan, as applicable, remains engaged by Silexion Israel (or a Silexion Israel affiliate), and is subject to the Silexion Israel Plans.

Upon consummation of an initial public offering of Silexion Israel’s securities or an M&A Transaction (as defined in Silexion Israel’s articles of association), which included the Business Combination, the vesting of those options was to accelerate, such that all unvested options were to immediately vest, provided that such IPO or M&A Transaction was to be consummated after January 1, 2023.

That acceleration of vesting occurred upon the Closing of the Business Combination on August 15, 2024.

The expense that we realized for each year in respect of the option award to the applicable NEO is reflected in the “Stock Awards” column of the above Summary Compensation Table.

Employment Agreements

Following the Closing, Silexion has entered or will enter into employment agreements with each of its NEOs.

Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive Plan

Silexion (and, following the Business Combination, New Silexion) has maintained the Silexion Plans in order to provide additional incentives for employees, directors and consultants, and to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to Silexion’s (and New Silexion’s) success.

The base salary and other compensation paid to our NEOs reflected in the above Summary Compensation Table is provided to them pursuant to employment agreements to which our wholly-owned subsidiary Silexion Israel is party with each of them.

Hadar’s employment agreement, as amended, with Silexion Israel provides for him a gross monthly salary of NIS 110,000, which amounts to an annual base salary of $382,398 (based on the average exchange rate for 2025, as published by the Bank of Israel), customary disbursements toward his providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

Mirit Horenshtein Hadar’s employment agreement with Silexion Israel provides for her a gross monthly salary of NIS 72,000, which amounts to an annual base salary of $250,297 (based on the average exchange rate for 2025, as published by the Bank of Israel), as well as customary disbursements toward her providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

Mitchell Shirvan’s employment agreement with Silexion Israel provides for him a gross monthly salary of NIS 80,000, which amounts to an annual base salary of $278,108 (based on the average exchange rate for 2025, as published by the Bank of Israel),, as well as customary disbursements toward his providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

Silexion Israel 2013 Equity Incentive Plan and Silexion Israel 2023 Equity Incentive Plan

The equity awards for which compensation expense is reflected in the above Summary Compensation Table for our NEOs have been granted under equity incentive plans.

Silexion Israel (and, following the Business Combination, Silexion) has maintained the Silexion Israel Plans in order to provide additional incentives for employees, directors and consultants, and to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to Silexion Israel’s (and Silexion’s) success.

The 2013 Plan was adopted on July 25, 2013 and was replaced by the 2023 Plan, which was adopted on April 4, 2023.

For a complete description of the 2013 Plan and the 2023 Plan, please see “ Silexion Share Incentive Plans ” below.

The Silexion Plans provide for grants of options to purchase ordinary shares of Silexion (following the Business Combination, New Silexion), shares, restricted shares and RSUs.

As described above, during 2022, Silexion granted option awards under the Silexion Plans to Ilan Hadar and Dr.

Mitchell Shirvan and during 2024, Silexion granted RSUs to Ilan Hadar, Mirit Horenshtein Hadar, and Dr.

Mitchell Shirvan, respectively.

Immediately prior to the effective time of the merger of Merger Sub 1 with and into Silexion pursuant to the Business Combination, all outstanding Silexion options and Silexion RSUs accelerated and became fully vested (and, in the case of RSUs, settled for underlying shares).

At the effective time of that merger, all Silexion options outstanding immediately prior to the merger automatically and without any action on the part of any Silexion option holder or beneficiary thereof, were assumed by New Silexion, and each such Silexion option was converted into an option to purchase New Silexion ordinary shares (based on the equity exchange ratio for Silexion under the Business Combination Agreement).

In addition, immediately prior to the completion of the Business Combination, New Silexion adopted the 2024 Equity Incentive Plan (described below), which provides for the grant of equity-based incentive awards to its employees, directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on behalf of New Silexion and to promote the success of New Silexion’s business.

For a complete description of the 2013 Plan and the 2023 Plan, please see “ Silexion Israel Share Incentive Plans ” below.

The Silexion Israel Plans provide for grants of options to purchase ordinary shares of Silexion Israel (following the Business Combination, Silexion), shares, restricted shares and RSUs.

As described above, during 2022, Silexion Israel granted option awards under the Silexion Israel Plans to Ilan Hadar and Dr.

Mitchell Shirvan, and during 2024, Silexion Israel granted RSUs to Ilan Hadar, Mirit Horenshtein Hadar, and Dr.

Mitchell Shirvan.

Immediately prior to the effective time of the merger of Merger Sub 1 with and into Silexion Israel pursuant to the Business Combination, all outstanding Silexion Israel options and Silexion Israel RSUs accelerated and became fully vested (and, in the case of RSUs, settled for underlying shares).

At the effective time of that merger, all Silexion Israel options outstanding immediately prior to the merger automatically and without any action on the part of any Silexion Israel option holder or beneficiary thereof, were assumed by Silexion, and each such Silexion Israel option was converted into an option to purchase Silexion ordinary shares (based on the equity exchange ratio for Silexion Israel under the Business Combination Agreement).

In addition, immediately prior to the completion of the Business Combination, Silexion adopted the 2024 Equity Incentive Plan (described below), which provides for the grant of equity-based incentive awards to its employees, directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on behalf of Silexion and to promote the success of Silexion’s business.

Outstanding Equity Awards at Fiscal Year-End

The following table provides information regarding equity awards held by Silexion’s named executive officers that were outstanding as of December 31, 2025.

The awards listed in this table were granted under the Silexion Plans, which are summarized above under “ — Narrative Disclosure to Summary Compensation Table — Silexion 2013 Equity Incentive Plan and Silexion 2023 Equity Incentive Plan .”

The awards listed in this table were granted under the Silexion Israel Plans, which are summarized above under “ - Narrative Disclosure to Summary Compensation Table - Silexion Israel 2013 Equity Incentive Plan and Silexion Israel 2023 Equity Incentive Plan ” and below under “ Silexion Israel Share Incentive Plans ”.

Option awards

5 unchanged sentences

Option expiration date

Chief Executive Officer (formerly Managing Director of Silexion

Chief Executive Officer (formerly Managing Director of Silexion Israel)

Mirit Horenshtein Hadar

Chief Financial Officer (formerly EVP Finance of Silexion

Chief Financial Officer (formerly EVP Finance of Silexion Israel)

Mitchell Shirvan

1 unchanged sentence

Director Compensation

The following table lists the fees earned or paid to each of our directors in respect of the year ended December 31, 2025:

Fees earned or paid in cash

6 unchanged sentences

See Summary Compensation Table above

Ilan Shiloah ( former director )

(1) Represents a consulting fee at a rate of $10,000 per month payable to Ilan Levin, as provided for under the Business Combination Agreement, as amended, for the four and one-half months following the Closing of the Business Combination through the end of 2024.

In the year ended December 31, 2024, other than the monthly consulting fees paid to Mr.

Levin following the Closing of the Business Combination, as reflected in the “Director Compensation” table, we did not pay any cash fees to, but we did grant equity awards, consisting of 22,070 RSUs that could be settled for New Silexion ordinary shares (such number of RSUs reflects the one-for-nine reverse share split of New Silexion), all of which became fully vested at the Closing, to each non-employee member of our board of directors for his or her service as a director.

New Silexion Executive Compensation

Following the Closing, we are developing an executive compensation program that is designed to align compensation with our business objectives and the creation of shareholder value, while enabling us to attract, retain, incentivize and reward individuals who contribute to the long-term success of New Silexion.

Decisions regarding the executive compensation program will be made by our compensation committee.

New Silexion Equity Compensation

It is anticipated that equity-based compensation will continue to be an important element of executive compensation following the consummation of the Business Combination in order to maintain a strong link between executive incentives and the creation of shareholder value.

Upon the consummation of the Business Combination, we granted 78,650 RSUs, in the aggregate, to directors of New Silexion and employees of New Silexion and its subsidiaries (of which 22,070 RSUs were granted to New Silexion directors) as a means of incentivizing them and aligning their interests with those of the shareholders of the Company.

We furthermore expect that the additional 63,953 New Silexion ordinary shares that will be available under the 2024 Equity Incentive Plan (as referenced below) following the consummation of the Business Combination will be an important element of the new compensation arrangements for New Silexion.

Silexion Share Incentive Plans

Represents a consulting fee at a rate of $10,000 per month payable to Ilan Levin, as provided for under the Business Combination Agreement, as amended.

Represents a consulting fee at a rate of $10,000 per month payable to Shlomo Noy, effective as of November 2025.

In December 2024, our compensation committee and Board approved an annual compensation package for our non-employee/non-affiliate directors (consisting of all directors other than our Chairman and Chief Executive Officer, Ilan Hadar, and our consultant, Ilan Levin), which was effective for the 2025 year.

That compensation package consisted of:

Annual cash compensation:

Annual equity compensation valued at $30,000, to be split 50%-50% between RSUs ($15,000 value) and options ($15,000 value)

Annual cash fee for Board committee members:

$1,500 per committee

Annual cash fee for Board committee chairpersons (in lieu of committee membership fees):

$3,000 per committee.

The amounts set forth for each director (other than Messrs.

Hadar and Levin) in the above Director Compensation table are based on our non-employee/non-affiliate director annual compensation package, as applied to the particular director based on his or her participation in Board committees.

Silexion Executive Compensation

Following the Closing, we have been developing an executive compensation program that is designed to align compensation with our business objectives and the creation of shareholder value, while enabling us to attract, retain, incentivize and reward individuals who contribute to the long-term success of Silexion.

Decisions regarding the executive compensation program are recommended by our compensation committee and approved by our Board.

Silexion Equity Compensation

It is anticipated that equity-based compensation will continue to be an important element of executive compensation as we proceed in the longer-term period following the consummation of the Business Combination, in order to maintain a strong link between executive incentives and the creation of shareholder value.

During the year ended December 31, 2025, we did not grant any new equity compensation to our executive officers, due to limitations on our available authorized share capital and the pressing need for us to utilize our available authorized share capital primarily for financing purposes, which enabled us to restore and maintain compliance with Nasdaq listing requirements related to shareholders’ equity.

In the previous year (2024), upon the consummation of the Business Combination, we granted 5,242 RSUs, in the aggregate, to directors of Silexion and employees of Silexion and its subsidiaries (of which 1,471 RSUs were granted to Silexion directors) as a means of incentivizing them and aligning their interests with those of the shareholders of the Company.

We have furthermore utilized the initial additional 156,333 ordinary shares that were added to the pool of shares for the 2024 Equity Incentive Plan (described below) pursuant to the automatic increase to that plan as of January 1, 2026 under the existing “evergreen” provision of that plan and granted fully-vested RSUs to our executive officers in February 2026.

We await the outcome of the proposed increase to the “evergreen” provision under the 2024 Equity Incentive Plan at our extraordinary general meeting that was scheduled for March 16, 2026, which was adjourned by one week.

If that increase is approved by our shareholders, the total automatic increase to the pool of shares under that plan will be by 594,900 ordinary shares for 2026 (which includes the 156,333 ordinary shares that were already added to the pool), and future automatic annual increases under that plan will yield a total number of reserved shares under all of our equity incentive plans equal to 10% of our issued and outstanding share capital on a fully diluted basis as of each January 1.

Our annual evergreen increases will be an important means to supply the equity compensation arrangements for our executive officers in 2026 and beyond.

Silexion Israel Share Incentive Plans

2013 Share Option Plan

Shares Reserved under the 2013 Share Option Plan.

The total number of authorized but unissued Silexion ordinary shares available for issuance under Silexion’s 2013 Share Option Plan (the “ 2013 Plan ”) is 33,828 (which number does not reflect the exchange ratio in the Business Combination or New Silexion’s one-for-nine reverse share split).

Upon the termination of the 2013 Plan, any unissued New Silexion ordinary shares available under the 2013 Plan ceased to be reserved for the purpose of the 2013 Plan, other than New Silexion ordinary shares underlying then-outstanding options under the 2013 Plan.

The total number of authorized but unissued ordinary shares available for issuance under the 2013 Share Option Plan (the “ 2013 Plan ”) (which we assumed from Silexion Israel as part of the Business Combination) is 1,579.

All of those ordinary shares are subject to outstanding grants.

Upon the termination of the 2013 Plan (which occurred prior to the Business Combination), any unissued ordinary shares that were then available under the 2013 Plan ceased to be reserved for purposes of the 2013 Plan, other than ordinary shares underlying outstanding options under the 2013 Plan, which remain subject to the terms of the plan.

Administration.

Our board of directors, or a duly authorized compensation committee of the board of directors, has the power to administer the 2013 Plan.

Subject to applicable laws and the relevant provisions of the 2013 Plan, any member of the designated committee is eligible to receive options under the 2013 Plan.

The committee has the authority, subject to applicable law and our articles of association, to interpret the terms of the 2013 Plan and any option agreements granted thereunder, designate participants in the 2013 Plan, determine and amend the terms of respective option agreements, including the exercise price of an option, the fair market value of the New Silexion ordinary shares, the time and vesting schedule applicable to the option, accelerate or amend the vesting schedule applicable to an option, prescribe the forms of option agreement for use under the 2013 Plan and take all other actions and make all other determinations necessary for the administration of the 2013 Plan.

The 2013 Plan provides for granting options under various tax regimes, including, without limitation, in compliance with Section 102 or Section 3(i) of the Israeli Tax Ordinance (the “ Ordinance ”), and for awards granted to Silexion’s United States employees or service providers, including those who are deemed to be residents of the United States for tax purposes, Section 422 of the U.S.

Our Board, or a duly authorized compensation committee of the Board, has the power to administer the 2013 Plan.

The committee has the authority, subject to applicable law and our Articles, to interpret the terms of the 2013 Plan and any option agreements entered into thereunder, determine and amend the terms of respective option agreements, including the exercise price of an option, the fair market value of the underlying ordinary shares, the time and vesting schedule applicable to the option, accelerate or amend the vesting schedule applicable to an option, and take all other actions and make all other determinations necessary for the administration of the 2013 Plan.

The 2013 Plan provides for granting options under various tax regimes, including, without limitation, in compliance with Section 102 or Section 3(i) of the Israeli Income Tax Ordinance (New Version), 5721-1961, as amended (the “ Ordinance ”), and for awards granted to Silexion Israel’s United States employees or service providers, including those who are deemed to be residents of the United States for tax purposes, Section 422 of the U.S.

Internal Revenue Code of 1986, as amended (the “ Code ”) and Section 409A of the Code.

All options granted pursuant to the 2013 Plan are evidenced by an option agreement, in a form approved, from time to time, by the committee in its sole discretion.

The option agreement sets forth the terms and conditions of the number of shares to which the option relates and the type of option granted thereunder, the purchase price per share and the vesting schedule to which such option shall become exercisable.

Unless otherwise determined by the committee or the board of directors and as stated in the option agreement, and subject to the conditions of the 2013 Plan, options become exercisable under the following schedule:

25% of the shares covered by the option on the first anniversary of the date on which such option was granted and 12.5% of the shares covered by the option at the end of each subsequent six-month period during the second, third and fourth years from the date of grant, with the committee and/or board of directors reserving the exclusive authority to accelerate the periods for exercising an option.

Each option shall expire 10 years from the date of the grant thereof, or five years with respect to an incentive stock option, unless a shorter term of expiration is otherwise designated by the committee.

The 2013 Plan provides for the grant of options (including incentive stock options and nonqualified stock options).

Options granted under the 2013 Plan to Silexion employees who are U.S.

All options granted pursuant to the 2013 Plan are evidenced by an option agreement, in a form that was previously approved.

The option agreement sets forth the terms and conditions and the number of shares to which the option relates and the type of option granted thereunder, the purchase price per underlying share and the vesting schedule by which such option shall become exercisable.

Unless otherwise determined by the committee or the Board and as stated in the option agreement, and subject to the conditions of the 2013 Plan, options become exercisable under the following schedule:

25% of the shares covered by the option on the first anniversary of the date on which such option was granted and 12.5% of the shares covered by the option at the end of each subsequent six-month period during the second, third and fourth years from the date of grant, with the committee and/or Board possessing the exclusive authority to accelerate the periods for exercising an option.

Each option shall expire 10 years from the date of the grant thereof, or five years with respect to an incentive stock option, unless a shorter term of expiration has been otherwise designated.

Grants to U.S.

The 2013 Plan provides for the grant of options in accordance with the Code, including incentive stock options and nonqualified stock options.

Options granted under the 2013 Plan to Silexion Israel employees who are U.S.

residents may qualify as “incentive stock options” within the meaning of Section 422 of the Code, or may be non-qualified stock options.

The exercise price of an option may not be less than the par value of the shares (if the shares bear a par value) for which such option is exercisable.

The exercise price of an option may not be less than the par value of the share for which such option is exercisable.

The exercise price of an Incentive Stock Option may not be less than 100% of the fair market value of the underlying share on the date of grant or such other amount as may be required pursuant to the Code, and in the case of Incentive Stock Options granted to ten percent (10%) shareholders, not less than 110%.

An option under the 2013 Plan may be exercised by providing us with a written notice of exercise and full payment of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the committee and the trustee and permitted by applicable law.

Transferability.

No option shall be assignable, transferable or given as collateral or any right with respect to them given to any third party whatsoever, and during the lifetime of the option-holder each and all of such option-holder’s rights to purchase New Silexion ordinary shares thereunder shall be exercisable only by the option-holder.

No option shall be assignable, transferable or given as collateral, nor may any right with respect to an option be given to any third party whatsoever, and during the lifetime of the option-holder each and all of such option-holder’s rights to purchase ordinary shares thereunder shall be exercisable only by the option-holder.

Termination of Employment.

An option may be exercised after the date of termination of option-holder’s service or employment with Silexion or any of its affiliates or termination of an affiliate’s status as such only with respect to the number of options already vested and unexpired at the time of such termination according to the vesting and expiration periods of the options set forth in the 2013 Plan, or under a different period prescribed by the committee or by the board of directors and specified in relevant option agreement, provided however, that (i) such termination is without cause, in which case the options shall be exercisable within not more than 90 days from the effective date of such termination, or (ii) such termination is the result of death or disability of the option-holder, in which case the options shall be exercisable within 12 months, and in the event of death, the option shall be exercisable by the option-holder’s estate, all in accordance the 2013 Plan.

If termination of employment or service is for cause, any outstanding unexercised option (whether vested or non-vested), will immediately expire and terminate, and the option-holder shall not have any right in connection to such outstanding options.

An option may be exercised after the date of termination of an option-holder’s service or employment with Silexion Israel or any of its affiliates or termination of an affiliate’s status as such only with respect to the number of options already vested and unexpired at the time of such termination according to the vesting and expiration periods of the options set forth in the 2013 Plan, or under a different period prescribed by the committee or by the Board and specified in the relevant option agreement, provided, however, that (i) such termination is without cause, in which case the options shall be exercisable within not more than 90 days from the effective date of such termination, or (ii) such termination is the result of death or disability of the option-holder, in which case the options shall be exercisable within 12 months, and in the event of death, the option shall be exercisable by the option-holder’s estate, all in accordance the 2013 Plan.

Voting Rights.

Option-holders shall not have any of the rights or privileges of shareholders of New Silexion in respect of any New Silexion ordinary shares purchasable upon the exercise of any part of an option unless and until, following exercise in accordance with the terms of the 2013 Plan and the option, registration of the option-holder as holder of such New Silexion ordinary shares in New Silexion’s register of members, but in case of options and New Silexion ordinary shares held by the trustee, subject to the provisions of the 2013 Plan.

With respect to all New Silexion ordinary shares (in contrast to options not exercised for New Silexion ordinary shares) issued upon the exercise of options purchased by an option holder, the option holder, as a shareholder of New Silexion shall be entitled to receive dividends in accordance with the quantity of such New Silexion ordinary shares and the amended and restated memorandum and articles of association of New Silexion, and subject to any applicable taxation on distribution of dividends.

Option-holders shall not have any of the rights or privileges of shareholders of Silexion in respect of any ordinary shares purchasable upon the exercise of any options unless and until, following exercise in accordance with the terms of the 2013 Plan and the options, registration of the option-holder as a holder of such ordinary shares in our register of shareholders is complete, but in case of options and underlying ordinary shares to be held by the trustee, subject to the provisions of the 2013 Plan.

With respect to all ordinary shares (as opposed to unexercised options) issued upon the exercise of options, the option holder, as a shareholder of Silexion shall be entitled to receive dividends in accordance with the quantity of such ordinary shares and the Articles, and subject to any applicable taxation on distribution of dividends.

Transactions.

If the outstanding shares of New Silexion shall at any time be changed or exchanged by declaration of a dividend, split, share subdivision, combination or exchange of shares, recapitalization, or any other like event of New Silexion, then in such event only and as often as the same shall occur, the number, class and kind of New Silexion ordinary shares (including New Silexion ordinary shares issuable pursuant to the 2013 Plan, in respect of which options have not yet been exercised) subject to the 2013 Plan or subject to any options granted thereunder, and the purchase prices of the options, shall be appropriately and equitably adjusted so as to maintain the proportionate number of New Silexion ordinary shares without changing the aggregate purchase price of the options.

In the event of a merger or consolidation of New Silexion or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on New Silexion, or change in the composition of the board of directors, or such other transaction or circumstances that the New Silexion Board determines to be a relevant transaction, the merger agreement will provide for one or more of the following, without the consent of the option-holder:

If the outstanding shares of Silexion shall at any time be changed or exchanged by declaration of a dividend, split, share subdivision, combination or exchange of shares, recapitalization, or any other like event, then in such event only and as often as the same shall occur, the number, class and kind of ordinary shares (including ordinary shares issuable pursuant to the 2013 Plan, in respect of which options have not yet been exercised) subject to the 2013 Plan or subject to any options granted thereunder, and the exercise price of the options, shall be appropriately and equitably adjusted so as to maintain the proportionate number of ordinary shares without changing the aggregate exercise price of the options.

In the event of a merger or consolidation of Silexion or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on Silexion, or change in the composition of the Board, or such other transaction or circumstances that the Board determines to be a relevant transaction, the merger agreement will provide for one or more of the following, without the consent of the option-holder:

(i) any outstanding option will be assumed or substituted by the successor corporation;

(ii) the cancellation of such options and a payment to the option-holder, as provided in the 2013 Plan;

and (iii) the full exercisability of the option and full vesting of the New Silexion ordinary shares subject to the option, followed by the cancellation of the option.

The foregoing description of the 2013 Plan is qualified in its entirety by the full text of the 2013 Plan, which is attached as Exhibit 10.9 to this Annual Report and is incorporated herein by reference.

(ii) the option will be cancelled and a payment will be made to the option-holder, as provided in the 2013 Plan;

or (iii) the option will be fully exercisable and the underlying ordinary shares will be issuable upon exercise, followed by the cancellation of the option.

The foregoing description of the 2013 Plan is qualified in its entirety by the full text of the 2013 Plan, which serves as Exhibit 10.9 to this Annual Report and is incorporated herein by reference.

2023 Equity Incentive Plan

The 2023 Equity Incentive (the “2023 Plan” ) was adopted by Silexion’s board of directors in 2023.

The purpose of the 2023 Plan is to provide equity-based incentive awards in order to link the compensation and benefits of the individuals and entities providing services to Silexion or its affiliates with the success of Silexion and long-term shareholder value.

The 2023 Plan enabled Silexion to grant options to purchase ordinary shares of Silexion (currently, following the Business Combination, New Silexion ordinary shares), restricted shares and restricted share units, all of which are referred to as “awards”.

Shares Available for Grants.

The total number of shares available for issuance under the 2023 Plan was determined from time to time by our board of directors, subject to certain adjustments as described in the 2023 Plan.

If any shares subject to awards under the 2023 Plan expires or otherwise terminates in accordance with the terms thereunder, such shares shall become available for future grants thereunder.

Administration.

our board of directors (currently, following the Business Combination, the board of directors of New Silexion), or a duly authorized committee of its board of directors (the “Administrator” ), is authorized to administer the 2023 Plan.

Under the 2023 Plan, the Administrator has the authority, subject to applicable law, to interpret the terms of the 2023 Plan and any award agreements or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including the number of awards granted, the exercise price of an award, the time and vesting schedule applicable to an award or the method of payment for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2023 Plan and take all other actions and make all other determinations necessary for the administration of the 2023 Plan.

The Administrator also has the authority to determine the circumstances under which awards may be settled, cancelled, forfeited, exchanged, or surrendered under and in accordance with the 2023 Plan of any or all awards or shares, and the authority to prescribe, amend and rescind rules and regulations relating to the 2023 Plan, including the form of award agreements and rules governing the grant of awards in jurisdictions in which Silexion or any affiliate operate, or to terminate the 2023 Plan at any time before the date of expiration of its ten-year term, provided that such termination shall not materially affect the rights of grantees, to whom awards have already been granted.

The 2023 Plan provides for granting awards under the Israeli tax regime, including compliance with Section 102 or Section 3(i) of the Ordinance.

All awards granted pursuant to the 2023 Plan are evidenced by an award letter, in a form approved, from time to time, by the administrator in its sole discretion.

The award letter sets forth the terms and conditions of the award, including the type of award, number of shares subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if applicable.

Unless otherwise determined by the Administrator and stated in the award letter, and subject to the conditions of the 2023 Plan, awards vest and become exercisable under the following schedule:

25% of the shares covered by the award on the first anniversary of the vesting commencement date determined by the Administrator (and in the absence of such determination, the date on which such award was granted) and the remaining 75% of the award shall vest (equally) on a quarterly basis, over 12 quarters as of the commencement date’s first annual anniversary;

provided that the grantee remains continuously as an employee or provides services to Silexion throughout such vesting dates.

Each award will expire ten years from the date of the grant thereof, unless a shorter term of expiration is otherwise designated by the Administrator.

The 2023 Plan provides for the grant of options, shares, restricted shares, RSUs, and other share-based awards.

An award under the 2023 Plan may be exercised by providing Silexion (currently, New Silexion) a written notice of exercise and full payment of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the Administrator and permitted by applicable law.

The 2023 Plan allows for a net exercise of awards (as may be included in the award letter or otherwise approved by the Administrator).

An award may not be exercised for a fraction of a share.

Transferability.

No person other than the grantee shall have any right with respect to any award granted under the 2023 Plan.

No transfer of any right to any award or its underlying shares, by will or by the laws of descent, shall effectively bind Silexion (currently, New Silexion) unless and until furnished with the certain signed and notarized documents, as described in the 2023 Plan.

Termination of Engagement.

In the event of termination of a grantee’s employment or service with Silexion or any of its affiliates, for any reason other than death, retirement, disability or cause, any vested and unexercised awards held by such grantee as of the date of termination may be exercised within 90-days after such date of termination, unless otherwise determined by the Administrator, but in no event later than the date of expiration of the award as set forth in the award letter.

After such 90-days period, all such unexercised awards will terminate and the shares covered by such awards become available for issuance under the 2023 Plan.

In the event of termination of a grantee’s employment or service with Silexion or any of its affiliates due to such grantee’s death, retirement or permanent disability, any vested but unexercised awards shall be exercisable (a) in the case of death, by such grantee’s estate, personal representative or beneficiary, or (b) in the case of retirement or Disability, by such grantee or his/her personal representative (as the case may be), until the earlier of (i) 180 days following the date of termination for any such reason;

or (ii) the date of expiration of each such as set forth in the award letter.

All such grantee’s other awards shall expire upon the date of such termination.

Notwithstanding any of the foregoing, if a grantee’s employment or services with Silexion or any of its affiliates is terminated for “cause” (as defined in the 2023 Plan), all outstanding awards held by such grantee (whether vested or unvested) shall expire.

With respect to any and all shares owned by such grantee pursuant to the exercise of any and all awards granted under the 2023 Plan, the board of directors of Silexion may convert such shares into deferred shares of Silexion.

Voting Rights.

Until consummation of our initial public offering (or equivalent transaction, such as the Business Combination), shares underlying awards held by grantees or the trustee, as applicable, were to be voted by an irrevocable proxy assigned to a person appointed by the board of directors.

Grantees holding shares issuable or issued upon exercise of awards granted under the 2023 Plan will, as a shareholder of New Silexion, be entitled to receive dividends and other distributions with respect to the underlying shares.

Transactions.

In the event of any division or subdivision of Silexion’s (currently, New Silexion’s) issued and outstanding share capital, any distribution of bonus shares (share split or subdivision), consolidation or combination of the share capital (reverse share split), reclassification of the shares or any similar recapitalization event, as well as any reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of the shares or other securities of Silexion (currently, New Silexion), or any other change in Silexion’s (currently, New Silexion’s) corporate structure affecting the shares, the administrator may, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the 2023 Plan, adjust (A) the number and class of shares that may be issued under the 2023 Plan;

(B) the number, class, and exercise price of underlying shares for each outstanding award;

(C) any other term of the awards that in the administrator’s opinion should be adjusted (including those concerning the vesting, exercisability and term of outstanding awards);

provided, that no adjustment shall be made by reason of the distribution of subscription rights (rights offering) on outstanding shares.

Upon any such adjustment, references herein to shares and underlying shares shall be construed to mean those shares of Silexion (currently, New Silexion) subject to the 2023 Plan as determined by the Administrator following such adjustment.

Any fractional shares resulting from such adjustment shall be rounded down to the nearest whole number of share and Silexion (currently, New Silexion) shall have no obligation to make any cash or other payment with respect to such fractional shares.

The adjustments shall be made by the Administrator.

If the applicable awards or underlying shares are deposited with a trustee, all of the shares formed by such adjustments shall also be deposited with the trustee on the same terms as such awards or underlying shares.

In the event of a merger, reorganization or consolidation of Silexion (currently, New Silexion) with or into another incorporated entity, or its acquisition by another incorporated entity by means of any transaction or series of related transactions, except any such merger, reorganization or consolidation in which the issued shares of Silexion (currently, New Silexion) as of immediately prior to such transaction continue to represent, or are converted into or exchanged for shares that represent, immediately following such merger, reorganization, or consolidation, at least a majority, by voting power, of the outstanding shares of the surviving or acquiring incorporated entity;

or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on our company, or change in the composition of the board of directors, or liquidation or dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction, then without the consent of the grantee, (i) unless otherwise determined by the Administrator, any outstanding award will be assumed or substituted by such successor corporation or substituted by our company or by any affiliate of the successor corporation, as determined by the Administrator, and (ii) regardless of whether or not the award is assumed or substituted, the Administrator may:

entitle a grantee to exercise an award, or to otherwise provide for the acceleration of such award’s vesting schedule, as to all or part of its underlying shares, including with respect to awards that would not otherwise be exercisable or vested, under such terms and conditions as the Administrator shall determine, including the cancellation of all unexercised awards upon or immediately prior to the closing of a transaction or as of such other date (the “Cut-Off Date” ), and/or the termination of all awards (whether vested but un-exercised or un-vested) as of the relevant Cut-Off Date, as of which they shall no longer be exercisable by the applicable grantees;

provide for the cancellation of outstanding awards at or immediately prior to the closing of a transaction, and payment to the applicable grantee of a consideration determined by the Administrator to be fair in the circumstances (whether in shares, cash, other securities, property, or any combination thereof), taking into account the value of each underlying share of any such award’s vested portion as reflected by the terms of such transaction, and the exercise price of each such underlying share, and subject to such terms and conditions as determined by the Administrator.

The Administrator shall have full authority to select the method for determining the payment to the grantees, as well as to set such payment to zero, with respect to underlying shares valued at less than their exercise price or to those of awards that would not otherwise be exercisable or vested, or to determine that such payment be made only in excess of the exercise price.

The foregoing description of the 2023 Plan is qualified in its entirety by the full text of the 2023 Plan, which is attached as Exhibit 10.8 to this Annual Report and is incorporated herein by reference.

New Silexion Share Incentive Plans

Silexion Israel’s board of directors adopted a 2023 Equity Incentive Plan (the “2023 Plan” ) in 2023.

The purpose of the 2023 Plan was to provide equity-based incentive awards in order to link the compensation and benefits of the individuals and entities providing services to Silexion Israel or its affiliates with the success of Silexion Israel and long-term shareholder value.

There are no currently outstanding awards under the 2023 Plan.

Because Silexion adopted a new equity incentive plan, the 2024 Equity Incentive Plan (as described below) prior the Closing of the Business Combination, we do not intend to make any further grants under the 2023 Plan.

Silexion Share Incentive Plans

2024 Equity Incentive Plan

Pursuant to written resolutions adopted by our board of directors and shareholders prior to the Closing of the Business Combination, we have approved and adopted the 2024 Equity Incentive Plan (the “ 2024 Plan ”), which became effective immediately upon the Closing.

Upon the Closing, a total of 63,953 New Silexion ordinary shares were reserved for issuance under the terms of the 2024 Plan, which, together with New Silexion ordinary shares allocated for issuance under the existing 2013 Plan and 2023 Plan, equaled 10% of the total number of New Silexion ordinary shares on a fully diluted basis immediately following the Closing.

A summary of the other material terms of the 2024 Incentive Plan is provided below:

Pursuant to written resolutions adopted by our Board and shareholders prior to the Closing of the Business Combination, we have approved and adopted the 2024 Equity Incentive Plan (the “ 2024 Plan ”), which became effective immediately upon the Closing.

Upon the Closing, a total of 4,264 ordinary shares were reserved for issuance under the terms of the 2024 Plan, which, together with Silexion ordinary shares allocated for issuance under the existing 2013 Plan and 2023 Plan, equaled 10% of the total number of our issued and outstanding ordinary shares on a fully diluted basis immediately following the Closing.

A summary of the material terms of the 2024 Plan is provided below:

Administration

The compensation committee of our board of directors is the administrator of the 2024 Plan.

The compensation committee of our Board is the administrator of the 2024 Plan.

Except as provided otherwise under the 2024 Plan, the administrator has plenary authority to grant awards pursuant to the terms of the 2024 Plan to eligible individuals, determine the types of awards and the number of shares covered by the awards, establish the terms and conditions for awards and take all other actions necessary or desirable to carry out the purpose and intent of the 2024 Plan.

5 unchanged sentences

Share Pool Under the 2024 Plan

The initial number of New Silexion ordinary shares allocated to the 2024 Plan was 63,953.

The number of New Silexion ordinary shares available under the 2024 Plan (the “ Share Pool ”) is subject to the following annual allocations and adjustments:

The Share Pool will be increased automatically on January 1 of each calendar year, beginning on January 1, 2025 and for each of the subsequent nine calendar years, through (and including) January 1, 2034, in an amount equal to the lesser of (i) 5% of the number of New Silexion ordinary shares issued and outstanding as of that January 1 date, or (ii) an amount determined by our board of directors prior to such date.

Pursuant to that annual increase, the Share Pool increased by 92,457 ordinary shares on January 1, 2025.

The following additional rules apply to the number of New Silexion ordinary shares available under the Share Pool on an ongoing basis:

The initial number of Silexion ordinary shares allocated to the 2024 Plan (the “ Share Pool ”) was 4,264.

At our 2025 annual general meeting held in July 2025, our shareholders approved a special one-time increase to the number of ordinary shares available under the 2024 Plan by 84,791 ordinary shares.

The 2024 Plan furthermore provides for an automatic annual allocation/adjustment to the Share Pool (the “ evergreen provision ”) whereby the number of shares reserved for issuance under the Share Pool increases on January 1 of each year.

As initially provided under the 2024 Plan, the evergreen provision increased the Share Pool by the lesser of (i) such number of shares as equaled 5% of our issued and outstanding shares as of January 1 of each year, or (ii) an amount determined by our board of directors prior to such date.

As implemented on January 1, 2025, 6,164 ordinary shares became available under the 2024 Plan pursuant to the original evergreen provision.

As implemented once again on January 1, 2026, 156,333 ordinary shares became available under that same evergreen provision.

As has been proposed for amendment by our compensation committee and Board, subject to the approval of our shareholders (the last of whom may provide their approval to the amendment at our extraordinary general meeting being held in March 2026), the evergreen provision of the 2024 Plan will provide instead as follows:

On January 1 of each calendar year, through (and including) January 1, 2034, the Share Pool under the 2024 Plan will increase by an amount equal to the lesser of (i) such number of ordinary shares as yields a total pool of shares reserved under the 2024 Plan and our prior equity incentive plans equal to 10% of the number of ordinary shares issued and outstanding, on a fully-diluted basis, on such January 1st date, or (ii) an amount determined by our Board prior to such date.

Pursuant to the proposed amended evergreen provision, the Share Pool under the 2024 Plan would increase by 594,900 ordinary shares (which includes the 156,333 ordinary shares under the existing evergreen provision) effective as of January 1, 2026, and would stand at 681,473 ordinary shares.

The following additional rules apply to the number of ordinary shares available under the Share Pool on an ongoing basis:

The Share Pool will be reduced by one share for each share made subject to an award granted under the 2024 Plan;

1 unchanged sentence

The Share Pool will be increased by the number of shares that are forfeited back or surrendered for no consideration to us after issuance due to a failure to meet an award contingency or condition with respect to any award or portion of an award granted under the 2024 Plan;

The Share Pool shall be increased, on the exercise date, by the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price of any award granted under the 2024 Plan;

The Share Pool shall be increased, on the relevant date, by the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding obligation that arises in connection with any award granted under the 2024 Plan.

In the event of a merger, consolidation, share rights offering, statutory share exchange or similar event affecting the Company or a share dividend, share split, reverse share split, separation, spinoff, reorganization, extraordinary dividend of cash or other property, share combination or subdivision, or recapitalization or similar event affecting the capital structure of the Company, our board of directors will make equitable and appropriate substitutions or proportionate adjustments to the Share Pool to reflect the transaction or event.

The Share Pool will be increased, on the exercise date, by the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of the exercise price of any award granted under the 2024 Plan;

The Share Pool will be increased, on the relevant date, by the number of shares withheld by or surrendered (either actually or through attestation) to the Company in payment of any tax withholding obligation that arises in connection with any award granted under the 2024 Plan.

In the event of a merger, consolidation, share rights offering, statutory share exchange or similar event affecting the Company or a share dividend, share split, reverse share split, separation, spinoff, reorganization, extraordinary dividend of cash or other property, share combination or subdivision, or recapitalization or similar event affecting the capital structure of the Company, our Board will make equitable and appropriate substitutions or proportionate adjustments to the Share Pool to reflect the transaction or event.

Similar adjustments will be made to the award limitations described below and to the terms of outstanding awards.

ISO Award Limit

The maximum number of New Silexion ordinary shares that may be issued in connection with awards granted under the 2024 Plan that are intended to qualify as incentive stock options under Section 422 of the Code is 63,953.

The maximum number of Silexion ordinary shares that may be issued in connection with awards granted under the 2024 Plan that are intended to qualify as incentive stock options under Section 422 of the Code is 95,218.

Types of Awards

The 2024 Plan enables the grant of share awards, performance shares, restricted share units, cash-based performance units, other share-based awards, share options, share appreciation rights, and share unit awards, each of which may be granted separately or in tandem with other awards.

The 2024 Plan enables the grant of share awards, performance shares, restricted share units (RSUs), cash-based performance units, other share-based awards, share options, share appreciation rights, and share unit awards, each of which may be granted separately or in tandem with other awards.

The administrator may establish sub-plans under the 2024 Plan under which awards that qualify for preferred tax treatment for recipients in jurisdictions outside the U.S.

may be granted.

We have adopted a sub-plan for Israeli participants, which provides for granting awards in compliance with Section 102 (“ Section 102 ”) and Section 3(i) of the Israeli Income Tax Ordinance (New Version), 5721-1961, as amended (the “ ITO ”).

We have adopted a sub-plan for Israeli participants, which provides for granting awards in compliance with Section 102 (“ Section 102 ”) and Section 3(i) of the Ordinance.

Section 102 allows employees, directors and officers who are not controlling shareholders and who are considered Israeli residents for tax purposes to receive favorable tax treatment for compensation in the form of shares, options or certain other types of equity awards, subject to certain terms and conditions.

Our non-employee service providers and controlling shareholders who are considered Israeli residents for tax purposes may be granted awards under Section 3(i) of the ITO, which do not provide for similar tax benefits as Section 102.

Our non-employee service providers and controlling shareholders who are considered Israeli residents for tax purposes may be granted awards under Section 3(i) of the Ordinance, which do not provide for similar tax benefits as Section 102.

Out of the three tax tracks that are available under Section 102 ((i) the “ordinary income track” with a trustee, (ii) the “capital gains track” with a trustee and (iii) grants without a trustee and without a trust period), we have elected the “capital gain track” for grants to eligible Israeli grantees as provided above, which may allow favorable tax treatment for such grantees.

19 unchanged sentences

Amendment and Termination

Our board of directors or the compensation committee may terminate, amend or modify the 2024 Plan or any portion of it at any time;

Our Board or the compensation committee may terminate, amend or modify the 2024 Plan or any portion of it at any time;

provided, that, (i) if required to comply with Cayman Islands law and any other applicable laws or marketplace or listing rules of a securities market or securities exchange (other than any requirement from which the Company may opt out based on any available home country exemption), the Company shall obtain shareholder approval of any 2024 Plan amendment in such a manner and to such a degree as required, and (ii) no such termination or amendment may materially impair the rights of a participant with respect to a previously granted award (other than as required to comply with applicable law or the rules of any securities exchange or market on which the shares are listed or to prevent adverse tax or accounting consequences to the Company or the participant) without such participant’s consent.

1 unchanged sentence

After that time, no further grants may be made under the 2024 Plan, but any then-outstanding grants will remain subject to the terms of the plan.

The foregoing description of the 2024 Incentive Plan is qualified in its entirety by the full text of the 2024 Incentive Plan, which is attached as Exhibit 10.7 to this Annual Report and is incorporated herein by reference.

The foregoing description of the 2024 Incentive Plan is qualified in its entirety by the full text of the 2024 Incentive Plan, which serves as Exhibit 10.5 to this Annual Report and is incorporated herein by reference.

Compensation Committee Interlocks and Insider Participation;

Compensation Committee Report

New Silexion is both an emerging growth company and a smaller reporting company and therefore need not provide the disclosure concerning “ Compensation Committee Interlocks and Insider Participation ” otherwise required under Item 407(e)(4) of Regulation S-K promulgated by the SEC, nor the report of its compensation committee otherwise required under Item 407(e)(5) of Regulation S-K.

Silexion is both an emerging growth company and a smaller reporting company and therefore need not provide the disclosure concerning “ Compensation Committee Interlocks and Insider Participation ” otherwise required under Item 407(e)(4) of Regulation S-K promulgated by the SEC, nor the report of its compensation committee otherwise required under Item 407(e)(5) of Regulation S-K.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

4 unchanged sentences

all our officers and directors as a group.

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days.

In computing the number of ordinary shares beneficially owned by a person and the percentage ownership, we include, as outstanding, those ordinary shares that are subject to warrants held by that person that are currently exercisable or exercisable within 60 days of March 1, 2025.

We do not deem those shares to be outstanding, however, for the purpose of computing the percentage ownership of any other person.

Unless otherwise indicated, we believe that all persons and entities named in the table below have sole voting and investment power with respect to all New Silexion ordinary shares beneficially owned by them.

The percentage ownership of New Silexion ordinary shares is based on 8,414,615 New Silexion ordinary shares outstanding as of March 1, 2025.

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security such as our ordinary shares if he, she or it possesses sole or shared voting or investment power over those ordinary shares, including based on the right to acquire those ordinary shares due to exercise of an option or warrant, or due to the settlement of an RSU, that may be currently exercised or settled (as of March 1, 2026), or that may be exercised or settled (as applicable) for an underlying ordinary share within 60 days following March 1, 2026.

In computing the number of ordinary shares beneficially owned by a person or entity and his/her or its percentage ownership, we include, as outstanding, those ordinary shares that are subject to options, warrants or RSUs held by that person or entity that may be currently exercised or settled (as of March 1, 2026), or that may be exercised or settled (as applicable) within 60 days of March 1, 2026.

We do not, however, deem those underlying shares to be outstanding for the purpose of computing the percentage ownership of any other person or entity.

Unless otherwise indicated, we believe that all persons and entities named in the table below have sole voting and investment power with respect to all ordinary shares beneficially owned by them.

The percentage ownership of ordinary shares is based on 3,330,785 ordinary shares outstanding as of March 1, 2026.

Name and Address of Beneficial Owner (1)

3 unchanged sentences

Ordinary Shares

Directors and Executive Officers of New Silexion:

Directors and Executive Officers of Silexion:

Ilan Levin (5)

5 unchanged sentences

Five Percent Holders:

Hudson Bay Master Fund (9)

Entities affiliated with Anson Advisors Inc and Anson Funds Management LP (10)

CVI Investments, Inc.

Lind Global Fund III LP (13)

Entities affiliated with Intracoastal Capital LLC (14)

Moringa Sponsor, LP and related persons (5)

Hudson Bay Master Fund Ltd.

Orca Capital AG (18)

Lincoln Alternative Strategies LLC (19)

Cedar Holdings Mgmt LLC

Alto Opportunity Master Fund, SPC—Segregated Master Portfolio B

Less than 1%.

Unless otherwise noted, the business address of each beneficial owner listed in the above table is c/o Silexion Therapeutics Corp, 12 Abba Hillel Road, Ramat Gan, Israel 5250606.

Includes 14,339 New Silexion ordinary shares issuable upon exercise of options, at an exercise price of $60.51 per share, all of which are vested and currently exercisable.

The shares reported in this row are held of record by the Sponsor, Moringa Sponsor, LP, and/or by the PIPE Investor, Greenstar, L.P., each a Cayman Islands exempted limited partnership, as described in footnote (4) below.

Includes 956 ordinary shares issuable upon exercise of options, at an exercise price of $907.71 per share, all of which are vested and currently exercisable.

Includes 935 ordinary shares issuable upon exercise of options, at an exercise price of $18.90 per share, all of which are vested and currently exercisable.

Based on a Schedule 13D/A filed with the SEC on September 23, 2025.

The shares reported in this row are held of record by the Moringa sponsor, Moringa Sponsor, LP and/or by Greenstar, L.P., each a Cayman Islands exempted limited partnership.

Moringa Partners Ltd., an Israeli company that is wholly-owned by Mr.

Ilan Levin, serves as the sole general partner of each of the Sponsor and the PIPE Investor.

Levin, a director of New Silexion, is the sole director of that general partner.

Ilan Levin, serves as the sole general partner of each of the Moringa sponsor and Greenstar, L.P.

Levin, a director of Silexion, is the sole director of that general partner.

As a result of his ownership of that general partner, Mr.

Levin possesses sole voting and investment authority with respect to the shares indirectly held by the Sponsor and the PIPE Investor.

The limited partnership interests of the Sponsor and the PIPE Investor are held by various individuals and entities, including Mr.

Levin disclaims beneficial ownership of the securities held by the Sponsor and the PIPE Investor other than to the extent of his direct or indirect pecuniary interest in such securities.

The address of each of the entities beneficially owning the shares that are reported in this row is c/o Moringa Acquisition Corp, 250 Park Avenue, 7 th floor, New York, NY 10177.

Consists of the total of:

(i) 148,592 New Silexion ordinary shares issued to the Sponsor as Sponsor Investment Shares (as defined under the Business Combination Agreement);

(ii) 39,206 New Silexion ordinary shares issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 352,857 Moringa private shares held by it;

(iii) 19,603 New Silexion ordinary shares underlying New Silexion warrants issued to the Sponsor upon the Closing of the Business Combination due to the conversion, on a one-for-one basis, of the 176,429 Moringa private warrants held by the Sponsor (which New Silexion warrants will be exercisable beginning 30 days after the Closing Date);

and (iv) 22,223 New Silexion ordinary shares issued to Greenstar, L.P., the PIPE Investor, as PIPE Shares in respect of the PIPE Financing.

The foregoing beneficial ownership of New Silexion ordinary shares by the Sponsor does not include any Note Shares that may be issued to the Sponsor following the Closing upon conversion of amounts owed by New Silexion to the Sponsor under the A&R Sponsor Promissory Note, as the potential number of Note Shares, and the timing of issuance of Note Shares, cannot be determined in advance.

The shares reported in this row consist entirely of New Silexion ordinary shares held of record by Guangzhou Sino-Israel Biotech Fund (“ GIBF ”), with respect to which Mr.

Levin possesses sole voting and investment authority with respect to the shares directly held by the Moringa sponsor and Greenstar, L.P.

The limited partnership interests of the Moringa sponsor and Greenstar, L.P.

are held by various individuals and entities, including Mr.

Levin disclaims beneficial ownership of the securities held by the Moringa sponsor and Greenstar, L.P., other than to the extent of his direct or indirect pecuniary interest in such securities.

The address of each of the persons and entities beneficially owning the shares that are reported in this row is c/o Moringa Acquisition Corp, 250 Park Avenue, 7th floor, New York, NY 10177.

Consists of (i) 6,970 ordinary shares, (ii) 372 ordinary shares underlying warrants, and (iii) 450,000 ordinary shares issued on September 15, 2025 upon conversion of an aggregate of $1.8 million of the outstanding amount under the Moringa sponsor promissory note, all of which are held by Moringa Sponsor, LP, and (iv) 1,482 ordinary shares held by Greenstar, L.P.

The shares reported in this row consist entirely of ordinary shares held of record by Guangzhou Sino-Israel Biotech Fund (“ GIBF ”), with respect to which Mr.

Lushi possesses shared voting and investment authority as a result of his serving as a Managing Partner and CEO of GIBF.

Includes 203,971 New Silexion ordinary shares issued to GIBF at the Closing in respect of its transfer of its noncontrolling interest in our Chinese subsidiary, Silenseed (China) Ltd., to New Silexion pursuant to the Chinese Subsidiary Transfer.

The shares reported in this row consist entirely of New Silexion ordinary shares held of record by GIBF, with respect to which Mr.

Includes 1,872 ordinary shares issuable upon exercise of options held by GIBF, at an exercise price of $18.90 per share, all of which are vested and currently exercisable.

The shares reported in this row consist entirely of ordinary shares held of record by GIBF, with respect to which Dr.

Noy possesses shared voting and investment authority as a result of his serving as Chief Medical Officer of GIBF.

Includes 7,170 New Silexion ordinary shares issuable upon exercise of options, at an exercise price of $60.51 per share, all of which are vested and currently exercisable.

Represents 740,741 ordinary shares issuable upon exercise of warrants issued in connection with the induced warrant exercise transaction in January 2025.

Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities.

Includes 780 ordinary shares issuable upon exercise of options, at an exercise price of $18.90 per share, all of which are vested and currently exercisable.

Includes 478 ordinary shares issuable upon exercise of options, at an exercise price of $907.71 per share, all of which are vested and currently exercisable.

The number of ordinary shares reported in this row for all executive officers and directors as a group includes (i) 5,956 shares underlying options granted to the Company’s non-employee directors in February 2025, as those options have fully vested as of March 1, 2026, as well as (ii) 372 ordinary shares underlying warrants that are fully exercisable as of March 1, 2026.

Based on a Schedule 13G/A filed by Lind Global Fund III LP with the SEC on November 14, 2025.

The ordinary shares reported in this row consist of (i) 106,250 ordinary shares underlying Series A-1 Warrants and (ii) 106,250 ordinary shares underlying Series A-2 Warrants.

None of these warrants may be exercised if, following such exercise, the beneficial ownership of Lind Global Fund III LP would exceed 9.9%.

Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, and Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.

The address of each of these entities is 444 Madison Avenue, Floor 41, New York, NY 10022.

Based on a Schedule 13G/A filed with the SEC on February 13, 2026.

The ordinary shares reported in this row are beneficially owned by Intracoastal Capital LLC, Mitchell P.

Kopin and Daniel B.

The ordinary shares beneficially owned consist entirely of shares underlying warrants.

Kopin and Mr.

Asher, as the controlling persons of Intracoastal Capital LLC, may be deemed to have shared voting and dispositive power with respect to these securities.

The principal business office of Mr.

Kopin and Intracoastal Capital LLC is 245 Palm Trail, Delray Beach, Florida 33483, and the principal business office of Mr.

Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.

Due to blocker provisions in the warrants under which the ordinary shares reported in this row may be issued, the maximum number of ordinary shares that may be actually held by the holders of the warrants upon exercise of those warrants may not exceed 9.99% of our issued and outstanding ordinary shares.

Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over the securities reported in this row.

Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP.

Each of Hudson Bay Master Fund Ltd.

and Sander Gerber disclaims beneficial ownership over these securities.

Represents (i) 577,778 ordinary shares issuable upon exercise of warrants issued in connection with the induced warrant exercise transaction in January 2025 that are held by Anson Investments Master Fund LP (“ AIMF ”) and (ii) 162,963 ordinary shares issuable upon exercise of warrants issued in connection with that induced warrant exercise transaction held by Anson East Master Fund LP (“ AEMF ”).

Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of AIMF and AEMF, hold voting and dispositive power over the ordinary shares held by each of AIMF and AEMF.

Tony Moore is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP.

Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc.

Kassam and Mr.

Nathoo each disclaim beneficial ownership of these ordinary shares except to the extent of their pecuniary interest therein.

The principal business address of each of AIMF and AEMF is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

Represents (i) 463,741 ordinary shares issuable upon exercise of warrant issued in our January 2025 financing, (ii) 277,000 ordinary shares issuable upon exercise of warrants issued in connection with the induced warrant exercise transaction in January 2025 and (iii) 25 ordinary shares issuable upon the exercise of warrants issued by Moringa that the Company assumed in connection with the Business Combination.

Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc.

(“ CVI ”), has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares.

Martin Kobinger, in his capacity as President of Heights Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI.

Kobinger disclaims any such beneficial ownership of the shares.

The ordinary shares reported in this row consist of 205,016 ordinary shares beneficially owned by Hudson Bay Master Fund Ltd., constituted by 106,250 ordinary shares issuable upon exercise of warrants issued in our September 2025 public offering and 98,766 ordinary shares issuable upon exercise of warrants issued in connection with our July/August 2025 warrant exercise inducement transaction.

The ordinary shares reported in this row are beneficially owned by 3i, LP.

3i Management LLC is the general partner of 3i, LP, and Maier Joshua Tarlow is the manager of 3i Management LLC.

Tarlow exercises sole voting and investment discretion over securities beneficially owned directly or indirectly by 3i, LP and 3i Management LLC.

The business address of each of the aforementioned parties is 2 Wooster Street, 2nd Floor, New York, NY 10013.

The ordinary shares reported in this row consist of 262,500 ordinary shares issuable upon exercise of warrants issued in our September 2025 public offering and 20,000 ordinary shares issuable upon exercise of warrants issued in connection with our July/August 2025 warrant exercise inducement transaction.

Based on Amendment No.

1 to a Schedule 13G filed with the SEC on September 15, 2025.

Represents 267,434 ordinary shares beneficially owned by Orca Capital AG, consisting of 4,934 ordinary shares issuable upon exercise of warrants issued in connection with our July/August 2025 warrant exercise inducement transaction and 262,500 ordinary shares underlying warrants acquired in our September 2025 public offering.

Due to blocker provisions in the warrants held by these persons, the maximum number of ordinary shares that may be actually held by these persons upon exercise of those warrants may not exceed 4.99% of our issued and outstanding ordinary shares.

Roman Grodon, Thomas Koenig, and Beate Ruhle‑Burkhardt have shared voting control and investment discretion over these securities.

The principal business address of Orca Capital AG is Sperl‑Ring 2, 85276 Hettenshausen, Germany.

The 269,168 ordinary shares reported in this row are beneficially owned by Lincoln Alternative Strategies LLC and consist of 6,668 ordinary shares issuable upon exercise of warrants issued in connection with our July/August 2025 warrant exercise inducement transaction and 262,500 ordinary shares underlying warrants acquired in our September 2025 public offering.

Stephen Temes, the control person of Lincoln Alternative Strategies LLC, has voting and investment control of these shares.

The registered address of Lincoln Alternative Strategies LLC is c/o 901 Pennsylvania Ave.

#3‑496, Miami Beach, FL 33139.

The ordinary shares reported in this row consist entirely of ordinary shares issuable upon exercise of warrants issued in our September 2025 public offering, all of which are currently exercisable.

Securities Authorized for Issuance Under Equity Compensation Plans

1 unchanged sentence

Plan category

Number of ordinary shares to be issued upon exercise of outstanding options

Number of ordinary shares to be issued upon exercise of outstanding options and RSUs

Weighted-average exercise price of outstanding options

6 unchanged sentences

Silexion Therapeutics Corp 2024 Equity Incentive Plan

(1) Effective as of January 1, 2026, the pool of ordinary shares available for future issuance under the 2024 Plan stood at 95,219 ordinary shares, and was automatically increased by an additional 156,333 ordinary shares, thereby increasing the total number of ordinary shares available for future issuance under the 2024 Plan to 251,552, and under all of our equity incentive plans, in the aggregate, to 253,131 ordinary shares.

Under Proposal 2 to be presented at an extraordinary general meeting of our company that was scheduled to take place on March 16, 2025, which meeting was adjourned to March 23, 2026, the “evergreen” provision under the 2024 Plan would add such number of ordinary shares as would result in a total pool of ordinary shares under all equity incentive plans equal to 10% of our issued and outstanding shares on a fully diluted basis—which would instead add 594,900 ordinary shares under the 2024 Plan effective as of January 1, 2026 (inclusive of the 156,333 ordinary shares added under the existing evergreen provision).

All together, the total number of shares reserved for issuance under our equity incentive plans after the January 1, 2026 increase would be 253,131 under the current, 5% evergreen provision or 691,698 under the proposed larger evergreen provision.

Potential Change in Control Transactions

2 unchanged sentences

Other than the compensation arrangements for our directors and executive officers, which are described above in “Item 11.

Executive Compensation”, below is a description of transactions since our formation on April 2, 2024 to which we have been a party, in which:

Executive Compensation”, below is a description of transactions since January 1, 2025, or currently proposed transactions, to which we have been a party, in which:

the amounts involved exceeded or will exceed $120,000;

2 unchanged sentences

Arrangements with Executive Officers

Ilan Hadar serves as our Chief Executive Officer and Chairman of the our Board.

Hadar’s employment agreement with us, as to be amended in the period following the Closing of the Business Combination, subject to corporate approvals, will provide for him to receive an annual base salary of $357,820 (based on the average exchange rate for 2023, as published by the Bank of Israel), customary disbursements toward his providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

During 2022, Silexion granted Mr.

Hadar 14,339 options to purchase New Silexion ordinary shares, vesting over a period of 48 months, provided that Mr.

Hadar remains engaged by us (or a Silexion affiliate) at the end of each vesting period and subject to the Silexion Plan.

Upon completion of the Business Combination, the vesting of all such options is expected to accelerate, such that all unvested options shall become fully vested at that time.

Mirit Horenshtein Hadar, our Executive VP of Finance, Chief Financial Officer and Secretary, is Mr.

Ilan Hadar serves as our Chief Executive Officer and Chairman of the Board.

Hadar’s employment agreement, as amended, with our wholly-owned subsidiary Silexion Israel provides for him to receive a gross monthly salary of NIS 110,000, which amounts to an annual base salary of $382,398 (based on the average exchange rate for 2025, as published by the Bank of Israel), customary disbursements toward his providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

Mirit Horenshtein Hadar, our Chief Financial Officer and Secretary, is Mr.

Hadar’s spouse.

Horenshtein Hadar’s employment agreement with us provides for her to receive an annual base salary of $234,210 (based on the average exchange rate for 2023, as published by the Bank of Israel), as well as customary disbursements toward her providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

Horenshtein Hadar’s employment agreement with our wholly-owned subsidiary Silexion Israel provides for her to a gross monthly salary of NIS 72,000, which amounts to an annual base salary of $250,297 (based on the average exchange rate for 2025, as published by the Bank of Israel),, as well as customary disbursements toward her providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

Mitchell Shirvan’s serves as our Chief Scientific and Development Officer.

His employment agreement with Silexion Israel provides for him a gross monthly salary of NIS 80,000, which amounts to an annual base salary of $278,108 (based on the average exchange rate for 2025, as published by the Bank of Israel), as well as customary disbursements toward his providence fund, further education fund and severance pay fund, and other fringe benefits commensurate with such position.

Indemnification Agreements

On the date of, and in connection with, the Closing of the Business Combination, the Company entered into indemnification agreements with each of its directors and executive officers, which provide for indemnification and advancements by the Company of certain expenses and costs under certain circumstances.

The indemnification agreements provide that we will indemnify each of its directors and executive officers against any and all expenses incurred by that director or executive officer because of his or her status as a director or officer of New Silexion, to the fullest extent permitted under Cayman law and the Articles.

The foregoing description of the indemnification agreements does not purport to be complete and is qualified in its entirety by reference to the text of the form of indemnification agreement that is filed as Exhibit 10.6 to the registration statement of which this prospectus forms a part, which is incorporated herein by reference.

Conversion Transaction with GIBF

Immediately following the Closing of the Business Combination, Guangzhou Sino-Israel Bio-Industry Investment Fund I (“ GIBF ”) beneficially owned 20.3% of our issued and outstanding share capital.

GIBF had held the remaining 49% of the issued and outstanding share capital of our 51%-held Chinese subsidiary, Silenseed (China) Ltd.

(which 49% interest had been received by it in return for its equity investments in the Chinese subsidiary, rather than equity investments directly in us).

In connection with the consummation of the Business Combination, GIBF was to exchange its entire holdings in the Chinese subsidiary for preferred shares of Silexion according to the terms set out in the contract for the establishment of the Chinese subsidiary, dated August 30, 2021, as amended, which preferred shares were to be automatically converted into 203,971 New Silexion ordinary shares in accordance with the equity exchange ratio for our shareholders’ exchange of shares of Silexion for our shares under the Business Combination Agreement.

However, in order to simplify the transfer of GIBF’s 49% interest in our Chinese subsidiary to our company, in lieu of transferring that interest to Silexion, GIBF instead transferred the interest directly to New Silexion pursuant to an Agreement on Arrangements Related to Equity Interest Conversion, dated as of August 5, 2024 (the “GIBF Conversion Agreement”).

As consideration for its transfer of that 49% interest to us, GIBF received 203,971 New Silexion ordinary shares at the Closing.

GIBF furthermore received an additional 16,817 of our ordinary shares upon consummation of the Business Combination due to the conversion of our shares that were issued to it upon settlement of RSUs of Silexion that were subject to accelerated vesting at the Closing.

Those RSUs were granted to GIBF subject to GIBF’s providing certain services to us in connection with the transfer of funds from our Chinese subsidiary to us.

Avner Lushi and Shlomo Noy, both of whom serve as our directors since the Closing, share voting and investment power over the 220,788 of our ordinary shares beneficially owned by GIBF after the Closing.

PIPE Financing

In connection with, and immediately prior to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the “ PIPE Financing ”), whereby Moringa sold to Greenstar, LP (the “ PIPE Investor ”), a Cayman Islands exempted limited partnership and affiliate of the Moringa Sponsor, 200,000 newly issued Moringa ordinary shares (the “ PIPE Shares ”) (which does not reflect the reverse share split) at a price of $10.00 per share, pursuant to the PIPE Agreement, dated as of August 15, 2024, by and among Moringa, us and the PIPE Investor.

Those 200,000 shares automatically converted upon the Closing of the Business Combination into an equivalent number of our ordinary shares (at a number prior to the effectiveness of the reverse share split), or the PIPE Shares.

The PIPE Investor is entitled to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant to which we have agreed that, within 60 days after the Closing Date, it will file with the SEC a registration statement registering the resale of the PIPE Shares by the PIPE Investor, and use its commercially reasonable efforts to have that registration statement be declared effective by 180 days after the Closing Date (or 90 days after the Closing Date if the SEC does not review that filing).

The funds raised from the PIPE Financing, together with remaining funds in Moringa’s trust account after payments to redeeming public shareholders of Moringa, were used for financing support for Moringa and New Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading up to the Closing.

On the date of, and in connection with, the Closing of the Business Combination, we entered into indemnification agreements with each of our directors and executive officers, which provide for indemnification and advancements by us of certain expenses and costs under certain circumstances.

The indemnification agreements provide that we will indemnify each of our directors and executive officers against any and all expenses incurred by that director or executive officer because of his or her status as a director or officer of Silexion, to the fullest extent permitted under Cayman law and the Articles.

The foregoing description of the indemnification agreements does not purport to be complete and is qualified in its entirety by reference to the text of the form of indemnification agreement that serves as Exhibit 10.3 to this Annual Report, and which is incorporated herein by reference.

Registration Rights Related to PIPE Financing

In connection with, and immediately prior to the Closing of, the Business Combination, Moringa raised $2.0 million via a private investment in public entity financing (the “ PIPE Financing ”), whereby Moringa sold to Greenstar, LP (the “ PIPE Investor ”), a Cayman Islands exempted limited partnership and affiliate of the Moringa sponsor, 1,482 newly issued Moringa ordinary shares at a price of $1,350 per share, pursuant to the PIPE Agreement, dated as of August 15, 2024, by and among Moringa, the Company and the PIPE Investor.

Those 1,482 shares automatically converted upon the Closing of the Business Combination into an equivalent number of our ordinary shares (the “ PIPE Shares ”).

The PIPE Investor is entitled to customary registration rights in respect of the PIPE Shares under the PIPE Agreement, pursuant to which we agreed that, within 60 days after the Closing Date, we would file with the SEC a registration statement registering the resale of the PIPE Shares by the PIPE Investor, and use our commercially reasonable efforts to have that registration statement be declared effective by 180 days after the Closing Date (or 90 days after the Closing Date if the SEC would not review that filing).

In keeping with our obligations under those registration rights, we have registered the resale of the PIPE Shares by the PIPE Investor, initially, in a registration statement on Form S-1 (SEC file number 333-282556) and, subsequently, in a registration statement on Form S-3 (SEC file number 333-291210).

The funds raised from the PIPE Financing, together with remaining funds in Moringa’s trust account after payments to redeeming public shareholders of Moringa, were used for financing support for Moringa and Silexion, as well as for payment to service providers to whom outstanding amounts were owed by Moringa, including parties that had provided financial advisory services and capital markets advisory services to Moringa during the period leading up to the Closing.

Amended and Restated Sponsor Promissory Note

Effective as of the Closing, we issued to the Sponsor, and Sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes issued by Moringa to the Sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to us upon the Closing), the A&R Sponsor Promissory Note in an amount of $3,433,000, which reflected the total amount owed by Moringa to the Sponsor through the Closing Date.

Effective as of the Closing, we issued to the Moringa sponsor, and the Moringa sponsor accepted, in amendment and restatement, and replacement, in their entirety, of all existing promissory notes issued by Moringa to the Moringa sponsor from the IPO until the Closing (and as to which the obligations of Moringa were assigned to us upon the Closing), the A&R Sponsor Promissory Note in a principal amount of $3,433,000, which reflected the total amount owed by Moringa to the sponsor through the Closing Date.

The maturity date of the A&R Sponsor Promissory Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027).

Amounts outstanding under the A&R Sponsor Promissory Note may be repaid (unless otherwise decided by us) only by way of conversion into our ordinary shares (“ Note Shares ”) in accordance with the terms set forth in the form of A&R Sponsor Promissory Note.

Us and the Sponsor may also convert amounts outstanding under the A&R Sponsor Promissory Note at the price per share at which we conduct an equity financing following the Closing, subject to a minimum conversion amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of the number of our ordinary shares issued and sold by us in such equity financing.

The Sponsor may also elect to convert amounts of principal outstanding under the note into our ordinary shares at any time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $10,000, at a price per share equal to the volume weighted average price of the our ordinary shares on the principal market on which they are traded during the 20 consecutive trading days prior to the conversion date.

We or the sponsor may also convert amounts outstanding under the A&R Sponsor Promissory Note at the price per share at which we conduct an equity financing following the Closing, subject to a minimum conversion amount of $100,000, in an amount of Note Shares constituting up to thirty percent (30%) of the number of our ordinary shares issued and sold by us in such equity financing.

The sponsor may also elect to convert amounts of principal outstanding under the note into our ordinary shares at any time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $10,000, at a price per share equal to the volume weighted average price of our ordinary shares on the principal market on which they are traded during the 20 consecutive trading days prior to the conversion date.

On September 15, 2025, in connection with the closing of our September 2025 public offering, we elected to convert $1.8 million of the outstanding amount under the A&R Sponsor Promissory Note into 450,000 ordinary shares that we issued to the Moringa sponsor.

The conversion price of $4.00 per ordinary share reflected the price per ordinary share (including ordinary shares issuable upon exercise of pre-funded warrants) and accompanying two ordinary warrants to purchase two ordinary shares that we sold in that public offering.

As a result of that conversion, the outstanding amount owed by us to the Moringa sponsor under the A&R Sponsor Promissory Note was reduced to $1,633,000.

The foregoing summary provides only a brief description of the A&R Sponsor Promissory Note and does not purport to be complete.

1 unchanged sentence

Amended and Restated Registration Rights and Lock-Up Agreement

Prior to the Closing under the Business Combination Agreement, on August 14, 2024, us, Moringa, Moringa Sponsor, the distributees of the Sponsor Investment Shares (as defined under the Business Combination Agreement), certain of our pre-Business Combination shareholders and the PIPE Investor entered into (and EarlyBird will be bound by) an amended and restated registration rights and lock-up agreement which became effective as of the Closing of the Business Combination (the “A&R Registration Rights and Lock-Up Agreement”).

Under the agreement, we have assumed Moringa’s existing obligations under Moringa’s prior registration rights agreement (entered into in connection with Moringa’s initial public offering, or IPO) and has granted registration rights to the Moringa Sponsor, the distributees of Sponsor Investment Shares, certain of our pre-Business Combination shareholders, the PIPE Investor and EarlyBird with respect to certain securities of ours.

Under the A&R Registration Rights and Lock-Up Agreement, we have agreed to provide the holders party thereto customary demand and shelf registration rights (subject to certain minimum size offerings) and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.

Under the lock-up provisions of the agreement, lock-up periods apply following the Closing to of our securities that are held by the holders who are party to the agreement, subject to permitted transfers to certain categories of “Permitted Transferees”.

Specifically, those lock-up periods apply to the following categories of securities for the following periods of time post-Closing:

Sponsor Investment Shares and securities held by former Silexion shareholders :

(A) 50% of the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of the New Silexion securities held by the former Silexion shareholders who are party to the agreement, in each case, upon the Closing, are subject to a lock-up period ending on the earlier of (i) six (6) months after the completion of the Business Combination, and (ii) the date on which New Silexion will consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (B) the other 50% of the Sponsor Investment Shares held by the Sponsor and its distributees and 50% of our securities held by the former Silexion shareholders party to the agreement, in each case, upon the Closing, were to be subject to a lock-up period that was to end on the earliest of (x) six (6) months after the date of the consummation of the Business Combination, (y) the date on which we consummate a liquidation, merger, amalgamation, share exchange, reorganization, or other similar transaction after the Business Combination that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property, or (z) the date on which the closing price of our ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period.

Private Shares and Private Warrants:

The lock-up period on all New Silexion ordinary shares issued pursuant to the SPAC Merger in exchange for private placement shares and private placement warrants purchased by or issued to the Sponsor and EarlyBird concurrently with Moringa’s initial public offering remained (as provided in the documentation for Moringa’s initial public offering) 30 days after the Closing.

Representative Shares .

The lock-up period on all Representative Shares (as defined in the Amended and Restated Registration Rights and Lock-Up Agreement) that are held by EarlyBird was to remain (as provided in the documentation for Moringa’s initial public offering) three months after the Closing.

Note Shares and PIPE Shares .

Note Shares issued to the Sponsor upon conversion of amounts due under the A&R Sponsor Promissory Note and PIPE Shares issued to the PIPE Investor were not subject to any lock-up periods following the Closing.

Prior to the Closing under the Business Combination Agreement, on August 14, 2024, our company, Moringa, the Moringa sponsor, the distributees of certain of our ordinary shares previously held by the sponsor, certain of our pre-Business Combination shareholders, and the PIPE Investor entered into an amended and restated registration rights and lock-up agreement which became effective as of the Closing of the Business Combination (the “ A&R Registration Rights and Lock-Up Agreement ”).

Under the agreement, we assumed Moringa’s existing obligations under Moringa’s prior registration rights agreement and granted registration rights to the Moringa sponsor, certain distributees of shares held by the Moringa sponsor, certain of our pre-Business Combination shareholders, and the PIPE Investor with respect to certain ordinary shares and warrants of ours.

Under the A&R Registration Rights and Lock-Up Agreement, we agreed to provide the holders party thereto customary demand and shelf registration rights (subject to certain minimum size offerings) and piggy-back rights on primary and secondary offerings, subject to customary cut-back provisions.

Under the lock-up provisions of the agreement, certain lock-up periods following the Closing applied to our securities that were held by our security holders who are party to the agreement, subject to permitted transfers to certain categories of permitted transferees.

Each of those lock-up periods has already expired as of the date of this Annual Report.

In keeping with our registration rights obligations under the A&R Registration Rights and Lock-Up Agreement, we have registered the resale of the securities covered by the agreement, initially, in a registration statement on Form S-1 (SEC file number 333-282556) and, subsequently, in a registration statement on Form S-3 (SEC file number 333-291210).

The foregoing summary provides only a brief description of the A&R Registration Rights and Lock-Up Agreement and does not purport to be complete.

The summary is qualified in its entirety by the full text of the A&R Registration Rights and Lock-Up Agreement, which serves as Exhibit 10.1 to this Annual Report, and which is incorporated herein by reference.

Related Party Transactions Policies

We have not yet adopted a formal policy for the review, approval or ratification of related party transactions.

Warrant Exercise Inducement Transactions

During 2025, we completed two warrant exercise inducement transactions with existing warrant holders, including security holders that beneficially owned, at the time of those transactions, 5% or more of our outstanding ordinary shares.

On January 29, 2025, we entered into an inducement offer letter agreement with holders of 148,102 of our existing ordinary warrants.

On January 30, 2025, those holders exercised their warrants for cash and purchased 148,102 ordinary shares at a cash exercise price of $20.25 per share, in consideration of our issuance to them of new ordinary warrants to purchase up to an aggregate of 148,102 ordinary shares at an exercise price of $22.50 per share.

The exercising holders also paid us an additional $1.88 per new ordinary warrant issued to them.

We received aggregate gross proceeds of approximately $3.3 million from this transaction, before deducting placement agent fees and other offering expenses.

On July 31, 2025, we entered into a second inducement offer letter agreement with holders of 152,106 of our existing ordinary warrants.

On August 1, 2025, those holders exercised their warrants for cash and purchased 152,106 ordinary shares at a cash exercise price of $11.57 per share, in consideration of our issuance to them of new ordinary warrants to purchase up to an aggregate of 304,212 ordinary shares at an exercise price of $11.32 per share.

We received aggregate gross proceeds of approximately $1.8 million from this transaction, before deducting placement agent fees and other offering expenses.

For both transactions, we engaged H.C.

Wainwright to act as our exclusive placement agent and paid it cash fees equal to 7.0% of the aggregate gross proceeds received, as well as management fees equal to 1.0% of the gross proceeds.

We also issued to H.C.

Wainwright or its designees placement agent warrants to purchase up to 10,368 and 10,647 ordinary shares, respectively, with exercise prices of $27.66 per share and $14.46 per share, respectively.

Related Party Transactions Policies and Procedures

We have not adopted a formal policy for the review, approval or ratification of related party transactions.

Accordingly, the transactions discussed above were not reviewed, approved or ratified in accordance with any such policy.

As described above in “ Item 10.

Directors, Executive Officers and Corporate Governance— Corporate Governance— Code of Business Conduct and Ethics ,” we have adopted a written code of business conduct and ethics that applies to our directors, officers and employees and that requires us to avoid, wherever possible, all conflicts of interest, except under guidelines or resolutions approved by our board of directors (or the appropriate committee of our board) or as disclosed in our public filings with the SEC.

Under our code of business conduct and ethics, conflict of interest situations include any financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) involving the company.

Our audit committee, pursuant to a written charter that we adopted upon the Closing of the Business Combination, is responsible for reviewing and approving related party transactions to the extent that we enter into such transactions.

Instead, however, as described above in “ Item 10.

Directors, Executive Officers and Corporate Governance— Corporate Governance Practices— Code of Business Conduct and Ethics ,” we have adopted a written code of business conduct and ethics that applies to our directors, officers and employees and that requires us to avoid, wherever possible, all conflicts of interest, except under guidelines or resolutions approved by our board of directors (or the appropriate committee of our board) or as disclosed in our public filings with the SEC.

Our audit committee, pursuant to its written charter that we adopted upon the Closing of the Business Combination, is responsible for reviewing and approving related party transactions to the extent that we seek to enter into any such transactions.

An affirmative vote of a majority of the members of the audit committee present at a meeting at which a quorum is present is required in order to approve a related party transaction.

1 unchanged sentence

Without a meeting, the unanimous written consent of all of the members of the audit committee is required to approve a related party transaction.

Our audit committee reviews on a quarterly basis all payments that were made to our sponsor, officers or directors, or our or any of their affiliates.

Our audit committee reviews on a quarterly basis all payments that were made to our officers or directors, any of their affiliates, or any of our affiliates.

These procedures are intended to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on the part of a director, employee or officer.

Director Independence

Nasdaq listing standards require that a majority of the New Silexion Board be independent.

An “independent director” is defined generally as a person who has no disqualifying relationship with the Company described under Nasdaq Listing Rule 5605(a)(2), as well as no other material relationship with the Company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the listed company) that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

In making a determination of director independence, the New Silexion Board considers the current and prior relationships that each director has with the Company and all other facts and circumstances the New Silexion Board deems relevant in determining his or her independence, including the beneficial ownership of our securities by such director, and the transactions described in the sub-section above titled “ Related Party Transactions .”

The New Silexion Board has determined that each of Messrs.

Nasdaq listing standards require that a majority of the members of our Board be independent.

An “independent director” is defined generally as a person who has no disqualifying relationship with the Company described under Nasdaq Listing Rule 5605(a)(2), as well as no other material relationship with the Company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the Company) that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

In making a determination of director independence, our Board considers the current and prior relationships that each director has with the Company and all other facts and circumstances that the Board deems relevant in determining the director’s independence, including the beneficial ownership of our securities by such director, and the transactions described in the sub-section above titled “ Related Party Transactions .”

The Board has determined that each of Messrs.

Abramov, Ilan Levin, Avner Lushi, Shlomo Noy, and Amon Peled, and Ms.

2 unchanged sentences

Abramov and Peled, and Ms.

Alon, is deemed independent.

Alon, who together constitute all members of those committees, has been determined to be independent.

Principal Accountant Fees and Services

The following table provides a summary of fees paid or to be paid to Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, which served as our principal accountant with respect to the years ended December 31, 2025 and 2024 (“ PwC Israel ”), for services rendered for the years ended December 31, 2025 and 2024.

The services related to the below fees were rendered:

(i) for the period following the Closing of the Business Combination on August 15, 2024 through December 31, 2024, to New Silexion and its consolidated subsidiaries, including Silexion, through which our business is primarily conducted, and (ii) with respect to the year ended December 31, 2023 and the period from January 1, 2024 through August 15, 2024, to Silexion and its consolidated subsidiaries.

in thousands)

For the year ended December 31, 2024, the services related to the below fees were rendered:

(i) for the period following the Closing of the Business Combination on August 15, 2024 through December 31, 2024, to Silexion and its consolidated subsidiaries, including Silexion Israel, through which our business is primarily conducted, and (ii) for the period from January 1, 2024 through August 15, 2024, to Silexion Israel and its consolidated subsidiaries.

in thousands)

7 unchanged sentences

Exhibits and Financial Statement Schedules

The following documents are filed as part of this Form 10-K:

Financial Statements:

SILEXION THERAPEUTICS CORP

CONSOLIDATED FINANCIAL STATEMENTS

AS OF DECEMBER 31, 2024

Report of Independent Registered Public Accounting Firm

CONSOLIDATED FINANCIAL STATEMENTS:

Consolidated Balance Sheets

Consolidated Statements of Operations

Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency

Consolidated Statements of Cash Flows

Notes to Consolidated Financial Statements

Financial Statement Schedules:

The following Exhibit Index lists those exhibits that we are filing as part of this Annual Report:

The following documents are filed as part of this Annual Report:

Our financial statements as of, and for the year ended December 31, 2025, which are included in the “F-“ pages of this Annual Report.

The exhibits listed in the following Exhibit Index:

Amended and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)

Ordinary Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on November 29, 2024)

Ordinary Resolution Effecting 1‑for‑15 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on July 29, 2025)

Ordinary Resolution Approving Increase in Authorized Share Capital to $121,500 (9,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on August 19, 2025)

Proposed Ordinary Resolution Approving Increase in Authorized Share Capital to $ 796,500 (59,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Annex B to Silexion Therapeutics Corp’s Proxy Statement on Schedule 14A, filed with the SEC on February 23, 2026)

Description of Securities of Silexion Therapeutics Corp registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended

Warrant Agreement, dated February 19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to Moringa Acquisition Corp’s Current Report on Form 8-K, filed with the SEC on February 22, 2021)

1 unchanged sentence

Warrant Adjustment Notice, dated November 29, 2024, in respect of 1-for-9 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on November 29, 2024)

Description of securities of Silexion Therapeutics Corp registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended

Final invoice issued by EarlyBirdCapital, Inc.

to Moringa Acquisition Corp under the Business Combination Marketing Agreement, dated February 16, 2021, by and between EarlyBirdCapital, Inc.

and Moringa Acquisition Corp (incorporated by reference to Exhibit 10.1.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)

Convertible Promissory Note, dated August 15, 2024, in an amount of $1,250,000, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to EarlyBirdCapital, Inc.

(incorporated by reference to Exhibit 10.1.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)

Letter agreement regarding inducement to convert Silexion convertible promissory note, entered into by Silexion Therapeutics Corp and EarlyBirdCapital, Inc.

on March 13, 2025 (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on March 14, 2025)

Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)

Amendment No.

1, effective January 14, 2025, to Ordinary Share Purchase Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics Corp and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.2 to Silexion Therapeutics Corp’s Registration Statement on Form S-1 (File No.

333-284873), filed with the SEC on February 12, 2025)

Registration Rights Agreement, dated August 13, 2024 and effective as of the closing date of the Business Combination, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and White Lion Capital, LLC (incorporated by reference to Exhibit 10.3.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)

Warrant Adjustment Notice, dated July 29, 2025, in respect of 1‑for‑15 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on July 29, 2025)

Amended and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.’s pre-Business Combination shareholders and Greenstar, L.P.

13 unchanged sentences

Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)

Silexion Therapeutics Ltd.

2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.13 to Silexion Therapeutics Corp’s Registration Statement on Form S-1 (File No.

333-282017), filed with the SEC on September 10, 2024)

Proposed Amendment to Section 5(b)(i) of the Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Annex C to Silexion Therapeutics Corp’s Proxy Statement on Schedule 14A, filed with the SEC on February 23, 2026)

Silexion Therapeutics Ltd.

1 unchanged sentence

333-282017), filed with the SEC on September 10, 2024)

Securities Purchase Agreement, dated January 15, 2025, by and between the Company and each investor party thereto (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)

Form of Ordinary Warrant (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)

Form of Inducement Letter (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)

Form of New Warrant (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)

Form of Placement Agent Warrant (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)

Insider Trading Policy of Silexion Therapeutics Corp

List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)

Form of Ordinary Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)

Form of Placement Agent Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)

Form of Ordinary Share Purchase Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)

Form of Placement Agent Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)

Form of Ordinary Share Purchase Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 1, 2025)

Form of Placement Agent Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 1, 2025)

Form of Series A Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)

Form of Series B Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.2 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)

Form of Placement Agent Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.4 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)

At‑The‑Market Offering Agreement, dated September 26, 2025, by and between Silexion Therapeutics Corp and H.C.

Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 26, 2025)

Insider Trading Policy of Silexion Therapeutics Corp (incorporated by reference to Exhibit 19.1 to Silexion Therapeutics Corp’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025)

List of Subsidiaries

Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm of Silexion Therapeutics Corp

3 unchanged sentences

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Silexion Therapeutics Corp Policy for Recovery of Erroneously Awarded Compensation

Silexion Therapeutics Corp Policy for Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to Silexion Therapeutics Corp’s Annual Report on Form 10-K for the year ended December 31, 2024 , filed with the SEC on March 18, 2025)

101.INS*Inline XBRL Instance Document.

101.SCH*Inline XBRL Taxonomy Extension Schema Document.

101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Filed herewith.

6 unchanged sentences

Chairman of the Board and Chief Executive Officer

M arch 18, 2025

March 17, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

3 unchanged sentences

(Principal Executive Officer)

/s/ Mirirt Horenshtein Hadar

/s/ Mirit Horenshtein Hadar

Chief Financial Officer

March 17, 2026

Mirirt Horenshtein Hadar

Mirit Horenshtein Hadar

(Principal Financial and Accounting Officer)

22 unchanged sentences

Consolidated Statements of Operations

Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Capital Deficiency

Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Shareholders’ Equity (Capital Deficiency)

Consolidated Statements of Cash Flows

4 unchanged sentences

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Silexion Therapeutics Corp and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in redeemable convertible preferred shares and capital deficiency and cash flows for the each of the two years then ended, including the related notes (collectively referred to as the “consolidated financial statements”).

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

We have audited the accompanying consolidated balance sheets of Silexion Therapeutics Corp and its subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, changes in redeemable convertible preferred shares and shareholders' equity (capital deficiency) and cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”).

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

As discussed in Note 1j to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from operating activities that raise substantial doubt about its ability to continue as a going concern.

Management’s plans in regard to these matters are also described in Note 1j.

As discussed in Note 1g to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from operating activities that raise substantial doubt about its ability to continue as a going concern.

Management’s plans in regard to these matters are also described in Note 1g.

The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

6 unchanged sentences

Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.

As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.

Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.

8 unchanged sentences

We have served as the Company's auditor since 2023.

Kesselman & Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103, Israel,

P.O Box 50005 Tel-Aviv 6150001, Telephone:

+972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il

SILEXION THERAPEUTICS CORP

9 unchanged sentences

Restricted cash

Long-term deposit

Long-term deposit and other non-current assets

Property and equipment, net

5 unchanged sentences

dollars in thousands, except share data)

Liabilities and redeemable convertible preferred shares, net of capital deficiency

Liabilities and shareholders’ equity (capital deficiency)

CURRENT LIABILITIES:

1 unchanged sentence

Current maturities of operating lease liability

Warrants to preferred shares (including $ 0 and $ 186 due to related party, as of December 31, 2024 and December 31, 2023, respectively)

Employee related obligations

Accrued expenses and other accounts payable

Other accounts payable

Private warrants to purchase ordinary shares (including $ * and $ 1 due to related party, as of December 31, 2025 and December 31, 2024, respectively)

7 unchanged sentences

COMMITMENTS AND CONTINGENT LIABILITIES (Note 7)

Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of December 31, 2024 and 2023, 0 and 43,121 shares issued and outstanding as of December 31, 2024 and 2023);

Convertible Series A-1 Preferred Shares (NIS 0.09 par value per share, 0 and 13,334 shares authorized as of December 31, 2024 and 2023, 0 and 10,136 shares issued and outstanding as of December 31, 2024 and 2023);

Convertible Series A-2 Preferred Shares (NIS 0.09 par value per share, 0 and 22,223 shares authorized as of December 31, 2024 and 2023, 0 and 5,051 shares issued and outstanding as of December 31, 2024 and 2023);

Convertible Series A-3 Preferred Shares (NIS 0.09 par value per share, 0 and 8,889 shares authorized as of December 31, 2024 and 2023, 0 and 7,037 shares issued and outstanding as of December 31, 2024 and 2023);

Convertible Series A-4 Preferred Shares (NIS 0.09 par value per share 0 and 90,556 and shares authorized as of December 31, 2024 and 2023, respectively 0 and 2,413 ** shares issued and outstanding as of December 31, 2024 and 2023, respectively);

TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES

CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS

TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS

CAPITAL DEFICIENCY:

Ordinary shares ($ 0.0009 par value per share, 22,222,222 shares authorized as of December 31, 2024 and 2023;

1,848,711 **** and 97,120 shares issued and outstanding as of December 31, 2024 and 2023, respectively)

SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY):

Ordinary shares ($ 0.0135 par value per share, 9,000,000 and 1,481,482 shares authorized as of December 31, 2025 and December 31, 2024, respectively;

3,126,651 and 123,290 ** shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively)

Additional paid-in capital

Accumulated deficit

TOTAL CAPITAL DEFICIENCY

TOTAL REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CONTINGENTLY REDEEMABLE NON-CONTROLLING INTERESTS, NET OF CAPITAL DEFICIENCY

TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE

PREFERRED SHARES AND NON-CONTROLLING INTEREST, NET OF CAPITAL DEFICIENCY

TOTAL SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)

All share amounts have been retroactively adjusted to reflect a 1-for-15 reverse share split as discussed in Note 1(e)

* Represents an amount less than $1

** Net of 13,458 treasury shares held by the Chinese Subsidiary as of December 31, 2023

*** All share amounts have been retroactively adjusted to reflect a 1-for-9 reverse share split as discussed in Note 1h

** Net of 28 treasury shares held by the Company as of December 31, 2024

6 unchanged sentences

Research and development (including $ 0 and $ 1,796 from related party, for the year ended December 31, 2025 and December 31, 2024, respectively)

General and administrative (including $ 2,972 and $ 48 from related party, for the year ended December 31, 2024 and December 31, 2023, respectively)

General and administrative (including $ 134 and $ 2,972 from related party, for the years ended December 31, 2025 and December 31, 2024, respectively)

TOTAL OPERATING EXPENSES

OPERATING LOSS

Financial expenses (income), net (including $( 1,249 ) and $ 83 from related party, for the year ended December 31, 2024 and December 31, 2023, respectively)

Financial expenses (income), net (including $ 232 and $( 1,249 ) from related party, for the years ended December 31, 2025 and December 31, 2024, respectively)

LOSS BEFORE INCOME TAX

5 unchanged sentences

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE*:

* All share amounts have been retroactively adjusted to reflect a 1-for-9 reverse share split as discussed in Note 1h

* All share amounts have been retroactively adjusted to reflect a 1-for-15 reverse share splits as discussed in Note 1(e)

The accompanying notes are an integral part of these consolidated financial statements.

SILEXION THERAPEUTICS CORP

CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND CAPITAL DEFICIENCY

CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY (CAPITAL DEFICIENCY)

dollars in thousands, except per share data)

3 unchanged sentences

Accumulated deficit

Total capital deficiency

Total redeemable convertible preferred shares and contingently redeemable non-controlling interests, net of capital deficiency

Total shareholders' equity (capital deficiency)

Total redeemable convertible preferred shares and contingently redeemable non-controlling interests and shareholders' equity (capital deficiency)

Series A preferred shares

6 unchanged sentences

CHANGES DURING 2024:

Issuance of Preferred A-4 shares, net of issuance cost, see Note 9(1)

Share-based compensation

BALANCE AT DECEMBER 31, 2023

CHANGES DURING 2024:

Exercise of pre-funded options

5 unchanged sentences

BALANCE AT DECEMBER 31, 2024

CHANGES DURING 2025:

Exercise of pre-funded options

Issuance of ordinary shares and warrants upon January 2025 and September 2025 public offerings, net of issuance costs and exercise of pre-funded warrants to ordinary shares (see Note 8(a))

Exercise of warrants, January 2025 and September 2025 (see Note 8(a))

Issuance of ordinary shares and warrants upon warrants inducement transactions, January 2025 and August 2025, net of issuance costs (see Note 8(b))

Share-based compensation

Conversion of Underwriters Promissory Note (see Note 3(a))

Conversion of Sponsor Promissory Note (see Note 3(b))

BALANCE AT DECEMBER 31, 2025

* Represents an amount less than $1

** Represents exercises of fully vested pre-funded options for the Company’s ordinary shares at an exercise price of $0.339 or 0.339 NIS per share

*** All share amounts have been retroactively adjusted to reflect a 1-for-9 reverse share split as discussed in Note 1h

*** All share amounts have been adjusted (in the case of prior periods, retroactively) to reflect the 1-for-9 and 1-for-15 reverse share splits effected in November 2024 and July 2025, respectively, as discussed in Note 1(e)

**** Net of 28 treasury shares held by the Company as of December 31, 2024

12 unchanged sentences

Changes in operating assets and liabilities:

Increase in prepaid expenses

Decrease (increase) in prepaid expenses

Decrease (increase) in other current assets

Increase in trade payable

Increase (decrease) in trade payable

Net change in operating lease

Increase (decrease) in employee related obligations

Increase (decrease) in accrued expenses and other accounts payable

Increase in employee related obligations

Increase (decrease) in other accounts payable

Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:

Proceeds from short-term deposit

Investment in long-term deposits

Purchase of property and equipment

Proceeds from sale of property and equipment

Net cash provided by (used in) investing activities

Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of preferred shares and warrants, net of issuance costs

Proceeds from issuance of ordinary shares upon January 2025 and September 2025 public offerings

Issuance costs related to public offerings

Proceeds from exercise of warrants

Proceeds from issuance of ordinary shares upon January 2025 and August 2025 warrants inducement transactions

Issuance costs related to warrants inducement transactions

Payment of Underwriters Promissory Note

Prepaid of issuance cost related to At the Market Offering

Proceeds from exercise of pre-funded options

1 unchanged sentence

Cash received from Transactions upon the effectiveness of the SPAC Merger

Payment of Underwriters Promissory Note

Net cash provided by financing activities

DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

16 unchanged sentences

Conversion of warrants to preferred shares on a cashless basis

Conversion of non-controlling interests to New Silexion ordinary shares

Conversion of non-controlling interests to Silexion ordinary shares

Conversion of Underwriters Promissory Note to ordinary shares

Conversion of Related Party Promissory Note to ordinary shares

Accrued and unpaid issuance expenses in respect of public offering

Shares issued for ELOC financing liability

4 unchanged sentences

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 1 - GENERAL:

Silexion Therapeutics Corp (“New Silexion”) (hereinafter - the “Company” or the “Combined Company”) is a recently formed entity that was formed for the purpose of effecting the Transactions (as defined below).

Following the closing of the Transactions on August 15, 2024 (the “Closing”), New Silexion now serves as a publicly-traded holding company that has two primary wholly-owned subsidiaries —Moringa Acquisition Corp (“Moringa” or the “SPAC”), a Cayman Islands exempted company, and Silexion Therapeutics Ltd.

(formerly known as Silenseed Ltd.) (“Silexion”), an Israeli limited company.

Introduction :

Silexion Therapeutics Corp (“Silexion”, the “Company” or the “Combined Company”) is a clinical-stage biotechnology company developing, through its subsidiaries, RNA interference (RNAi) therapies for KRAS-driven cancers.

Silexion’s approach targets a significant unmet medical need, as treatment innovation for KRAS-driven cancers has historically lagged despite KRAS being one of the most common oncogenic drivers across solid tumors.

Silexion’s lead product candidate, SIL204, is a second-generation siRNA therapy, designed to silence mutant KRAS, using an integrated treatment approach that combines intratumoral and systemic administration.

The Company was originally formed for the purpose of effecting the Transactions (as defined below).

Following the closing of the Transactions on August 15, 2024 (the “Closing”), the Company became a publicly-traded holding company that has one primary active wholly-owned subsidiary — Silexion Therapeutics Ltd.

(formerly known as Silenseed Ltd.) (“Silexion Israel”), an Israeli limited company, through which much of its operations are conducted, along with certain additional inactive subsidiaries, including Moringa Acquisition Corp (“Moringa” or the “SPAC”), a Cayman Islands exempted company.

On April 3, 2024, the Company entered into an Amended and Restated Business Combination Agreement (hereinafter, the “A&R BCA”) with the SPAC, Silexion Israel, August M.S.

an Israeli company and wholly-owned subsidiary of the Company (“Merger Sub 1”), and Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and additional wholly-owned subsidiary of the Company (“Merger Sub 2”).

Pursuant to the closing under the A&R BCA, which occurred on August 14, 2024, both Silexion Israel and the SPAC became wholly-owned subsidiaries of the Company, which became a publicly-held, Nasdaq-listed entity whose securities are traded under the ticker symbols “SLXN” and “SLXNW” (the A&R BCA and related transactions:

the “Transactions”).

Financial Information Presented :

From its formation on April 2, 2024 until the Closing of the Transactions on August 15, 2024, the Company had no operations and had been formed for the sole purpose of entering into the Transactions and serving as the publicly-traded company following the Transactions.

Silexion, on the other hand, as the accounting acquirer in the Transactions and the predecessor entity to the Company from an accounting perspective, had active operations during earlier periods of time, prior to the Transactions.

Consequently, these financial statements reflect the financial information of Silexion (as the predecessor entity to the Company) through August 15, 2024 and the financial information of New Silexion (as the combined company following the Transactions) from August 16, 2024 forward.

Silexion Israel, on the other hand, as the accounting acquirer in the Transactions and the predecessor entity to the Company from an accounting perspective, had active operations during earlier periods of time, prior to the Transactions.

Consequently, these financial statements reflect the financial information of Silexion Israel (as the predecessor entity to the Company) through August 15, 2024 and the financial information of Silexion (as the Combined Company following the Transactions) from August 16, 2024 forward.

Subsidiaries :

The Company has three subsidiaries as of December 31, 2025:

Silexion was incorporated in Israel and began its operations on November 30, 2008.

Since its incorporation, Silexion has been engaged in one operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production of a specific pancreatic cancer-causing protein known as the KRAS mutation.

Silexion’s long-lived assets are located in Israel.

Silexion Israel .

Silexion Israel was incorporated in Israel and began its operations on November 30, 2008.

Since its incorporation, Silexion Israel has been engaged in one operating segment - the research and development of innovative treatments for pancreatic cancer based on siRNAs, aiming to stop the production of a specific pancreatic cancer-causing protein known as the KRAS mutation.

Silexion Israel takes an integrated approach to treatments, combining intratumoral and systemic administration of its RNAi therapies.

Silexion Israel’s long-lived assets are located in Israel.

Silenseed (China) Ltd.

On April 28, 2021, Silexion (as the predecessor entity to the Company) signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (“GIBF”) to establish a new company in China.

On April 28, 2021, Silexion Israel (as the predecessor entity to the Company) signed an agreement with Guangzhou Sino-Israel Biotech Investment Fund (“GIBF”) to establish a new company in China.

On June 15, 2021 a company was established in China, named Silenseed (China) Ltd.

1 unchanged sentence

As of December 31, 2025, following transfer of all interests in the Chinese Subsidiary to the Company as part of the Transactions, the Company owns (directly or indirectly) 100 % of the shares of the Chinese Subsidiary.

The Chinese Subsidiary has no significant operations as of December 31, 2024.

Prior to the Transactions (commencing on February 17, 2021), Moringa’s class A ordinary shares and warrants were listed for trading on the Nasdaq Capital Market (Nasdaq:

MACA and MACAW).

As part of the Transactions, Moringa merged with a wholly-owned subsidiary of the Company and now serves as an inactive, wholly-owned subsidiary of the Company.

Following the Transactions, Moringa is no longer listed for trading on the Nasdaq Capital Market.

The Company, the Chinese Subsidiary, Moringa and Silexion are together referred to hereinafter as the “Group”.

The Chinese Subsidiary has had no significant operations during the reporting periods.

SILEXION THERAPEUTICS CORP

2 unchanged sentences

NOTE 1 - GENERAL (continued):

On April 3, 2024, Silexion entered into an Amended and Restated Business Combination Agreement (hereinafter, the “A&R BCA”) with the SPAC, New Silexion, August M.S.

an Israeli company and wholly-owned subsidiary of New Silexion (“Merger Sub 1”), and Moringa Acquisition Merger Sub Corp, a Cayman Islands exempted company and wholly-owned subsidiary of New Silexion (“Merger Sub 2”).

Under the A&R BCA, both Silexion and the SPAC were to become wholly-owned subsidiaries of New Silexion, which was to become a publicly-held, Nasdaq-listed entity (the A&R BCA and related transactions:

the “Transactions”).

On August 15, 2024, the parties completed the Transactions pursuant to which Merger Sub 2 merged with and into the SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the “SPAC Merger”), and Merger Sub 1 merged with and into Silexion, with Silexion continuing as the surviving company of such merger and a wholly-owned subsidiary of New Silexion (the “Acquisition Merger”).

Upon the effectiveness of the SPAC Merger, each outstanding SPAC Class A ordinary share and the sole outstanding SPAC Class B ordinary share was converted into an ordinary share of New Silexion on a one-for-one basis.

Each outstanding warrant to purchase one SPAC Class A ordinary share was converted into a warrant to purchase one New Silexion ordinary share, at the same exercise price.

Upon the effectiveness of the Acquisition Merger, each outstanding ordinary share and each outstanding preferred share of Silexion was converted into 3.9829 ordinary shares of New Silexion, before adjustment for a subsequent reverse share split (the “Silexion Equity Exchange Ratio”).

See Note 1h for post-reverse share split figures.

Each outstanding Silexion warrant and Silexion option to purchase one Silexion share, and Silexion restricted share unit (RSU) that may be potentially settled for one Silexion share, was to become exercisable for, or became subject to settlement for (as applicable), such number of New Silexion ordinary shares as were equal to the Silexion Equity Exchange Ratio.

The exercise price per New Silexion ordinary share of each such converted Silexion option and Silexion warrant was to be adjusted based on dividing the existing per share exercise price by the Silexion Equity Exchange Ratio.

The terms of vesting, exercise and/or settlement, as applicable, of such converted options, warrants and RSUs were to remain the same following such conversion, except that the vesting of each Silexion option was to accelerate immediately prior to the Acquisition Merger, such that the New Silexion option into which it was to be converted was to be fully vested, and all Silexion warrants were to be exercised (on a cashless basis) immediately prior to the Acquisition Merger.

Immediately prior to the Closing seven directors were elected to New Silexion’s board of directors, of whom five were designated by Silexion and two were designated by the SPAC’s sponsor (the “Sponsor”).

The A&R BCA also required, as a closing condition, the transfer of the remaining outstanding shares of the Chinese Subsidiary held by GIBF to Silexion prior to the closing of the Business Combination in exchange for the issuance to GIBF of shares of Silexion, which were converted into ordinary shares of New Silexion in accordance with the Silexion Equity Exchange Ratio upon the closing.

In connection with the closing of the Transactions, the ordinary shares and warrants of New Silexion are now listed on the Nasdaq Global Market and began trading under the symbols “SLXN” and “SLXNW”, respectively.

Prior to the Transactions (commencing on February 17, 2021), Moringa’s class A ordinary shares and warrants were listed for trading on the Nasdaq Capital Market (Nasdaq:

MACA and MACAW).

As part of the Transactions, Moringa merged with Merger Sub 2 and now serves as an inactive, wholly-owned subsidiary of the Company.

Following the Transactions, Moringa is no longer listed for trading on the Nasdaq Capital Market.

On February 9, 2026 the Company purchased a German shelf company, subsequently renamed Silexion Therapeutics GmbH (“Silexion Germany”), to conduct the Company’s clinical trials in Germany.

The Company, the Chinese Subsidiary, Moringa and Silexion Israel (and, when describing any event following its having been acquired in February 2026, Silexion Germany as well) are together referred to hereinafter as the “Group”.

Business Combination :

On August 15, 2024, the parties completed the Transactions pursuant to which Merger Sub 2 merged with and into the SPAC, with the SPAC continuing as the surviving company of such merger and a wholly-owned subsidiary of Silexion (the “SPAC Merger”), and Merger Sub 1 merged with and into Silexion Israel, with Silexion Israel continuing as the surviving company of such merger and a wholly-owned subsidiary of Silexion (the “Acquisition Merger”).

In connection with the Closing of the Transactions, the ordinary shares and warrants of Silexion were listed on the Nasdaq Global Market (currently, they are listed on the Nasdaq Capital Market) and began trading under the symbols “SLXN” and “SLXNW”, respectively.

For more information on instruments issued as part of the Transactions, see Note 3.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 1 - GENERAL (continued):

The Transactions were accounted for as a reverse recapitalization in accordance with US GAAP.

Under this method of accounting, Silexion was treated as the accounting acquirer and the SPAC was treated as the “acquired” company for financial reporting purposes.

Silexion was determined to be the accounting acquirer based on evaluation of the following facts and circumstances:

• Silexion’s shareholders hold approximately 61.55 % of the outstanding voting interests in New Silexion upon the closing of the Transactions;

• Silexion’s senior management comprise the senior management of New Silexion;

• the directors nominated by Silexion constitute a majority of the board of directors of New Silexion (five out of seven of the initial directors);

• Silexion’s operations comprise the ongoing operations of New Silexion;

• Silexion’s name is the name used by New Silexion (in replacement of Biomotion Sciences).

Under the reverse recapitalization accounting method, the Transactions were deemed to be the equivalent of a capital transaction in which Silexion issued shares for the net assets of the SPAC.

Under this method of accounting, Silexion Israel was treated as the accounting acquirer and the SPAC was treated as the “acquired” company for financial reporting purposes.

Under the reverse recapitalization accounting method, the Transactions were deemed to be the equivalent of a capital transaction in which Silexion Israel issued shares for the net assets of the SPAC.

The net assets of the SPAC were stated at fair value, with no goodwill or other intangible assets recorded.

Operations prior to the Transactions are those of Silexion.

In accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative periods up to the date of the Closing (the “Closing Date”), to reflect the number of New Silexion’s ordinary shares, $ 0.0001 par value per share (before adjustment for a subsequent reverse share split, which reverse share split is described in Note 1h) issued to legacy Silexion shareholders in connection with the reverse recapitalization transaction.

As such, the shares and corresponding capital amounts and earnings per share related to legacy Silexion shareholders prior to the reverse recapitalization have been retroactively restated as shares reflecting the exchange ratio established pursuant to the Transactions.

In conjunction with the reverse recapitalization, Silexion’s ordinary shares underwent a 1-for-3.9829 conversion (before adjustment for a subsequent reverse share split).

Reconciliation of the SPAC Merger to the Company's Consolidated Financial Statements

The following table reconciles the elements of the Transactions to the consolidated statements of cash flows:

Recapitalization

Accrued expenses assumed

Warrants to ordinary shares assumed

Related Party Promissory Note issued

Underwriters Promissory Note issued

Loss upon entering Transactions

Effect of reverse recapitalization, net of transaction costs

On November 22, 2024, the Company announced a prospective 1-for-9 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares.

The reverse share split resulted a corresponding increase in the par value of the Company’s ordinary shares, from $ 0.0001 per share to $ 0.0009 per share.

No fractional shares have been issued as a result of the reverse split, as any fractional share totals to which shareholders become entitled have been rounded up to the nearest whole number of shares.

The reverse share split became effective after market close on November 27, 2024, and the Company’s ordinary shares began trading on a reverse split-adjusted basis on the Nasdaq Global Market on November 29, 2024.

All references made to ordinary shares, preferred shares and per share amounts (for each of New Silexion, Silexion and Moringa) in these consolidated financial statements, unless otherwise indicated, have been retroactively adjusted to reflect the reverse share split.

Operations prior to the Transactions are those of Silexion Israel.

In accordance with the applicable guidance to reverse recapitalization, the equity structure has been retroactively adjusted in all comparative periods up to the date of the Closing (the “Closing Date”), to reflect the number of Silexion’s ordinary shares, $ 0.0001 par value per share (before adjustment for two subsequent reverse share splits, which are described in Note 1(e)) issued to legacy Silexion Israel shareholders in connection with the reverse recapitalization transaction.

As such, the shares and corresponding capital amounts and earnings per share related to legacy Silexion Israel shareholders prior to the reverse recapitalization have been retroactively restated as shares reflecting the exchange ratio established pursuant to the Transactions.

In conjunction with the reverse recapitalization, Silexion Israel’s ordinary shares underwent a 1-for-3.9829 conversion (before adjustment for subsequent reverse share splits).

SILEXION THERAPEUTICS CORP

2 unchanged sentences

NOTE 1 - GENERAL (continued):

In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets.

Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and other terrorist organizations.

In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization), Israel’s southern border with the Gaza Strip (with the Hamas terrorist organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq.

Further, on April 13, 2024, and on October 1, 2024, Iran launched a series of drone and missile strikes against Israel.

As of December 31, 2024 a ceasefire agreement has been reached between Israel and Lebanon.

The Company’s headquarters are located in the central region of Israel.

As of the issuance date of these consolidated financial statements, these conflicts have not had a material impact on the Company’s results of operations or financial position, if at all.

The Company cannot currently predict the intensity or duration of Israel’s war, however, as most of the Company’s trials are not executed in Israel, the Company does not believe that the war will have any material impact on its ongoing operations.

The Company continues to monitor its ongoing activities and will make any needed adjustments to ensure continuity of its business, while supporting the safety and well-being of its employees.

Any additional hostilities involving Israel, or the interruption or curtailment of trade between Israel and its trading partners, could adversely affect the Company’s operations and results of operations and could make it more difficult for the Company to raise capital.

Reverse share splits :

On November 27, 2024 and July 28, 2025, the Company effected 1-for-9 and 1-for-15 reverse share splits of all of its issued and outstanding, and authorized but unissued, ordinary shares.

The reverse share splits resulted in corresponding increases in the par value of the Company’s ordinary shares, from $ 0.0001 to $ 0.0009 , and from $ 0.0009 to $ 0.0135 , per share.

No fractional shares were issued as a result of the reverse splits, as any fractional share totals to which shareholders would have been entitled were rounded up to the nearest whole number of shares.

All references made to ordinary shares, preferred shares and per share amounts (for each of Silexion, Silexion Israel, and Moringa) in these consolidated financial statements, unless otherwise indicated, have been adjusted (for periods preceding either reverse share split, retroactively) to reflect those reverse share splits.

Israeli war :

In October 2023, Israel was attacked by Hamas, a terrorist organization and entered a state of war.

Since the commencement of these events, there have been additional active hostilities, including with Hezbollah in Lebanon, the Houthi movement which controls parts of Yemen, and with Iran.

In response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 12, 2025, Israel conducted a series of preemptive defensive air strikes in Iran targeting Iran’s nuclear program and military commanders.

On June 24, 2025, a ceasefire with Iran was reached.

On October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework for a ceasefire in Gaza between Israel and Hamas.

While that ceasefire has been mostly maintained, in late February 2026, Israel and the United States preemptively attacked Iran.

As part of this conflict, Iran and Hezbollah have launched missile attacks throughout Israel.

As a result, the Israeli government imposed restrictions on opening of non-essential places of business and announced recruitment of military reserves.

The Company’s employees and management personnel are located in Israel;

however, other core activities, including research and development, clinical, and regulatory, are conducted outside of Israel.

The Company considered the impact of the war and determined that (in part due to those core activities being conducted outside of Israel) there were no material adverse impacts on the consolidated financial statements, including related significant estimates made by management, for the period ended December 31, 2025.

Further, as the Company’s R&D activity is conducted outside of Israel, the Company does not expect future adverse effects of the war on its core activities.

On the other hand, travel restrictions imposed may impact the Company’s ability to raise funds to finance its activities in the near term.

At this stage, the Company is unable to estimate the impact of the developments on its future financial position, its results of operations, or its cash flows, if any.

However, as this event is outside the Company’s control, factors such as the continued duration of the military conflict and its potential expansion into additional areas, as well as other developments, may impact the Company, its financial position, its ability to conduct financing activities, its results of operations, and its cash flows.

The Company continues to monitor these developments in order to assess the potential effects of the military conflict on its activities.

Going concern:

Since its inception, the Company (and, prior to the Transactions, its predecessor, Silexion) has devoted substantially all its efforts to research and development, clinical trials, and capital raising activities.

Since its inception, the Company (and, prior to the Transactions, its predecessor, Silexion Israel) has devoted substantially all its efforts to research and development, clinical trials, and capital raising activities.

The Company is still in its development and clinical stage and has not yet generated revenues.

The Company (or, for those periods prior to the Transactions, its predecessor, Silexion) has incurred losses of $ 16,519 and $ 5,108 for the years ended on December 31, 2024 and December 31, 2023, respectively.

During the year ended on December 31, 2024, the Company (including Silexion, for periods prior to the Transactions) had negative operating cash flows of $ 8,396 .

The Company (or, for those periods prior to the Transactions, its predecessor, Silexion Israel) has incurred losses of $ 11,912 and $ 16,519 for the years ended December 31, 2025 and December 31, 2024, respectively.

During the year ended December 31, 2025, the Company had negative operating cash flows of $ 10,819 .

As of December 31, 2025, the Company had cash and cash equivalents of $ 5,991 .

On January 15, 2025, the Company raised financing of $ 5,000 by public offering of ordinary shares, pre-funded warrants, and ordinary warrants.

Additionally, a total of $ 864 was received from the exercise of warrants and pre-funded warrants.

On January 29, 2025, the Company raised financing of $ 3,267 by induced warrant exercise transaction (see Note 16).

The Company expects to continue incurring losses, and negative cash flows from operations.

1 unchanged sentence

However, there is no assurance that the Company will be successful in obtaining such funding.

Under these circumstances, in accordance with the requirements of ASC 205-40, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the date these financial statements are issued.

The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

SILEXION THERAPEUTICS CORP

1 unchanged sentence

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 1 - GENERAL (continued):

Under these circumstances, in accordance with the requirements of Accounting Standards Codification (“ASC”) 205-40, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued.

The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

4 unchanged sentences

GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.

As applicable to these financial statements, the most significant estimates and assumptions relate to fair value of financial instruments and share-based compensation (see Notes 12 and 11, respectively).

As applicable to these financial statements, the most significant estimates and assumptions relate to fair value of financial instruments (see Note 12).

These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.

1 unchanged sentence

Functional currency

The Company's operations are currently conducted in Israel and some of the Company's expenses are currently paid in new Israeli shekels ("NIS");

The Company's operations are currently conducted in Israel and some of the Company's expenses are currently paid in new Israeli shekels (“NIS”) and Euro;

however, the markets for the Company's future products are located outside of Israel.

Financing activities are conducted in U.S.

dollar (“dollar” or "$").

dollars (“dollars” or "$").

The Company's management believes that the US dollar is the currency of the primary economic environment in which the Company operates.

Thus, the functional and reporting currency of the Company is the dollar.

The functional currency of Silexion is the U.S.

The functional currency of Silexion Israel is the U.S.

dollar, inter alia, in light of the composition of expenses and expected volume of intercompany transactions with the Company.

11 unchanged sentences

The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group.

Cash and cash equivalents

The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

Bank balances for which use by the Company is subject to third party contractual restrictions are included as part of cash unless the restrictions result in a bank balance no longer meeting the definition of cash.

If the contractual restrictions to use the cash extend beyond 12 months after the end of the reporting period, the related amounts are classified as non-current in Balance sheets.

SILEXION THERAPEUTICS CORP

2 unchanged sentences

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

Cash and cash equivalents

The Company considers as cash equivalents all short-term, highly liquid investments, which include money market funds, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

If the contractual restrictions to use the cash extend beyond 12 months after the end of the reporting period, the related amounts are classified as non-current in Balance sheets.

Restricted cash

As of December 31, 2024 and 2023, the Company pledged an amount of $ 57 and $ 25 , respectively in favor of a bank as collateral for guarantees provided to secure the lease payments.

As of December 31, 2025 and 2024, the Company had pledged amounts of $ 57 , respectively in favor of a bank as collateral for guarantees provided to secure its operating lease payments.

The Company is required to hold a minimum amount of NIS 86 in its bank account in order to maintain availability of a credit line from its credit card company.

4 unchanged sentences

Office furniture

Leasehold improvements

* Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimated useful life of the improvements.

Employee rights upon retirement

18 unchanged sentences

Financial instruments issued

When the Company issues freestanding instruments, the Company first analyzes the provisions of ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.

If the instrument was not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-40 in order to determine whether the instrument should be classified within equity or classified as an asset or liability, with subsequent changes in fair value recognized in the statements of operations in each period.

When the Company issued preferred shares, it first considered the provisions of ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) in order to determine whether the preferred share should be classified as a liability.

4 unchanged sentences

The Redeemable Convertible Preferred Shares were converted into ordinary shares in the framework of the recapitalization transaction as described in Note 1(d).

When the Company issued other freestanding instruments, the Company first analyzed the provisions of ASC 480 in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.

If the instrument was not within the scope of ASC 480, the Company further analyzed the provisions of ASC 815-40 in order to determine whether the instrument should be classified within equity or classified as an asset or liability, with subsequent changes in fair value recognized in the statements of operations in each period.

The Company’s issued financial instruments convertible to preferred shares were in the scope of ASC 480.

For further details see Note 8.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

Contracts over Ordinary Shares

When the Company becomes party to freestanding financial instruments, the Company first analyzes the provisions of ASC 480 in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.

Warrants to purchase ordinary shares are not within the scope of ASC 480, and as such the Company further analyzes the provisions of ASC 815-40 in order to determine whether the contract should be classified within equity or classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.

Under ASC 815-40, contracts that are not indexed to the Company’s own stock are classified as liabilities recorded at fair value, As such, the Company classifies private warrants (see Note 3(e)) as liabilities and measures them at their fair value at each reporting period.

Under ASC 815-40, contracts that are not indexed to the Company’s own stock are classified as liabilities recorded at fair value.

As such, the Company classifies private warrants (see Note 3(e)) as liabilities and measures them at their fair value at each reporting period.

This liability is subject to re-measurement at each balance sheet date until the private warrants are exercised or expire, or upon reassessment of classification.

Similarly, the Company classifies the ELOC Agreement entered into (see Note 3(d)) as a derivative instrument measured at fair value at each reporting period, as settlement provisions under this agreement are not indexed to the Company’s own stock.

Other warrants convertible to ordinary shares are considered indexed to the Company’s own stock and meet the conditions for equity classification, and thus are presented within equity.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

The Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date.

1 unchanged sentence

When a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account for the contract at fair value during the period that the contract was classified as a liability are not reversed, and the contract is marked to fair value immediately before the reclassification.

The effect of Induced exercises of equity-classified warrants that is directly attributable to a proposed or actual equity offering are accounted for as an equity issuance cost.

Promissory Notes

3 unchanged sentences

Fair value gains and losses include interest expenses.

Redeemable Non-controlling Interest

Non-controlling interests with embedded redemption features, whose settlement is not at the Company’s discretion, are considered redeemable non-controlling interests.

Redeemable non-controlling interests are considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the Company's consolidated balance sheets.

Redeemable non-controlling interests are measured at the greater of the initial carrying amount adjusted for the non-controlling interest’s share of comprehensive income or loss or its redemption value.

Subsequent adjustment of the amount presented in temporary equity is currently not required because the Company's management estimates that it was not probable that the instrument will become redeemable.

Adjustments of redeemable non-controlling interest to its redemption value are recorded through additional paid-in capital.

As indicated in Note 1 above, following the Transaction, the redeemable non-controlling interests held by GIBF were converted into ordinary shares of the Company and are no longer outstanding.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

Share-based compensation

The Company’s employees and non-employees share-based payment awards are classified as equity awards.

The Company’s employee and non-employee share-based payment awards are classified as equity awards.

The Company accounts for these awards using the grant-date fair value method.

8 unchanged sentences

Such amounts are recognized as an expense as the related goods are used or the services are rendered.

Grants received from the Israeli Innovation Authority (“IIA”) for approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and included as a deduction from research and development expenses, see Note 7.

The Company did not receive any grants during 2023 and 2024.

Grants received from the Israeli Innovation Authority (“IIA”) for approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are included as a deduction from research and development expenses.

The Company did not receive any grants during 2025 or 2024.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

The Company recognizes operating lease payments in the consolidated statements of operations on a straight-line basis over the lease term.

2 unchanged sentences

The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term.

The discount rate for the lease is the rate in the lease unless that rate cannot readily determined.

The discount rate for the lease is the rate

in the lease unless that rate cannot readily determined.

As the Company's leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (“IBR”) based on the information available at commencement date in determining the present value of lease payments.

1 unchanged sentence

During the reporting periods, the Company has only operating leases.

Payments under the Company’s lease arrangements are primarily fixed, however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease right-of-use assets and liabilities.

Payments under the Company’s lease arrangements are primarily fixed;

however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease right-of-use assets and liabilities.

The Company elected the practical expedient not to separate lease and non-lease components.

The Company has made a policy election not to capitalize leases with a term of 12 months or less.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

Loss per share

9 unchanged sentences

Consequently, net loss for the applicable periods presented was not allocated to the Company's participating securities.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

Income taxes:

9 unchanged sentences

Concentration of credit risks

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits.

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and long-term deposits.

The Company deposits cash and cash equivalents mostly with four low risk financial institutions.

The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

Impairment of long-lived assets

12 unchanged sentences

As of December 31, 2025, and December 31, 2024, no contingent liabilities have been recognized.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

New accounting pronouncements:

The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”).

Using exemptions provided under the JOBS Act for EGCs, the Company has elected to defer compliance with new or revised ASUs until it is required to comply with such updates, which is generally consistent with the adoption dates of private companies.

Using exemptions provided under the JOBS Act for EGCs, the Company has elected to defer compliance with new or revised Accounting Standards Updates (“ASUs”) until it is required to comply with such updates, which is generally consistent with the adoption dates of private companies.

Recently Adopted accounting pronouncements:

In November 2023, the FASB issued ASU No.

2023-07 Segment Reporting (Topic 280):

Improvements to Reportable Segment Disclosures.

The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant segment expenses.

The ASU also requires that a public entity that has a single reportable segment must provide all the disclosures required by the amendments and all existing segment disclosures in Topic 280.

The Company adopted the ASU on January 1, 2024 - see Note 15.

In June 2022, the Financial Accounting Standards Board (“FASB”) issued ASU 2022-03 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”.

The ASU clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring its fair value.

The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction.

The ASU also introduces new disclosure requirements for equity securities subject to contractual sales restrictions.

The Company adopted the ASU on January 1, 2025 and it did not have a material impact on the Company’s consolidated financial statement.

Recently issued accounting standards not yet adopted:

9 unchanged sentences

The Company is in the process of assessing the impacts and method of adoption.

In September 2025, the FASB issued ASU 2025-07 “Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract”.

The ASU excludes from the derivative accounting certain non-exchange-traded contracts with contracts with underlying that are based on operations or activities specific to one of the parties to the contract.

The ASU is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods.

Early adoption is permitted.

The amendment can be applied either prospectively to new contracts entered into on or after the date of adoption or on a modified retrospective basis through cumulative effect adjustment to the opening balance of retained earnings as of the beginning of the annual reporting period of adoption.

The Company is in the process of evaluating the effects of the ASU on its contracts.

SILEXION THERAPEUTICS CORP

2 unchanged sentences

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):

In June 2022, the FASB issued ASU 2022-03 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”.

The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction.

The ASU also introduces new disclosure requirements for equity securities subject to contractual sale restrictions.

As an Emerging Growth Company, the ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years.

Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance.

The Company is currently evaluating the effect that ASU 2022-03 will have on its consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-10, Accounting for Government Grants Received by Business Entities, to amend the guidance in “Government Grants” (Topic 832).

The update provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income.

The guidance is effective for fiscal years beginning after December 15, 2029, including interim periods within those fiscal years.

The Company is in the process of assessing the impact on its results of operations, financial position and disclosures, and in particular the impact on future IIA Support Grants (see Note 7).

In December 2025, the FASB issued ASU 2025-11 to amend the guidance in “Interim Reporting” (Topic 270).

The update provides clarifications intended to improve the consistency and usability of interim disclosure requirements, including a comprehensive listing of required interim disclosures and a new disclosure principle for reporting material events occurring after the most recent annual period.

The amendments do not change the underlying objectives of interim reporting but are designed to enhance clarity in application.

The guidance is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years.

The Company is in the process of assessing the impacts of the ASU on its interim financial statements.

NOTE 3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS

The following financial instruments were issued and became outstanding in connection with the Transactions:

Underwriters Promissory Note

Prior to the Closing, Moringa reached agreement with EarlyBird Capital, Inc.

(“EarlyBird”), which served as the underwriter for Moringa’s IPO, on the reduction, to $ 1,600 , in the aggregate, of the fee payable to EarlyBird under the Marketing Agreement entered into by Moringa with EarlyBird at the time of Moringa’s initial public offering (“IPO”).

At the Closing, Moringa paid $ 350 of cash to EarlyBird from its trust account and New Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025, in an amount of $ 1,250 to be paid by New Silexion to EarlyBird in cash or, at the election of EarlyBird upon maturity, via conversion of outstanding amounts into ordinary shares of New Silexion (the “Underwriters Promissory Note”).

The Underwriters Promissory Note bears interest at a rate of 6 % per annum and matures on December 31, 2025.

If not repaid on or prior to that maturity date or such earlier date as to which the repayment obligation may be accelerated under the note, or not converted by EarlyBird upon maturity into ordinary shares of New Silexion in accordance with the terms thereof, the rate of interest applicable to the unpaid principal amount would be adjusted to 15 % per annum.

New Silexion is required to make mandatory prepayments on the note in amounts equal to 10 % of the gross proceeds received by New Silexion from any equity financing consummated by it prior to the maturity date.

New Silexion is entitled to voluntarily prepay, in cash, any additional part of, or all of, the principal and accrued interest, in one or more installments without penalty, prior to the maturity date.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 3 – FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS (continued):

EarlyBird, in turn, may elect, at its sole discretion, on the maturity date, to convert all or part of the then outstanding principal and/or accrued interest under the Underwriters Promissory Note into New Silexion ordinary shares, at a per share conversion price equal to 95 % of the volume weighted average price of a New Silexion ordinary share for the five trading days immediately prior to (but not including) the maturity date of the Underwriters Promissory Note .

As of December 31, 2024, the Company has repaid $ 250 of the principal amount of the Underwriters Promissory Note as required in connection with its equity financing activities under the ELOC Agreement;

(“EarlyBird”), which served as the underwriter for Moringa’s initial public offering (“IPO”), on the reduction, to $ 1,600 , in the aggregate, of the fee payable to EarlyBird under the Marketing Agreement entered into by Moringa with EarlyBird at the time of Moringa’s IPO.

At the Closing, Moringa paid $ 350 of cash to EarlyBird from its trust account and Silexion issued to EarlyBird a convertible promissory note, due December 31, 2025, in an amount of $ 1,250 to be paid by Silexion to EarlyBird in cash or, at the election of EarlyBird upon maturity, via conversion of outstanding amounts into ordinary shares of Silexion (the “Underwriters Promissory Note”).

The Underwriters Promissory Note bore interest at a rate of 6 % per annum and was to mature on December 31, 2025.

Silexion was required to make mandatory prepayments on the note in amounts equal to 10 % of the gross proceeds received by Silexion from any equity financing consummated by it prior to the maturity date.

As of December 31, 2024, the Company repaid $ 250 of the principal amount of the Underwriters Promissory Note as required in connection with its equity financing activities under the ELOC Agreement;

see Note 3(d).

As of the date these financial statements were authorized for issuance, the Company repaid $ 808 of the Underwriters Promissory Note plus $ 15 for EarlyBird’s legal expenses, in respect of the Note Conversion Inducement Agreement, followed by a final payment of $ 136 for the retirement of the Underwriters Promissory Note.

See Note 16(c).

During January 2025, the Company repaid $ 158 of the principal amount of the Underwriters Promissory Note.

On March 13, 2025, the Company entered into a letter agreement with EarlyBird, under which the remaining $ 880 of outstanding principal amount and accrued interest under the Underwriters Promissory Note was extinguished in exchange for a cash payment by the Company (including accrued interest) of $ 551 and the Company’s issuance to EarlyBird of 18,519 ordinary shares.

Sponsor/Related Party Promissory Note

Effective as of the Closing, New Silexion issued to the Sponsor in replacement in their entirety of all previously existing promissory notes issued by Moringa to the Sponsor from its IPO until the Closing, an amended and restated promissory note (the “Related Party Promissory Note”, and, together with the Underwriters Promissory Note, the “Promissory Notes”) in an amount of $ 3,433 .

Effective as of the Closing, Silexion issued to the Sponsor in replacement in their entirety of all previously existing promissory notes issued by Moringa to the Sponsor from its IPO until the Closing, an amended and restated promissory note (the “Related Party Promissory Note”, and, together with the Underwriters Promissory Note, the “Promissory Notes”) in an amount of $ 3,433 .

This reflected the total amount owed by Moringa to the Sponsor through the Closing Date.

The maturity date of the Related Party Promissory Note is the 30-month anniversary of the Closing Date (i.e., February 15, 2027).

Amounts outstanding under the Related Party Promissory Note may be repaid (unless otherwise decided by New Silexion) only by way of conversion into New Silexion ordinary shares (“Note Shares”).

New Silexion and the Sponsor may also convert amounts outstanding under the Related Party Promissory Note at the price per share at which New Silexion conducts an equity financing following the Closing, subject to a minimum conversion amount of $ 100 , in an amount of Note Shares constituting up to thirty percent ( 30 %) of the number of New Silexion ordinary shares issued and sold by New Silexion in such equity financing.

The Sponsor may also elect to convert amounts of principal outstanding under the note into New Silexion ordinary shares at any time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $ 10 , at a price per share equal to the volume weighted average price of the New Silexion ordinary shares on the principal market on which they are traded during the 20 consecutive trading days prior to the conversion date.

As of the date of these financial statements, neither the Company nor the Sponsor has converted into New Silexion ordinary shares, and the Company has not prepaid, any principal amounts under the Related Party Promissory Note.

PIPE Financing

In connection with, and immediately prior to the Closing of the Transactions, Moringa raised $ 2,000 via a private investment in public entity financing (the “PIPE Financing”), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa Sponsor (the “PIPE Investor”), 22,223 newly issued Moringa ordinary shares at a price of $ 90.00 per share, pursuant to a subscription agreement, dated as of August 15, 2024, by and among Moringa, New Silexion and the PIPE Investor (the “PIPE Agreement”).

Those 22,223 shares are automatically converted upon the Closing of the Transactions into an equivalent number of New Silexion ordinary shares (the “PIPE Shares”).

ELOC Financing

In connection with the Closing, New Silexion entered into an ordinary share purchase agreement, effective as of the Closing Date (the “ELOC Agreement”), for an equity line of credit (the “ELOC”) with White Lion Capital, LLC (the “ELOC Investor”), whereby New Silexion will be able to request to sell to the ELOC Investor, and the ELOC Investor will be required to purchase, via private placement transactions, up to $ 15,000 of New Silexion ordinary shares from time to time after the Closing, up until December 31, 2025 (unless the agreement is terminated sooner), subject to certain limitations and conditions as described therein.

The number of New Silexion ordinary shares that New Silexion may require the ELOC Investor to purchase in any single sales notice will depend on a number of factors, including the type of purchase notice that New Silexion delivers.

Similarly, the purchase price to be paid by the ELOC Investor for any shares that New Silexion requires it to purchase will depend on the type of sales notice that New Silexion delivers.

Amounts outstanding under the Related Party Promissory Note may be repaid (unless otherwise decided by Silexion) only by way of conversion into Silexion ordinary shares (“Note Shares”).

Silexion and the Sponsor may also convert amounts outstanding under the Related Party Promissory Note at the price per share at which Silexion conducts an equity financing following the Closing, subject to a minimum conversion amount of $ 100 , in an amount of Note Shares constituting up to thirty percent ( 30 %) of the number of Silexion ordinary shares issued and sold by Silexion in such equity financing.

The Sponsor may also elect to convert amounts of principal outstanding under the note into Silexion ordinary shares at any time following the 24-month anniversary of the Closing Date, subject to a minimum conversion of $ 10 , at a price per share equal to the volume weighted average price of the Silexion ordinary shares on the principal market on which they are traded during the 20 consecutive trading days prior to the conversion date.

SILEXION THERAPEUTICS CORP

2 unchanged sentences

NOTE 3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS (continued):

Purchase price is determined with reference to either the lowest daily volume-weighted average price of the Company’s ordinary shares during a period of three consecutive business days beginning on the notice date, multiplied by 0.97 , or by the lowest traded price of the Company’s ordinary shares on the notice date.

Pursuant to the ELOC Agreement, New Silexion agreed, among other things, that if New Silexion’s sales to the ELOC Investor under the ELOC exceed 19.99 % of New Silexion’s total number of ordinary shares outstanding, New Silexion will seek the approval of its shareholders for the issuance of any New Silexion ordinary shares under the ELOC in excess of that amount, in accordance with the Nasdaq Listing Rules, subject to certain exceptions based on the price of the New Silexion ordinary shares to be sold in excess of that limit.

In consideration for the commitments of the ELOC Investor, New Silexion agreed to issue to the ELOC Investor an aggregate of $ 337.5 of New Silexion ordinary shares (the “ELOC Commitment Shares”).

On September 18, 2024 the Company issued 40,602 ordinary shares to the ELOC Investor as the ELOC Commitment Shares.

Issuance expenses amounted to $ 52 .

On September 15, 2025, as part of its public offering (see Note 8(a)), the Company converted $ 1,800 of the Related Party Promissory Note into 450,000 ordinary shares at a fair value of $ 1,624 .

The converted amount represented 30 % of the funds raised by the Company in its September 2025 public offering, in accordance with the Company’s conversion right under the Related Party Promissory Note.

As of December 31, 2025, $ 1,633 of the Related Party Promissory Note’s principal amount remained outstanding.

PIPE Financing

In connection with, and immediately prior to the Closing of the Transactions, Moringa raised $ 2,000 via a private investment in public entity financing (the “PIPE Financing”), whereby Moringa sold to Greenstar, LP, an affiliate of the Moringa Sponsor (the “PIPE Investor”), 1,482 newly issued Moringa ordinary shares at a price of $ 1,350 .00 per share, pursuant to a subscription agreement, dated as of August 15, 2024, by and among Moringa, Silexion and the PIPE Investor (the “PIPE Agreement”).

Those 1,482 shares were automatically converted upon the Closing of the Transactions into an equivalent number of Silexion ordinary shares (the “PIPE Shares”).

ELOC Financing

In connection with the Closing, Silexion entered into an ordinary share purchase agreement, effective as of the Closing Date (the “ELOC Agreement”), for an equity line of credit (the “ELOC”) with White Lion Capital, LLC (the “ELOC Investor”), whereby Silexion was able to request to sell to the ELOC Investor, and the ELOC Investor was required to purchase, via private placement transactions, up to $ 15,000 of Silexion ordinary shares from time to time after the Closing, up until December 31, 2025.

During the year ended December 31, 2024, the Company sold 48,208 ordinary shares under the ELOC at an average price of $ 63.3 per share, net of fees of approximately $ 20 .

The net proceeds from those sales were $ 3,054 .

For further information see Note 12.

During the year ended December 31, 2025, the Company did not make any sales under the ELOC.

For further information see Note 12(b).

SPAC Warrants

On the Closing Date, Moringa, New Silexion and Continental Stock Transfer & Trust Company (“CST”) entered into a certain Assignment, Assumption and Amendment Agreement (the “New Warrant Agreement”).

The New Warrant Agreement amended Moringa’s Warrant Agreement, dated as of February 19, 2021, to provide for the assignment by Moringa of all its rights, title and interest in the warrants of Moringa to New Silexion.

Upon Closing, New Silexion assumed 638,889 warrants sold by Moringa in its IPO (“Public Warrants”) and 21,112 warrants sold by Moringa to the Sponsor and EarlyBird concurrently with its IPO (the “Private Warrants”, and together with the Public Warrants, the “Warrants”).

Each such Warrant entitles the holder thereof to purchase one ordinary share of New Silexion at a price of $ 103.5 per share, subject to adjustment.

On the Closing Date, Moringa, Silexion and Continental Stock Transfer & Trust Company (“CST”) entered into a certain Assignment, Assumption and Amendment Agreement (the “New Warrant Agreement”).

Upon Closing, Silexion assumed 42,592 warrants sold by Moringa in its IPO (“Public Warrants”) and 1,408 warrants sold by Moringa to the Sponsor and EarlyBird concurrently with its IPO (the “Private Warrants”, and together with the Public Warrants, the “Warrants”).

Each such Warrant entitles the holder thereof to purchase one ordinary share of Silexion at a price of $ 1,552.5 per share, subject to adjustment.

No fractional shares will be issued upon exercise of the Warrants.

Each Warrant became exercisable 30 days after the Closing and will expire five years after the Closing Date, or earlier upon liquidation of the Company.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 3 - FINANCIAL INSTRUMENTS ISSUED AND ASSUMED IN TRANSACTIONS (continued):

Once the Public Warrants became exercisable, the Company is permitted to redeem them in whole and not in part at a price of $0.01 per Warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last reported sale price of the Company’s ordinary shares equals or exceeds $2,430.00 per share (as adjusted) for any 20 trading days within any 30-trading day period, beginning on the 30 th day after the Closing and ending on the third trading day prior to the date on which the Company sends a notice of redemption to the Public Warrant holders.

8 unchanged sentences

Public Warrants meet the criteria for equity classification and are recognized as equity.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 4 - PROPERTY AND EQUIPMENT, NET:

The composition of property and equipment, grouped by major classifications, is as follows:

The composition of the Company’s property and equipment, grouped by major classifications, is as follows:

Office furniture

Leasehold improvements

Accumulated depreciation:

Office furniture

Leasehold improvements

Property and equipment, net

Depreciation expenses were $ 14 and $ 25 in the years ended December 31, 2025 and 2024, respectively.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 5 - LEASES:

On August 15, 2024, Silexion vacated its office spaces and facilities in Israel.

On August 15, 2024, Silexion Israel vacated its office spaces and facilities in Israel.

On September 8, 2024, an early termination agreement for the operating lease was signed with the landlord, which included a termination penalty.

As a result, Silexion derecognized the right-of-use asset and the lease liability in its financial statements, recording a loss of $ 68 from the lease termination and an additional loss of $ 16 from the disposal of leasehold improvements.

On September 26, 2024 Silexion signed a new lease agreement for an office in Israel starting November 1, 2024 and ending on October 31, 2026 (initial term of two years and extension options reasonably certain to be exercised ending October 31, 2028).

Silexion will pay quarterly fixed payments to the lessor (including payments for common area maintenance).

Lease payments are indexed to the Israeli consumer price index (“CPI”).

Silexion provided the lessor with a bank guarantee as a rental security.

As a result, Silexion Israel derecognized the right-of-use asset and the lease liability in its financial statements, recording a loss of $ 68 from the lease termination and an additional loss of $ 16 from the disposal of leasehold improvements.

On September 26, 2024 Silexion Israel signed a new lease agreement for an office in Israel starting on November 1, 2024 and ending on October 31, 2026 (initial term of two years and extension options reasonably certain to be exercised ending October 31, 2028).

Silexion Israel will pay quarterly fixed payments to the lessor (including payments for common area maintenance).

Lease payments are indexed to the Israeli consumer price index (the “CPI”).

Silexion Israel provided the lessor with a bank guarantee as a rental security.

The bank, in turn, placed a pledge over restricted cash of $ 57 .

6 unchanged sentences

Total operating lease costs

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 5 - LEASES (continued):

Operating cash flows, for amounts included in the measurement of lease liabilities, are as follows:

4 unchanged sentences

Year Ended December 31,

Operating lease right-of-use assets

Operating lease liabilities

Weighted average remaining lease term (years)

Weighted average discount rate

As of December 31, 2024, Silexion has not entered into lease agreements that include options to extend them that are not included in the measurement of the lease liability.

The following table outlines maturities of Silexion operating lease liabilities as of December 31, 2024:

As of December 31, 2025, Silexion Israel has not entered into lease agreements that include options to extend them that are not included in the measurement of the lease liability.

The following table outlines maturities of Silexion Israel’s operating lease liabilities as of December 31, 2025:

lease liabilities

2 unchanged sentences

Present value of lease liabilities

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 6 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:

Balance sheets:

Other accounts payable

Accrued expenses

Statement of operations:

5 unchanged sentences

Rent and maintenance

Travel expenses

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 6 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (continued):

General and administrative expenses:

7 unchanged sentences

Change in fair value of financial liabilities measured at fair value (including ELOC)

Issuance costs

Issuance costs - ELOC agreement

Loss upon entering Transactions

3 unchanged sentences

NOTE 7 - COMMITMENTS AND CONTINGENT LIABILITIES:

From 2009 to 2020, Silexion received several approvals from the IIA for participation in research and development activities performed by Silexion (“Support Grants”) in a total amount of $ 5.8 million.

From 2009 to 2020, Silexion Israel received several approvals from the IIA for participation in research and development activities performed by Silexion Israel (“Support Grants”) in a total amount of $ 5.8 million.

The Company is obligated to pay royalties to the IIA amounting to 3 %- 5 % of the sales of the core products and other related revenues generated from such projects, up to 100 % of the Support Grants received, linked to the U.S.

dollar and bearing interest at the rate of LIBOR.

dollar and bears a 12 -month term SOFR interest rate.

The obligation to pay these royalties is contingent upon actual sales of the products and, in the absence of such sales, no payment is required.

In October 2023, it was published that the interest rate on the Support Grants will be replaced with the 12 -month term Secured Overnight Financing Rate (SOFR) published on the first trading day of each calendar year.

As of January 1, 2024, due to the cancellation of the LIBOR interest rate, the amount of the obligation is bearing 12-month term SOFR interest rate.

As of December 31, 2024, the total royalty amount that may be payable by the Company is approximately $ 5.8 million ($ 6.5 million including interest).

NOTE 8 - WARRANTS TO PURCHASE PREFERRED SHARES:

Regarding the Series A-4 Preferred Shares of Silexion, Silexion issued warrants to acquire 2,413 Series A-4 Preferred Shares to various investors, with an exercise price of $ 222.92 per share and an expiration date of May 30, 2025.

Issuance expenses amounted to $ 3 .

On August 6, 2024, all of these warrants were exercised in a ‘cashless’ manner for 925 Preferred A4 shares of Silexion.

Silexion classified the warrants for the purchase of its convertible redeemable preferred shares as a liability in its (now, the Company’s) consolidated balance sheets, as these warrants were freestanding financial instruments for which the underlying shares were contingently redeemable and, therefore, may have obligated Silexion to transfer assets at some point in the future.

The warrant liability was initially recorded at fair value upon the date of issuance and was subsequently remeasured at fair value at each reporting date.

Silexion (and the Company, as its successor from an accounting perspective) recorded revaluation expenses amounting to $ 134 and $ 86 for the years ended 2024 and 2023, respectively, and accounted for such revaluation expenses as part of its financial (expense), net, in the statements of operations.

For further information in respect of a warrants issuance to a service provider, see Note 11(1).

As of December 31, 2025, the total royalty amount that may be payable by the Company to the IIA was approximately $ 5.8 million ($ 6.7 million including interest).

SILEXION THERAPEUTICS CORP

1 unchanged sentence

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 9 - REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY:

Issuance of shares:

On May 30, 2023, Silexion entered into an agreement to receive an investment in a total amount of $ 538 .

In exchange for this investment, Silexion issued 2,413 Series A-4 Preferred Shares with a par value of NIS 0.09 .

Issuance expenses amounted to $ 16 .

Additionally, Silexion issued 2,413 warrants to purchase Series A-4 Preferred Shares, each with a par value of NIS 0.09 , exercisable at a price of $ 222.92 per share.

In addition, on May 30, 2023, the Chinese Subsidiary made an investment totaling $ 3 million in Silexion.

This investment resulted in the acquisition by the Chinese Subsidiary of 13,458 Series A-4 Preferred Shares and 13,458 warrants convertible into Series A-4 Preferred Shares of Silexion.

Each warrant was exercisable for one Series A-4 Preferred Share at an exercise price of $ 222.92 per share.

As the acquisition was eliminated in consolidation, it had no impact on the consolidated financial statement.

See Note 1(d) for shares issued as part of Transactions.

See Note 3(d) for ELOC Financing.

NOTE 8 - WARRANTS TO PURCHASE ORDINARY SHARES:

January and September Public Offerings of Ordinary Shares, Pre-Funded Warrants, and Ordinary Warrants.

On January 15, 2025, and again on September 11, 2025, the Company offered and sold in, and on January 17, 2025 and September 12, 2025, the Company completed, public offerings (the “January Offering” and “September Offering”, respectively) of its securities.

In the January Offering, the Company offered and sold 143,067 ordinary shares and 143,067 ordinary warrants to purchase up to 143,067 ordinary shares, at a purchase price of $ 20.25 per ordinary share and accompanying warrant, and 103,847 pre-funded warrants to purchase up to 103,847 ordinary shares (the “January Pre-Funded Warrants”) and 103,847 ordinary warrants to purchase up to 103,847 ordinary shares, at a purchase price of $ 20.25 per pre-funded warrant and accompanying ordinary warrant (all such ordinary warrants sold with the ordinary shares and January Pre-Funded Warrants, the “January Ordinary Warrants”).

In the September Offering, the Company offered and sold 1,392,250 ordinary shares and 107,750 pre-funded warrants to purchase 107,750 ordinary shares (the “September Pre-Funded Warrants”), each of which ordinary share and pre-funded warrant was sold together with two ordinary warrants— one Series A ordinary warrant and one Series B ordinary warrant, or 1,500,000 Series A ordinary warrants and 1,500,000 Series B ordinary warrants in total (collectively, the “September Ordinary Warrants”).

The purchase price was $ 4.00 per ordinary share and accompanying two September Ordinary Warrants, and $ 3.9999 per pre-funded warrant and accompanying two September Ordinary Warrants.

The aggregate gross proceeds to the Company from the January Offering and September Offering were approximately $ 5,000 and $ 6,000 , respectively, net of transaction costs of $ 745 and $ 805 , respectively.

The January Pre-Funded Warrants were immediately exercisable at an exercise price of $ 0.0015 per ordinary share, and the September Pre-Funded Warrants were immediately exercisable at an exercise price of $ 0.0001 per ordinary share, and do not expire until exercised in full.

The January Ordinary Warrants are exercisable at a price of $ 20.25 per ordinary share.

and expire five years after issuance.

The September Ordinary Warrants are exercisable at a price of $ 4 per ordinary share, with Series A ordinary warrants and Series B ordinary warrants expiring five years and one year , respectively, after issuance.

As of December 31, 2025, all 103,847 January Pre-Funded Warrants had been exercised for 103,847 ordinary shares, and a total of 42,683 January Ordinary Warrants had been exercised for 42,683 ordinary shares, for total proceeds of $ 0.9 million.

As of December 31, 2025, all 107,750 September Pre-Funded Warrants had been exercised for 107,750 ordinary shares, and a total of 445,000 September Ordinary Warrants had been exercised for 445,000 ordinary shares, for total proceeds of $ 1.78 million.

These exercises of September Ordinary Warrants occurred subsequent to, and were not related to, the January Inducement Offer or July Inducement Offer transactions (which are described in b.

As compensation for the placement agent’s role in the January Offering and September Offering, the Company issued to it warrants to purchase up to 17,284 , and 105,000 , ordinary shares, respectively.

Those placement agent warrants had exercise prices of $ 25.31 and $ 5 per ordinary share, respectively, were exercisable for five years from the date of the commencement of sales in the January Offering or September Offering (as applicable), and otherwise reflected substantially the same terms as the January Ordinary Warrants or September Ordinary Warrants (as applicable) sold in the January Offering or September Offering (as applicable).

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 8 - WARRANTS TO PURCHASE ORDINARY SHARES (continued) :

Induced Warrant Exercise Transactions

On January 29, 2025, the Company entered into an inducement offer letter agreement (the “January Inducement Offer”) with holders of 148,102 of the Company’s January Ordinary Warrants.

Pursuant to the January Inducement Offer, on January 30, 2025, those holders exercised those warrants for cash and purchased 148,102 ordinary shares at a cash exercise price of $ 20.25 per share.

As consideration for the holders’ agreement to exercise, the Company issued to them new ordinary warrants to purchase up to an aggregate of 148,102 ordinary shares at an exercise price of $ 22.50 per share (the “January New Ordinary Warrants”).

The exercising holders also paid the Company an additional $ 1.88 per January New Ordinary Warrant issued to them.

The Company received aggregate gross proceeds of approximately $ 3,276 from the exercise of the existing January Ordinary Warrants by the holders, net of placement agent fees and other offering expenses of $ 462 .

Upon exercise for cash of any January New Ordinary Warrants, in certain circumstances, the placement agent will receive from the Company a cash fee of 8.0 % of the aggregate gross exercise price.

Pursuant to the January Inducement Offer transaction, the Company also issued to the placement agent warrants to purchase up to 10,368 ordinary shares, which have the same terms as the January New Ordinary Warrants issued in the transaction, except that the placement agent warrants have an exercise price equal to $ 27.66 per share.

Upon exercise for cash of any January New Ordinary Warrants, in certain circumstances, the Company will issue to the placement agent warrants that are exercisable for 7.0 % of the number of ordinary shares issuable upon the exercise of those January New Ordinary Warrants.

As of December 31, 2025, the payment of cash fees and issuance of additional warrants to the placement agent upon exercise of January New Ordinary Warrants were not probable.

Both the January New Ordinary Warrants and the placement agent warrants were immediately exercisable from the date of their issuance until April 1, 2027.

On July 31, 2025, the Company entered into an additional inducement offer letter agreement (the “July Inducement Offer”) with holders of 152,106 of the Company’s existing ordinary warrants, of which (i) 22,468 were January Ordinary Warrants, and (ii) 129,638 were January New Ordinary Warrants.

The closing under the July Inducement Offer occurred on August 1, 2025, when those holders exercised those warrants for cash and purchased 152,106 ordinary shares at a reduced cash exercise price of $ 11.57 per share.

The Company received aggregate gross proceeds of approximately $ 1,760 from the exercise of the existing ordinary warrants by the holders, net of placement agent fees and other offering expenses of $ 278 .

As consideration for the holders’ agreement to exercise, the Company issued to them new ordinary warrants to purchase up to an aggregate of 304,212 ordinary shares at an exercise price of $ 11.32 per share (the “July Ordinary Warrants”).

The July Ordinary Warrants are exercisable from August 19, 2025 until the 24-month anniversary of the effective date of the resale registration statement under which the Company registered the resale of the ordinary shares underlying those warrants and the placement agent warrants (as referenced below)—i.e., until September 4, 2027.

Pursuant to the July Inducement Offer transaction, the Company also issued to the placement agent warrants to purchase up to 10,647 ordinary shares, which have the same terms as the July Ordinary Warrants, except that the placement agent warrants have an exercise price equal to $ 14.46 per share.

Upon exercise for cash of any July Ordinary Warrants, in certain circumstances, the placement agent will receive from the Company a cash fee of 8.0% of the aggregate gross exercise price, as well as additional placement agent warrants exercisable for 7.0 % of the number of ordinary shares issuable upon the exercise of those July Ordinary Warrants.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 8 - WARRANTS TO PURCHASE ORDINARY SHARES (continued) :

Summary of Outstanding warrants to purchase ordinary shares:

Below is a summary of the Company's Outstanding warrants to purchase ordinary shares for the year ended December 31, 2025:

Exercise Price

Expiration date

Number of Ordinary Shares Issuable Upon Warrant Exercise

Ordinary Private Warrants

August 15, 2029

Ordinary Public Warrants

August 15, 2029

January Ordinary Warrants

January 17, 2030

January Placement Agent Warrants

January 15, 2030

January Inducement Ordinary Warrants

January 31, 2027

January Inducement Placement Agent Warrants

January 31, 2027

July Inducement Ordinary Warrants

August 12, 2027

July Inducement Placement Agent Warrants

August 12, 2027

September Ordinary Warrants - Series A

September 11, 2030

September Ordinary Warrants - Series B

September 11, 2026

September Placement Agent Warrants

September 11, 2030

NOTE 9 - SHAREHOLDERS’ EQUITY:

Issuances of shares:

See Note 1(d) for a description of the issuance of ordinary shares pursuant to the Transactions.

See Note 3(d) for a description of the issuances of ordinary pursuant to the ELOC Financing.

See Note 8 for descriptions of share issuances pursuant to the January Offering, September Offering, January Inducement Offer and July Inducement Offer.

Shareholders’ rights:

The ordinary shares of Silexion conferred upon their holders the right to participate and vote in general shareholders meetings of Silexion and to share in the distribution of dividends, if any declared by Silexion.

The ordinary shares of Silexion confer upon their holders the right to participate and vote in general meetings of Silexion and to share in the distribution of dividends, if any, declared by Silexion.

At the market offering agreement

On September 26, 2025 the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with a sales agent.

In accordance with the terms of the Sales Agreement, the Company may offer and sell up to $ 13,170 of its newly issued ordinary shares from time to time through the sales agent.

The sales agent will not sell ordinary shares unless instructed by the Company and will use commercially reasonable efforts to sell on the Company’s behalf all of the ordinary shares requested to be sold by the Company, subject to the terms of the Sales Agreement.

The sales agent will be entitled to cash compensation equal to 3.0 % of the gross sales price of ordinary shares sold under the Sales Agreement.

As of December 31, 2025, no ordinary shares had been sold under the Sales Agreement.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 10 - INCOME TAXES:

3 unchanged sentences

Corporate taxation of Israeli subsidiary

Silexion is taxed according to the regular corporate income tax rate in Israel.

Silexion Israel is taxed according to the regular corporate income tax rate in Israel.

The corporate tax rate was 23 % in 2025 and 2024.

2 unchanged sentences

Tax loss carryforwards

As of December 31, 2024, the expected tax loss carryforwards of Silexion were approximately $ 25,216 , which may be carried forward and offset against taxable income in the future for an indefinite period.

The Company has recognized valuation allowance for the full amount in respect of these tax loss carryforwards since their utilization is not expected in the foreseeable future.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 10 - INCOME TAXES (continued):

As of December 31, 2025, the expected tax loss carryforwards of Silexion Israel were approximately $ 35,264 , which may be carried forward and offset against taxable income in the future for an indefinite period.

The Company has recognized a valuation allowance for the full amount in respect of these tax loss carryforwards since their utilization is not expected in the foreseeable future.

The tax loss carryforwards generated in the Cayman Islands have no value, as the Cayman Islands do not impose an income tax on corporations.

Local and foreign components of loss from continuing operations, before income taxes consisted of the results of Silexion as the local entity, and the results of New Silexion, Moringa, and the Chinese Subsidiary as foreign entities.

Local and foreign components of loss from continuing operations, before income taxes, consisted of the results of Silexion Israel as the local entity, and the results of Silexion, Moringa, and the Chinese Subsidiary as foreign entities.

Year ended December 31

7 unchanged sentences

The applicable statutory rate in the Cayman Islands is 0 % for the Company for the year ended December 31, 2025.

For purposes of the reconciliation between the provision for income taxes at the statutory rate and the effective tax rate, an Israeli statutory tax rate of 23 % for the years ended December 31, 2024, and December 31, 2023 was applied, which is the rate that is applicable to the substantially all of the Group’s operations.

Income tax expense attributable to income from continuing operations was $ 10 and $ 32 for the years ended December 31, 2024 and 2023, respectively, and differed from the amounts computed by applying an Israeli statutory income tax rate of 23 % to pretax income from continuing operations, mainly as a result of changes in valuation allowance of $ 1,392 and $ 922 respectively, as well as nondeductible expenses.

The reconciliation of the theoretical tax benefit (expense) under the Israeli statutory tax rate to the Company's effective benefit (expense) taxes is as follows for the years ended December 31, 2024 and 2023, respectively:

For purposes of the reconciliation between the provision for income taxes at the statutory rate and the effective tax rate, an Israeli statutory tax rate of 23 % was applied for the years ended December 31, 2025, and December 31, 2024, which is the rate that is applicable to substantially all of the Group’s operations.

Income tax expense attributable to income from continuing operations was $ 3 and $ 10 for the years ended December 31, 2025 and 2024, respectively.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 10 - INCOME TAXES (continued):

The reconciliation of the theoretical tax benefit (expense) under the Israeli statutory tax rate to the Company's effective tax benefit (expense) is as follows for the years ended December 31, 2025 and 2024, respectively:

Year ended December 31

9 unchanged sentences

Reported taxes on income

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 10 - INCOME TAXES (continued):

Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

17 unchanged sentences

Balance as of December 31, 2025

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 10 - INCOME TAXES (continued):

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

2 unchanged sentences

Income tax assessments

Silexion has tax assessments that are considered to be final through tax year 2019.

Silexion Israel has tax assessments that are considered to be final through tax year 2019.

The Chinese Subsidiary does not have final tax assessments.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 11 - SHARE-BASED COMPENSATION:

Warrants to service provider

In conjunction with its Series A-4 Preferred Share financing, Silexion issued warrants to acquire 12 Series A-4 Preferred Shares to a service provider who assisted in raising the funds, which were recorded as part of issue expenses.

These warrants carried an exercise price as those issued to the investors in such round.

The warrants were recognized as issuance costs and the portion attributed to the issuance of Series A-4 Preferred Shares was classified as part of the shareholders’ equity.

The portion attributed to the issuance of the warrants was recognized as financial expenses.

These warrants were automatically exercised on a cashless basis upon the Closing of the Transactions.

Employee Stock Option Plan

As of December 31, 2024, the Board of Directors had approved a pool of 63,953 ordinary shares for grant to Company employees, consultants, directors and other service providers under the Company’s 2024 Equity Incentive Plan (the “2024 Plan”).

Under Silexion’s 2013 Share Option Plan and 2023 Equity Incentive Plan (collectively, the “Silexion Plans,” and, together with the 2024 Plan, the “Plans”), options to purchase ordinary shares of Silexion could have been granted to certain entities and individuals.

Each option granted under the Silexion Plans is now exercisable for ordinary shares of the Company, until 10 years from the date of grant, or earlier upon cessation of employment or engagement of the grantee and certain other occurrences.

Following adoption of the 2024 Plan in connection with the Closing of the Transactions, future grants to Company employees and directors will only be made under the 2024 Plan, although outstanding grants under the Silexion Plans will continue to be governed by the terms of those plans.

Grants to employees are made in accordance with the Plans and are carried out within the provisions of Section 102 of the Israel Income Tax Ordinance, under the capital gains track described in subsection (b)(2) of Section 102.

In accordance with such track selected by the Company and the provisions associated with it, the Company is not entitled to claim a tax deduction for the employee benefits.

Awards outstanding under the Silexion Plans prior to the Acquisition Merger accelerated immediately upon Closing, such that the New Silexion options into which Silexion options were converted were fully vested.

The Group's expenses related to equity grants amounted to a total of $ 5,862 and $ 130 in 2024 and 2023, respectively.

As of December 31, 2024, 63,953 New Silexion ordinary shares remain available for grant under the 2024 Plan.

Company Equity Incentive Plans

On July 14, 2025, the Company’s shareholders approved an increase in the number of ordinary shares authorized for issuance under the Company’s 2024 Equity Incentive Plan (the “2024 Plan”) by 84,791 ordinary shares, increasing the total number of ordinary shares reserved for issuance under the 2024 Plan to 95,219 ordinary shares.

Under Silexion Israel’s 2013 Share Option Plan and 2023 Equity Incentive Plan (collectively, the “Silexion Israel Plans,” and, together with the 2024 Plan, the “Plans”), options to purchase ordinary shares of Silexion Israel were granted to certain entities and individuals.

Each option granted under the Silexion Israel Plans is now exercisable for ordinary shares of the Company, until 10 years from the date of grant, or earlier upon cessation of employment or engagement of the grantee and certain other occurrences.

Following the adoption of the 2024 Plan in connection with the Closing of the Transactions, future grants to Company employees and directors will only be made under the 2024 Plan, although outstanding grants under the Silexion Israel Plans will continue to be governed by the terms of those plans.

Grants to employees and directors are made in accordance with the Plans and are carried out within the provisions of Section 102 of the Israel Income Tax Ordinance, under the capital gains track described in subsection (b)(2) of Section 102.

In accordance with such track selected by the Company and the provisions associated with it, the Company is not entitled to claim a tax deduction for the benefits derived by grantees under the Plans.

Awards outstanding under the Silexion Israel Plans prior to the Transactions accelerated immediately upon Closing, such that the Silexion options into which Silexion Israel options were converted were fully vested.

The Group's expenses related to equity grants amounted to totals of $ 134 and $ 5,862 in 2025 and 2024, respectively.

As of December 31, 2025, 86,573 Silexion ordinary shares remain available for grant under the 2024 Plan

RSU’s granted to employees:

On February 9, 2025, Silexion’s board of directors approved the grant of 3,968 RSUs, each of which may be settled for one underlying ordinary share, to Silexion’s directors (as part of the same grant pursuant to which options were granted to the directors, as described below in “c.

Options granted to employees”).

The aggregate grant date fair value of the RSUs was approximately $ 75 , based on a closing share price of $ 18.90 on the grant date.

SILEXION THERAPEUTICS CORP

2 unchanged sentences

NOTE 11 - SHARE-BASED COMPENSATION (continued):

Summary of outstanding and exercisable options:

Below is a summary of the Company's (or for periods prior to the Closing of the Transactions, Silexion’s) stock-based compensation activity and related information with respect to options granted to employees and non-employees for the year ended December 31, 2024 and 2023:

Number of options

Weighted-average

exercise price

Weighted- average

contractual term

On July 4, 2024, Silexion Israel’s board of directors approved granting 5,242 fully vested RSUs to Silexion Israel’s employees and directors, for which Silexion Israel recognized an expense amounting to $ 5,578 in total.

Number of RSU’s

Weighted- average remaining contractual term

Outstanding at December 31, 2024

Changes during the year:

Outstanding at December 31, 2025

Exercisable at December 31, 2024

Vested and expected to vest at December 31, 2024

* Represents an amount less than $1

In 2023 no option were exercised by employees and nonemployees.

RSUs granted to employees and non-employees:

On July 4, 2024, Silexion’s board of directors approved granting 78,650 fully vested RSUs to Silexion’s employees and directors, for which Silexion recognized an expense amounting to $ 5,578 in total.

The fair value for the RSUs granted in 2024 is based on the following assumptions:

The fair value for the RSUs granted in 2024, before the Company’s shares were exchange-traded, was based on the following assumptions:

Expected volatility

5 unchanged sentences

Expected return on Equity

The fair value of equity compensation granted during 2024 was $ 5,578 .

Options granted to employees and non-employees:

In the year ended December 31, 2024 and 2023, no options were granted, neither to employees nor to non-employees.

For the year ended December 31, 2024, there are no nonvested options outstanding.

As of December 31, 2024, there was no remaining unrecognized compensation cost related to unvested stock options granted under the Silexion Plans, as all outstanding options were fully accelerated during 2024.

The fair value of equity compensation granted during 2024 (all of which was attributable to the foregoing RSU grant) was $ 5,578 .

SILEXION THERAPEUTICS CORP

2 unchanged sentences

NOTE 11 - SHARE-BASED COMPENSATION (continued):

Options granted to employees

On February 9, 2025, Silexion’s board of directors approved granting 4,678 options (each exercisable for one underlying ordinary share) to Silexion’s directors (as part of the same grant pursuant to which RSUs were granted to the directors, as described above in “b.

RSUs granted to employees”) the aggregate grant-date fair value of the options was approximately $ 75 , as determined using the Black-Scholes valuation model, which resulted in a fair value of $ 16.03 per option.

Below is a summary of the Company's (or for periods prior to the Closing of the Transactions, Silexion Israel’s) options activity and related information with respect to options granted to employees for the years ended December 31, 2025:

Number of options

Weighted-average exercise price (in U.S.

Weighted- average remaining contractual term

value (in U.S.

Outstanding at December 31, 2024

Outstanding at December 31, 2025

Exercisable at December 31, 2025

Vested and expected to vest at December 31, 2025

Share-based compensation expense:

The share-based compensation expense by line item in the accompanying consolidated statements of operations is summarized as follows:

4 unchanged sentences

Financial instruments measured at fair value on a recurring basis

The Company’s assets and liabilities that are measured at fair value as of December 31, 2024, and December 31, 2023, are classified in the tables below in one of the three categories described in “Note 2 – Fair value measurement” above:

The Company’s assets and liabilities that are measured at fair value as of December 31, 2025 and December 31, 2024 are classified in the tables below in one of the three categories described in “Note 2 (Significant Accounting Policies)– (i) Fair value measurement” above:

December 31, 2025

4 unchanged sentences

Financial Liabilities

Warrants to preferred shares

Private Warrants to ordinary shares

Promissory Notes

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 12 - FAIR VALUE MEASUREMENTS (continued) :

The following is a roll-forward of the fair value of liabilities classified under Level 3:

preferred shares

Private Warrants

to ordinary shares

Promissory Notes

Private Warrants to purchase ordinary shares

Fair value at the beginning of the year

2 unchanged sentences

Fair value at the end of the year

preferred shares

* Represents an amount less than $1

Promissory Notes

Warrants to purchase preferred shares

Private Warrants to purchase ordinary shares

Fair value at the beginning of the year

Change in fair value

Conversion to equity

Fair value at the end of the year

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 12 - FAIR VALUE MEASUREMENTS (continued) :

ELOC Agreement

1 unchanged sentence

Once the Company sold shares under the agreement, the difference between cash raised (net of transaction costs) and the closing price of the Company’s ordinary shares as of the date of their issuance was recognized as financing income or expenses.

As of December 31, 2024 the ELOC’s fair value is zero.

Fair value gain and losses arising from the ELOC Agreement are measured with reference to the spot price of the Company’s shares sold, less consideration receivable from the ELOC Investor.

Warrant to purchase preferred shares

The fair value of Silexion’s warrant to purchase preferred shares as of December 31, 2023 was estimated using a hybrid model in order to reflect two scenarios:

(1) an IPO event (including de-SPAC transaction) involving Silexion and (2) other liquidation events involving Silexion.

The IPO scenario (including de-SPAC transaction) involving Silexion was based on management’s estimation regarding the expected value of the Company’s entire equity at the IPO event (including de-SPAC transaction).

Valuation under this scenario was assessed using the probability-weighted expected return method (PWERM).

The valuation under the ‘other liquidation events’ scenario was assessed using an option pricing model (OPM) by implementing a Monte Carlo simulation, which treats the financial instruments in Silexion’s equity as contingent claims whose future payoff depends on Silexion’s future equity value.

Silexion’s entire equity value in 2023 was calculated based, among others, on the financing round closest to the valuation date.

All warrants to purchase Silexion preferred shares were automatically exercised on a cashless basis immediately prior to the Closing;

see Note 1(d).

Promissory Notes

In measuring the fair value of the Company’s Promissory Notes in 2024, a discount rate of 11.63 %- 13.85 % was used, based on a B- rated US dollar zero-coupon discount curve, plus a credit spread of 6.67 %.

In measuring the fair value of the Company’s Promissory Notes in 2025 and 2024, discount rates of 11.85 %- 13.83 % were used, based on a B- rated US dollar zero-coupon discount curve, plus a credit spread of 6.67 % - 7.56 %.

The expected timing of conversion or repayment of the notes was determined using the Company’s forecasts.

Warrants over ordinary shares

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 12 - FAIR VALUE MEASUREMENTS (continued) :

Warrants to purchase ordinary shares

A Black-Scholes-Merton model with Level 3 inputs was used to calculate the Company’s warrants’ fair value.

Inherent in a Black-Scholes-Merton model are assumptions related to expected life (term), expected stock price, volatility, risk-free interest rate and dividend yield.

The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of selected peer companies’ Class A ordinary shares that matches the expected remaining life of the warrants.

Inherent in a Black-Scholes-Merton model are assumptions related to expected life (term), expected share price, volatility, risk-free interest rate and dividend yield.

The Company estimates the volatility of its warrants based on implied volatility from the Company’s traded warrants and from historical volatility of selected peer companies’ ordinary shares that matches the expected remaining life of the warrants.

The risk-free interest rate is based on the U.S.

2 unchanged sentences

The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 12 - FAIR VALUE MEASUREMENTS (continued) :

The following table provides quantitative information regarding Level 3 fair value measurement inputs of the warrants:

1 unchanged sentence

Financial instruments not measured at fair value

The carrying amounts of cash and cash equivalents, restricted cash, receivables, trade payables and other liabilities approximate their fair value due to the short-term maturity of such instruments.

The carrying amounts of cash and cash equivalents, restricted cash, prepaid expenses, and other assets, trade payables and other accounts payable approximate their fair value due to the short-term maturity of such instruments.

NOTE 13 - NET LOSS PER SHARE:

6 unchanged sentences

Net loss per share attributable to ordinary shareholders, basic and diluted

Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period, and fully vested pre-funded options for the Company’s (or Silexion’s, as applicable) ordinary shares at an exercise price of $ 0.0226 or 0.0226 NIS per share, as the Company (or Silexion, as applicable) considers these shares to be exercised for little to no additional consideration.

As of December 31, 2024 and 2023, the basic loss per share calculation included a weighted average number of 2,081 and 14,652 , respectively, fully vested pre-funded options.

The following instruments were not included in the computation of diluted earnings per share because of their anti-dilutive effect:

Redeemable convertible preferred shares (see Note 9);

Warrants to purchase redeemable convertible preferred shares (see Note 8);

Share-based compensation issuable for substantial consideration (see Note 11);

Warrants to purchase ordinary shares (which were originally SPAC warrants (see Note 3));

Underwriters Promissory Note and Related Party Promissory Note (see Note 3);

ELOC financing (see Note 3);

As such, diluted net loss per share is the same as basic net loss per share.

Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period, and fully vested pre-funded warrants or options to purchase the Company’s (or Silexion Israel’s, as applicable) ordinary shares at an exercise price of $ 0.339 or NIS 0.339 per share, respectively, as the Company (or Silexion Israel, as applicable) considers these shares to be exercised for little to no additional consideration.

SILEXION THERAPEUTICS CORP

1 unchanged sentence

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 13 - NET LOSS PER SHARE (continued) :

As of December 31, 2025 and 2024, the basic loss per share calculation included a weighted average number of 9 and 139 , respectively, fully vested pre-funded warrants or options.

The following instruments were not included in the computation of diluted earnings per share because of their anti-dilutive effect:

For the period ended on December 31, 2025:

Share-based compensation (see Note 11);

Private Warrants to purchase ordinary shares (the “Private Warrants”) that had been issued to former Moringa private warrant holders pursuant to the Transactions (see Notes 3(e) and 8));

Underwriters Promissory Note and Related Party Promissory Note (see Note 3(a)-(b));

For the period ended on December 31, 2024:

Redeemable convertible preferred shares;

Warrants to purchase redeemable convertible preferred shares;

Share-based compensation (see Note 11);

Private Warrants to purchase ordinary shares (see Notes 3(e) and 8));

Underwriters Promissory Note and Related Party Promissory Note (see Note 3(a)-(b));

ELOC financing (see Note 3(d));

As such, diluted net loss per share is the same as basic net loss per share.

NOTE 14 - TRANSACTIONS AND BALANCES WITH RELATED PARTIES :

Transactions with related parties— shareholders, executive officers and directors of the Company (including Silexion)—are quantified below:

Transactions with related parties— shareholders, executive officers and directors of the Company (including Silexion Israel)—are quantified below:

Transactions:

2 unchanged sentences

Share-based compensation included in general and administrative expenses

Financial expenses

Financial expenses (income)

Non-Current liabilities

Warrants to preferred shares

Private warrants to purchase ordinary shares

Sponsor Promissory Note

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 15 - SEGMENT INFORMATION

The Company operates as a single operating segment in the research and development of innovative treatments for pancreatic cancer based on siRNAs.

The Company operates as a single operating segment in the research and development of innovative treatments for pancreatic cancer based on siRNA.

The Company’s CODM is its Chief Executive Officer (CEO).

7 unchanged sentences

As such, information on segment loss and significant expenses is similar to the Company’s consolidated statements of operations.

The CODM is also regularly provided with information on significant ordinary-course expenses, including the following expenses.

the management does not segregate its business for internal reporting.

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 15 - SEGMENT INFORMATION (continued) :

The CODM is also regularly provided with information on significant ordinary-course expenses, including the expenses listed in the below table.

The Company’s management does not segregate its business for internal reporting.

Year ended December 31

Clinical trials and other services from R&D-related service providers

Payroll and related expenses, other than share-based compensation

Share-based compensation expenses

R&D payroll and related expenses, other than share-based compensation

R&D share-based compensation expenses

G&A payroll and related expenses, other than share-based compensation

G&A share-based compensation expenses

Professional services

Depreciation expenses

6 unchanged sentences

Expenditures for segment assets

(*) Other segment expenses include mainly general and administrative-related expenses, such as payments to advisors and consultants, office lease expenses and maintenance, HR and legal expenses.

Segment liabilities

(*) Other segment expenses include mainly general and administrative-related expenses, such as rent and maintenance expenses, travel and HR expenses.

Entity-Wide disclosures

All of the Company’s long-lived assets are located in Israel.

NOTE 16 - SUBSEQUENT EVENTS

Public Offering of Ordinary Shares, Pre-Funded Warrants, and Ordinary Warrants.

On January 15, 2025 and January 17, 2025, the Company offered and sold (“Offering”) 2,145,998 ordinary shares, 1,557,705 pre-funded warrants to purchase up to 1,557,705 ordinary shares and 3,703,703 ordinary warrants to purchase up to 3,703,703 ordinary shares, at a purchase price of $ 1.35 per share or $ 1.3499 per pre-funded warrant and accompanying ordinary warrant.

The aggregate gross proceeds from the Offering were approximately $ 5,000 , net of transaction costs of approximately $ 740 .

The pre-funded warrants are immediately exercisable at an exercise price of $ 0.0001 per ordinary share and will not expire until exercised in full.

The ordinary warrants have an exercise price of $ 1.35 per ordinary share, are immediately exercisable, and could be exercised for five years from issuance.

The Company also issued its placement agent warrants to purchase up to 259,259 ordinary shares.

Those placement agent warrants have an exercise price of $ 1.6875 per ordinary share, are exercisable for five years from the date of the commencement of sales in the Offering, and otherwise reflect substantially the same terms as the ordinary warrants sold in the Offering.

As of the date of these financial statements, a total of 640,257 investor warrants were exercised into 640,257 new Silexion ordinary shares, and 1,557,705 pre-funded warrants were exercised into 1,557,705 new Silexion ordinary shares, for total proceeds of $ 864 .

SILEXION THERAPEUTICS CORP

N OTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

DOLLARS IN THOUSANDS, EXCEPT SHARE DATA

NOTE 16 - SUBSEQUENT EVENTS (continued) :

Induced Warrant Exercise Transaction

On January 29, 2025, the Company entered into an inducement offer letter agreement with holders of (“Inducement Offer”) 2,221,523 of the Company’s existing ordinary warrants that had been issued in the Offering.

Under the Inducement Offer, on January 30, 2025, those holders exercised those warrants for cash and purchased 2,221,523 ordinary shares at a cash exercise price of $ 1.35 per share.

In consideration, the Company’s issued them new ordinary warrants to purchase up to an aggregate of 2,221,523 ordinary shares at an exercise price of $ 1.50 per share (“New Ordinary Warrants”).

The exercising holders also paid the Company an additional $ 0.125 per New Ordinary Warrants issued to them.

The Company received aggregate gross proceeds of approximately $ 3,276 from the exercise of the existing warrants by the holders, net of placement agent fees and other offering expenses of approximately $ 463 .

In connection with the issuance of the New Ordinary Warrants, the Company also issued to the placement agent warrants to purchase up to 155,507 ordinary shares, which have the same terms as the New Ordinary Warrants issued in the transactions, except that the placement agent warrants have an exercise price equal to $ 1.8438 per share.

Upon exercise for cash of any New Ordinary Warrants by the holders thereof, in certain circumstances, the placement agent will receive from the Company (i) a cash fee of 8.0 % of the aggregate gross exercise price, and (ii) additional placement agent warrants exercisable for 7.0 % of the ordinary shares issued upon exercise of those New Ordinary Warrants.

Both the New Ordinary Warrants and the placement agent warrants are immediately exercisable from the date of issuance until the 24 -month anniversary of the effective date of the resale registration statement.

Partial Conversion and Retirement of Underwriters Promissory Note

On March 13, 2025, the Company entered into a letter agreement (the “Note Conversion Inducement Agreement”) with EarlyBird pursuant to which the Company and EarlyBird agreed to the partial conversion and retirement of all remaining amounts due under the Underwriters Promissory Note.

Under the agreement, EarlyBird agreed that the $ 880 principal and interest amount then outstanding under the note as of the date of the Note Conversion Inducement Agreement (the “Outstanding Amount”) would be retired in consideration of:

(i) a cash payment by the Company in an amount of $ 400 (plus $ 15 for EarlyBird’s legal expenses) (the “Cash Amount”), (ii) conversion of a certain amount of the principal and interest due under the Underwriters Promissory Note via the issuance by the Company to EarlyBird of 277,777 ordinary shares (the “EBC Shares”), which conversion amount will be equal to the net proceeds received by EarlyBird from the sale of the EBC Shares (the “Conversion Amount”), and (iii) the payment in cash by the Company to EarlyBird of any remaining amount due under the Underwriters Promissory Note after deducting the Cash Amount and the Conversion Amount from the Outstanding Amount (the “Remaining Amount”).

On March 13, 2025, in accordance with the terms of the Note Conversion Inducement Agreement, the Company made the required payment of the Cash Amount to EarlyBird, and on March 14, 2025 the Company issued the EBC Shares to EarlyBird.

On March 17, 2025, EarlyBird sold the EBC Shares for a Conversion Amount of $ 344 , and on March 18, 2025, the Company paid the Remaining Amount of $ 136 that was due to EarlyBird under the Underwriters Promissory Note, resulting in the retirement of the Underwriters Promissory Note on March 18, 2025.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 9A. Controls and Procedures